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Abstract 
Prior research suggests that people with psychotic disorders have an excess risk of individual 
chronic conditions, however less is known about their risk of co-occurring multiple chronic 
health conditions; that is, multimorbidity. The overall objective of this thesis was to examine 
the association between psychotic disorders and multimorbidity using two complementary 
studies. First, our systematic review and meta-analysis of fourteen studies found that people 
with psychotic disorders had an increased risk of 2+ chronic conditions relative to those 
without psychosis (RR=1.69, 95%CI=1.37,2.08). Second, our retrospective matched cohort 
study found that people with psychotic disorders treated by an early psychosis intervention 
program (n=439) may have a 26% higher prevalence of multimorbidity relative to people 
without psychosis (n=1,759), although our findings include the possibility of a null effect 
(PR=1.26, 95%CI=0.96,1.66). We suggest future research using larger sample sizes and 
longer follow-up periods to better understand the association between psychotic disorders 
and multimorbidity. 
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Summary for Lay Audience 
Chronic health conditions such as diabetes, cardiovascular disease and cancer require long-
term ongoing management by patients, clinicians, and healthcare systems. Mental illnesses 
such as depression and schizophrenia are also examples of chronic conditions. Psychosis or 
the presence of sensory perceptions or false beliefs is present in schizophrenia and other 
psychotic disorders. Prior research indicates that people with psychotic disorders experience 
a higher percentage of one other chronic health condition (e.g. diabetes or cancer) as 
compared to people without psychosis. However, we do not know whether people with 
psychotic disorders also experience multimorbidity or the co-occurrence of two or more (2+) 
chronic health conditions, e.g. psychosis in addition to diabetes and cancer. Multimorbidity is 
challenging for clinicians who provide treatment to patients and for healthcare systems which 
allocate the appropriate number of resources for patient care. Therefore, it is important to 
understand multimorbidity so that we can better meet the needs of patients with psychotic 
disorders. The overall goal of this thesis was to compare the occurrence of multimorbidity 
between people with psychosis and those without psychotic disorders through two research 
studies. Our first study pooled findings from fourteen prior research studies and found that 
people with psychotic disorders may have a higher risk of developing 2+ other chronic health 
conditions as compared to people without psychosis. Our second study focussed on people 
with psychotic disorders who were treated by an early psychosis intervention program in 
London, Ontario. We tracked healthcare records for people with and without psychotic 
disorders for ten years to estimate the percentage of people who experienced 2+ other chronic 
health conditions in each of these groups, and we then compared those two estimates. We 
found that there was a higher percentage of multimorbidity among people with psychotic 
disorders as compared to people without psychosis. It is recommended that future researchers 
follow the health records of patients with psychotic disorders for a longer period of time to 
better estimate multimorbidity. 
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Chapter 1  
 Overview of Thesis 
People with psychotic disorders have a reduced life expectancy compared to members of 
the general population, which is primarily due to differences in physical health and 
preventable physical health conditions.1–3 Compared to people without psychotic 
disorders, those with psychosis have a higher prevalence of conditions such as diabetes 
mellitus and various cardiovascular and respiratory ailments.4 Ongoing treatment with 
second-generation antipsychotic medications, which results in weight gain and other 
metabolic side effects4–7 and increases risk for cardiometabolic conditions,8–10 may 
explain to some extent this excess prevalence observed by people with psychosis. 
Additionally, lifestyle factors such as smoking11–13 and poor nutritional habits14,15 may 
explain why this clinical population has an excess prevalence of respiratory and 
cardiovascular conditions.4  
Although there is evidence on the association between psychosis and individual chronic 
conditions, there is limited research on the co-existence of multiple co-occurring chronic 
conditions – known as multimorbidity – among people with psychotic disorders.3 Both 
psychosis and multimorbidity share common risk factors, such as smoking, sedentary 
behaviour, older age, and material deprivation, which may be interrelated and form a 
unique cluster of conditions.11–13,16–22 
We sought to investigate whether people with psychotic disorders may have an excess 
risk or prevalence of multimorbidity through two complementary studies. Our systematic 
review and meta-analysis synthesized the existing body of evidence and found that 
people with psychotic disorders had an increased risk of 2+ chronic conditions (risk ratio 
(RR)=1.69, 95%CI=1.37,2.08), relative to those without psychosis (Chapter 3). We then 
assessed the excess prevalence of multimorbidity experienced by people treated by an 
early psychosis intervention program in London, Ontario, compared to those without 
psychosis through a retrospective matched cohort study (Chapter 4). We found that 
people with psychotic disorders may have a 26% higher prevalence of multimorbidity ten 
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years following first diagnosis, although our findings include the possibility of a null 
effect (prevalence ratio (PR)=1.26, 95%=CI 0.96,1.66).  
1.1 Role of the Student 
The research question was identified by Myanca Deanne Rodrigues and her supervisor 
Dr. Kelly K. Anderson, and refined through consultation with Drs. Saverio Stranges and 
Bridget L. Ryan, members of her supervisory committee. All chapters of this thesis were 
written by Ms. Rodrigues as partial fulfillment of requirements for the Master of Science 
degree in Epidemiology and Biostatistics, and she incorporated feedback from Drs. 
Anderson, Stranges and Ryan. 
Ms. Rodrigues conducted the search for the systematic review, extracted data, and 
performed and interpreted results of the meta-analysis (Chapter 3). Feedback for this 
chapter was also sought from Mr. Joshua C. Wiener who was a secondary reviewer, in 
addition to members of the supervisory committee (Drs. Anderson, Stranges, and Ryan).  
The retrospective matched cohort study used data from the Prevention and Early 
Intervention Program for Psychoses program, which was linked to ICES datasets. Access 
was granted to Ms. Rodrigues through the Data & Analytics Services department of 
ICES. The thesis student was added to an existing Health Sciences Research Ethics Board 
application at Western University (protocol #112446), which was used for the 
aforementioned data linkage study. The statistical methods for the primary analysis 
(Chapter 4) were developed by Ms. Rodrigues and Dr. Anderson. Coding and cleaning of 
data, and interpretation of results was conducted by Ms. Rodrigues, in consultation with 
Drs. Anderson, Stranges and Ryan.  
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Chapter 2  
 Psychosis, Chronic Health Conditions, and 
Multimorbidity 
People with psychosis often have other co-occurring chronic health conditions. This 
chapter describes the natural history of psychosis, the chronic conditions faced by this 
clinical population, and the phenomenon of multiple chronic conditions or 
multimorbidity.  
2.1 Psychosis and Psychotic Disorders  
This section will provide an overview of psychosis and psychotic disorders and their 
prevalence, risk factors, and impact on patients, clinical teams, and healthcare systems. 
2.1.1 Psychosis and Psychotic Symptoms 
The American Psychiatric Association and World Health Organization characterize 
psychosis by the presence of hallucinations (without insight), delusions, or both 
hallucinations without insight and delusions.23,24 Hallucinations are sensory perceptions 
that occur without corresponding external or somatic stimuli, whereas delusions are fixed 
false beliefs.25 People with psychosis therefore experience a break with reality, and a 
psychotic episode occurs when a person has trouble distinguishing reality from these false 
perceptions. The first episode of psychosis is a person’s first experience of the symptoms 
of psychosis that would meet the threshold for a psychotic disorder,26 and may be defined 
by the duration of prior antipsychotic medication use, duration of psychosis, or the first 
treatment contact for psychosis.27 
Psychotic episodes are characterized by the presence of positive or negative symptoms. 
Positive symptoms can be thought of as symptoms added to a person’s usual behaviour 
and may include: hallucinations, delusions, disorganized speech or thoughts, or catatonia 
(disorganized motor behaviours).23,25,26,28 Negative symptoms can be thought of as 
symptoms missing from a person’s usual behaviour and include: alogia (restricted 
speech), affective flattening (blunted emotional or facial expressions), anhedonia 
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(inability to feel pleasure), avolition (reduced motivation) and asociality (reduced desire 
to partake in social activities).23,25,26,28–30  
2.1.1.1 Psychotic Disorders  
Psychosis occurs in several mental illnesses such as schizophrenia spectrum disorders, 
mood disorders, and substance abuse disorders. Schizophrenia spectrum disorders are 
primary psychotic disorders for which psychosis is the hallmark and include: 
schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder, 
brief psychotic disorder, and psychosis not-otherwise-specified (NOS).23,25,26,28,31 People 
with major depressive disorder (MDD), bipolar disorder, or other affective disorders may 
also experience psychosis.23,25,26,28 Psychosis may also develop due to intoxication or 
withdrawal from substances, neurocognitive or neurodegenerative disorders (e.g. 
Alzheimer’s or Parkinson’s Disease), or as a result of traumatic brain injury.25 Psychotic 
disorders can be broadly categorized as affective or non-affective. Affective psychotic 
disorders are primarily defined by mood symptoms and include MDD with psychosis or 
bipolar disorder with psychosis.32 Non-affective psychotic disorders do not have 
prominent mood symptoms and include delusional disorder and schizophrenia spectrum 
disorders.32 
2.1.2 Risk Factors for Psychosis 
Factors that are associated with an increased risk of psychosis include: family history, 
sex, socioeconomic status (SES), ethnicity, migrant status, and age.33 Psychosis is 
thought to be the result of a complex interplay between genetic susceptibility and familial 
environmental influences,34,35 and offspring of parents with schizophrenia have an 
increased risk of developing psychotic disorders (relative risk (RR) = 7.54, 95% 
confidence interval (CI) 4.02, 14.13; 33 studies).36 Psychotic symptoms also emerge at 
different ages in males and females. The mean age of onset for males is 18-25,37 whereas 
females have a bimodal onset profile – after puberty and over the age of 40.38,39 
Furthermore, several studies have demonstrated that incidence of schizophrenia is higher 
in those from low-socioeconomic classes or materially-deprived areas.40–42 Black 
Caribbean and African groups have a three to six times higher incidence of schizophrenia 
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and other psychotic disorders compared to White groups.43,44 Migrant status and ethnic 
background may also interact to influence risk of psychosis, with immigrants from the 
Caribbean and Bermuda (Incidence Rate Ratio (IRR) = 1.60, 95% CI 1.29, 1.98) and 
refugees from East Africa (IRR = 1.95, 95% CI 1.44, 2.65) shown to have higher 
incidence of psychotic disorders than those from Europe or Asia.45 Given the early age of 
onset for the condition, adolescence and young adulthood is a risk period for psychosis. It 
is thought that high levels of depression, long duration of psychotic symptoms, and 
family history of psychosis in youth are associated with onset of psychosis.46 
Furthermore, heavy cannabis use among youth is associated with onset of psychotic 
symptoms,47 as demonstrated by a recent meta-analysis across 35 studies (adjusted odds 
ratio (OR) = 1.41, 95% CI 1.20, 1.65).48 
2.1.3 Incidence, Prevalence and the Impact of Psychotic Disorders 
A meta-analysis of 177 studies estimated the pooled incidence of all psychotic disorders 
at 26.6 per 100,000 person-years (95% CI 22.0, 31.7),49 whereas the lifetime prevalence 
of schizophrenia across 46 countries is estimated to be 0.4% (90% CI 0.18%, 1.16%).50 
Schizophrenia was ranked the 16th leading cause of disability worldwide in 201251 due to 
its impact on patients, caregivers, and health systems. People with psychosis often feel 
stigma and shame52 and chronic sufferers of the condition may also experience work-
related absences and unemployment.53 Additionally, they are often cared for by family 
members or other caregivers, which places a significant burden on the caregivers.54 
Caregivers often experience constraints in leisure time, social isolation, and lower 
physical and mental health-related quality of life.55–58 Chronic psychosis also results in 
morbidity and mortality; as such, treatment of those with psychotic disorders comprises 
3% of the budget in Ontario,59 and schizophrenia alone costs the Canadian health system 
$6.85 billion CAD (2004 dollars).26,60  
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2.2 Physical Health of People with Psychosis: An Overview 
The following section provides an overview of the physical health of people with 
psychosis and potential reasons for physical health ailments among this clinical 
population. 
2.2.1 Chronic Conditions: Definition and Prevalence 
Chronic conditions are physical or mental health issues which require long-term ongoing 
management.61 Both non-communicable diseases which cannot be transmitted between 
people (e.g. cardiovascular disease or cancer), and communicable diseases which can be 
transmitted between people (e.g. Human Immunodeficiency Virus, HIV) may be 
regarded as chronic conditions.61,62 Common features of chronic conditions include: 
multiple risk factors, long development periods, prolonged course of illness which may 
result in other health issues, and functional impairment and disability.62,63 Chronic 
conditions are regarded as the leading cause of death worldwide, responsible for 38 
million deaths in 2012, and projected to be responsible for 52 million deaths in 2030.64,65 
In Canada alone, one in three Canadians lives with one or more major chronic disease.66  
2.2.2 Psychosis and Physical Health 
Psychotic disorders have been associated with a reduced life expectancy of 10-25 years,67 
with findings from a systematic review and meta-analysis demonstrating that people with 
psychotic disorders have a reduced life expectancy of 14.5 years (95% CI 11.2, 17.8) 
compared to the general population.68 This premature mortality is primarily due to 
differences in physical health and chronic conditions experienced by people with 
schizophrenia and other psychotic disorders.2,3,69,70 A population-based repeated cross-
sectional study conducted using Canadian data found that people with schizophrenia had 
mortality rates which were three times higher than controls (mortality rate ratios (MRR) 
= 3.12, 95% CI 3.06, 3.17).71 The following sub-sections will discuss potential reasons 
for these differences in physical health, and common chronic conditions experienced by 
people with psychosis will be detailed in Section 2.3. 
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2.2.3 Second-Generation Antipsychotic Medications and Physical 
Health Consequences 
People with schizophrenia and other psychotic disorders are commonly treated using 
second-generation antipsychotic (SGA) medications. Commonly-used SGAs include 
clozapine, olanzapine, risperidone, and quetiapine.72,73 SGAs are prescribed for their 
efficacy in reducing acute symptoms commonly associated with psychosis, i.e. positive 
and negative symptoms. A Bayesian meta-analysis found a significant reduction of 
overall acute symptoms in people with schizophrenia (adjusted standardized mean 
difference (SMD) of 0.38, 95% CI 0.33, 0.43) across 105 studies.74 SGAs were 
developed in the 1990s to address the limitations of first-generation antipsychotics 
(FGAs).75 The use of FGAs, commonly known as neuroleptics or conventional/typical 
antipsychotics,76 resulted in extrapyramidal side effects and tardive dyskinesia.77 SGAs 
are associated with a lower incidence of these aforementioned unintended 
consequences,72,75 but also result in other side effects that serve as risk factors for several 
chronic conditions and are discussed in Sections 2.2.3.1 and 2.3. 
2.2.3.1 Side Effects of SGAs 
Use of SGAs are associated with cardiometabolic and other unintended side effects. 
Common cardiometabolic side effects of SGA use include weight gain, impaired ability 
to metabolize glucose, insulin resistance, and dyslipidemia4–7 which in turn, serve as risk 
factors for cardiovascular disease (CVD) and Type 2 diabetes.8–10 It is postulated that 
SGAs increase oxidative stress, which triggers pathways leading to glucose 
dysregulation, dyslipidemia, and insulin resistance, and weight gain.78 Weight gain is the 
most significant cardiometabolic outcome associated with use of SGAs79,80 due to its 
association with a host of chronic cardiometabolic conditions. A Bayesian network meta-
analysis (NMA) across 212 randomized controlled trials (RCTs) found that SGAs result 
in significantly greater weight gain compared to placebos, with SMDs ranging from 0.10 
(95% credible interval (CrI) -0.02, 0.22) to 0.74 (95% CrI 0.67, 0.81).81 A frequentist 
meta-analysis also found that use of SGAs results in significantly greater weight gain 
than FGAs (RR = 2.26, 95% CI 1.33, 3.69, 7 RCTs).82 Use of SGAs may also result in 
impaired glucose metabolization, with dose-response associations demonstrated between 
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increasing SGA dosage and increased hemoglobin A1C (HbA1C) levels.83–85 
Furthermore, SGA use is associated with increased secretion of insulin from β-islet cells 
in the pancreas, thereby resulting in insulin resistance.86,87 Lastly, imbalances in serum 
cholesterol, including decreased HDL-cholesterol and increased LDL-cholesterol and 
triglyceride levels may result from SGA use, as evidenced by findings from several 
prospective cohort studies.8,9,88–90  
Although SGA use is primarily associated with cardiometabolic side effects, there are 
other unintended consequences which merit consideration. Anticholinergic effects may 
result from SGA use and include: impaired cognition and memory, constipation, and 
erectile dysfunction.79,91 Additionally, SGAs may lead to increased prolactin synthesis 
and secretion through blocking dopamine receptors, thereby resulting in 
hyperprolactinaemia. A Bayesian NMA assessing prolactin elevation from use of 
antipsychotic agents compared to placebos across 90 RCTs found that several SGAs were 
associated with elevated prolactin levels, with weighted mean differences (WMDs) 
ranging from -4.47 ng/mL (95% CrI 1.60, 7.38) to 48.51 ng/mL (95% CrI 43.52, 
53.51).92 Increased prolactin levels may lead to menstrual disturbances and loss of bone 
mineral density.79,93–97   
2.2.4 Behavioural Risk Factors for Chronic Physical Health 
Conditions Among People with Psychotic Disorders 
Behavioural risk factors associated with an increased risk of various chronic conditions 
are also highly prevalent among people with schizophrenia and other psychotic disorders. 
These include smoking, sedentary behaviour, poor nutrition, disrupted sleep patterns, and 
substance use.  
Firstly, smoking is highly prevalent among people with psychotic disorders, who may use 
nicotine to self-medicate and manage the negative symptoms of psychosis.11,12,98,99 A 
meta-analysis of 42 studies across 20 countries found that people with schizophrenia have 
a five-times higher odds of being smokers compared to the general population (OR=5.3, 
95% CI 4.9, 5.7).100 Smoking has been shown to be a risk factor for a range of chronic 
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disease including cancer, cardiometabolic conditions, such as CVD and diabetes,16,17,19,101 
and respiratory conditions such as asthma.18  
Secondly, people with psychosis are more likely to engage in sedentary behaviour or low 
levels of physical activity, relative to those without psychotic disorders, potentially due to 
the side effects of SGAs and the negative symptoms of psychosis.102 Findings from a 
meta-analysis demonstrated that people with psychosis spend 2.8 (95% CI 1.5, 4.1) more 
hours per day engaging in sedentary behaviours, as compared to the general population.13 
Sedentary behaviour is associated with cardiometabolic conditions both independently103 
and through the mediating effects of high body mass index (BMI) and obesity.104,105  
Thirdly, people with psychosis engage in poor nutritional habits more often than 
members of the general population, both in terms of composition of dietary 
macronutrients and caloric intake.14,15 Scoping and systematic reviews have found that 
people with schizophrenia often have a higher intake of saturated fat and lower 
consumption of fruit and fibre.106,107 Another study demonstrated that people with 
psychosis made similar dietary choices but had a higher caloric intake than members of 
the general population.108 Diets high in saturated fat are associated with obesity, insulin 
resistance and increased LDL-cholesterol,109 and low intake of fruit and fibre is 
associated with higher overall caloric intake and reduced control of plasma lipid levels.110 
These, in turn serve as risk factors for CVD and Type II diabetes.8–10 
Fourthly, a systematic review suggests that people with schizophrenia and other 
psychotic disorders often have a disrupted sleep patterns and other comorbid sleep 
disorders, the latter of which include insomnia, obstructive sleep apnea, and restless leg 
syndrome.111 These sleep abnormalities are often present during the prodromal period of 
psychotic illness and may exacerbate symptoms associated with psychotic disorders.112 
Findings from a meta-analysis suggest that both the quantity (<5-6 hours of sleep a night: 
RR= 1.28, 95% CI 1.03, 1.60) and quality (difficulty initiating sleep: RR=1.57, 95% CI 
1.25, 1.97) of sleep are associated with a higher incidence of Type II diabetes.113  
Lastly, damage to organs and tissue systems are consequences of misusing alcohol, 
cocaine, and other substances, and may lead to several chronic physical conditions.114 For 
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instance, frequent users of alcohol suffer from reduced bone density and overall skeletal 
frailty,115 which are risk factors for osteoporosis.116 Furthermore, cocaine use is 
associated with increased risk of cardiovascular and pulmonary conditions, such as 
myocardial infarctions117–119 and asthma.120,121 There is an overlap of risk factors for 
psychotic disorders and substance abuse, including younger age, male sex, and low 
SES.122–126 Additionally, people with psychotic disorders may use alcohol and other 
substances to cope with both the symptoms of psychosis and the side effects associated 
with using antipsychotic medications.127–129 Thus, it is unsurprising that substance use is 
highly prevalent among people with psychosis.126,130–132 A large population-based study 
found that people with severe psychotic disorders had increased odds of both alcohol 
(OR=4.0, 95% CI 3.6, 4.4) and recreational drug use (OR=4.6, 95% CI 4.3, 5.0).133  
2.3 Common Chronic Health Conditions Experienced by 
People with Psychosis 
As the previous section indicates, use of SGAs may result in cardiometabolic and other 
consequences, thereby increasing the risk of chronic health conditions experienced by 
people with psychotic disorders. This section is not an exhaustive list, but outlines several 
chronic conditions commonly experienced by this clinical population. 
2.3.1 Diseases of the Cardiovascular and Circulatory Systems 
People with psychosis and psychotic disorders may develop several diseases of the 
cardiovascular and circulatory systems, such as CVD, congestive heart failure (CHF), 
stroke/ transient ischemic attack, and hypertension. There is an interplay between these 
conditions, both with respect to common cardiometabolic risk factors, as well as these 
conditions serving as predictors of each other, which has been summarized below. 
2.3.1.1 Hypertension 
High blood pressure or hypertension describes the pressure from the force of blood 
against arterial walls. Hypertension is a chronic condition in itself, but is also a risk factor 
for other chronic cardiometabolic conditions, including CVD, stroke, and Type II 
diabetes. Risk factors for hypertension include: obesity, increased age, chronic stress, and 
 
11 
 
family history of disease.134 Excess body fat, especially central adiposity, has been shown 
to be one of the primary risk factors associated with development of hypertension 
through the Minnesota Health Survey, China Stroke Primary Prevention trial, and the 
National Health and Nutrition Examination Survey.135–137 Weight gain is the most 
pertinent cardiometabolic consequence associated with SGAs; as such, people with 
psychotic disorders have an increased risk of developing hypertension.138 A meta-
analysis found that the prevalence of hypertension is higher among people with chronic 
schizophrenia who receive treatment with SGAs (39.7%, 95% CI 36.4%, 43.1%), 
compared to people with a first episode of psychosis (30.4%, 95% CI 21.3%, 40.3%) or 
unmedicated people with psychosis (24.3%, 95% CI 11.2%, 40.5%).139 These findings 
were corroborated by another meta-analysis across 28 studies which demonstrated 
increased odds of hypertension among people who had experienced multiple episodes of 
schizophrenia, compared to age-, sex- and cohort-matched controls from the general 
population (OR = 1.36, 95% CI 1.21, 1.53).140 
2.3.1.2 Cardiovascular Diseases  
Cardiovascular disease (CVD) is a term given to a wide range of conditions affecting the 
cardiovascular system, including coronary heart disease, peripheral artery disease, 
arrythmias, congenital heart defects, angina, and myocardial infarction (MI).4,79,141 Risk 
factors for CVDs are a combination of genetic and lifestyle factors, which include but are 
not limited to: obesity, hypertension, lack of physical activity and low SES.16,17 Given 
that the use of SGAs results in several cardiometabolic consequences that are known risk 
factors for CVDs, the most pertinent of which is weight gain, it is unsurprising that 
people with schizophrenia have a marked increase in the incidence of CVDs. A 
systematic review demonstrated that risk for CVDs is not different between untreated 
patients after a first episode of psychosis, but that this risk increases after first exposure to 
SGAs.142 A comprehensive meta-analysis of cross-sectional studies demonstrated that 
people with schizophrenia had greater odds of coronary heart disease (adjusted OR = 
1.52, 95% CI 1.48, 1.56; 8 studies, 187,359 patients, 4,086,191 controls). This review 
also pooled hazards ratios (HRs) from longitudinal studies and found that people with 
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schizophrenia have an increased risk of developing CVD (adjusted HR = 1.95, 95% CI 
1.41, 2.70; 16 studies, 361,294 patients, 16,096,125 controls).143 
2.3.1.3 Congestive Heart Failure 
Congestive heart failure (CHF) is a chronic condition affecting the circulatory system. It 
develops from weakening of the heart muscle, and characterizes the heart’s inability to 
pump blood, particularly under duress, e.g. exercise or stressful conditions. The most 
common risk factor for heart failure is a heart attack or myocardial infarction (MI), after 
which patients’ hearts are weakened and damaged.144 Narrowing of the arterial walls 
through conditions such as coronary heart disease may restrict blood flow and result in 
CHF. Since people who use SGAs have an increased incidence of developing coronary 
heart disease and experiencing MIs, they are also at increased risk for developing CHF. A 
meta-analysis across 5 cross-sectional studies which included 40,984 patients and 
3,743,431 controls found that people with schizophrenia have an increased odds of CHF 
(adjusted OR = 1.60, 95% CI 1.06, 2.40).143 These findings were also consistent with the 
findings of a meta-analysis of 3 cohort studies (RR = 1.80, 95% CI 1.15, 2.79; 85,290 
patients, 9,050,272 controls).143 
2.3.1.4 Stroke/Transient Ischemic Attack 
Cerebrovascular disease is a broad grouping which characterizes conditions that impede 
blood flow to the brain. When a blood vessel in the brain is prevented from receiving 
oxygen and nutrients, this is known as a cerebrovascular accident or stroke.145–147 A 
transient ischemic attack is the term given to a mini-stroke which lasts for a shorter 
period of time and does not result in permanent damage. It may also be a warning sign 
and eventually lead to the occurrence of a stroke.148 Risk factors for both strokes and 
transient ischemic attacks include: obesity, hypertension, diabetes and high cholesterol 
levels, which may result from use of SGAs among people with psychosis.145–147 A 
comprehensive meta-analysis of cross-sectional studies demonstrated that people with 
schizophrenia had greater odds of cerebrovascular disease (adjusted OR = 2.05, 95% CI 
1.59, 2.64; 5 studies, 41,071 patients and 3,777,039 controls).143 A more recent meta-
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analysis found that SGA use was associated with an increased risk of stroke (adjusted HR 
= 1.71, 95% CI 1.16, 2.53).149 
2.3.2 Type II Diabetes 
Diabetes mellitus characterizes the body’s impaired ability to use glucose or blood sugar, 
and includes both Type I and Type II sub-types. The causes of Type I diabetes remain 
unclear, but insulin resistance, obesity, hypertension and abnormal serum cholesterol and 
triglyceride levels are known to be associated with Type II diabetes.150 Treatment with 
SGAs results in an increased incidence of these aforementioned cardiometabolic 
consequences. As such, people with schizophrenia and other psychotic disorders have an 
increased risk of developing Type II diabetes. A meta-analysis of 25 studies across 
145,718 patients and 4,343,407 controls found that people with schizophrenia have an 
82% increased risk of developing this chronic condition (RR = 1.82, 95% CI 1.56, 
2.13).151 Another meta-analysis found that the prevalence of diabetes was lower among 
people with first episode psychosis (1.3%, 95% CI 0.5%, 2.4%) relative to those with 
chronic schizophrenia (12.8%, 95% CI 8.44%, 17.9%), as may be expected by increasing 
use of SGAs by the latter group.139 
2.3.3 Cancer 
Cancer is the term given to diseases which result from abnormal cell proliferation and 
subsequent destruction of body tissue. Given that cancer may affect several body systems 
and tissues, there are several types of cancer, such as breast, prostate, lung, colorectal, 
thyroid, and liver cancers.152 Risk factors for cancer include both lifestyle factors (e.g. 
smoking and lack of physical activity), and family history.152,153 There is mixed evidence 
regarding the incidence of cancer for people with psychosis and other psychotic 
disorders. Meta-analyses have demonstrated a slight decreased overall risk (RR = 0.90, 
95% CI 0.81, 0.99)154 or no difference in risk (standardized incidence ratio (SIR) = 1.05, 
95% CI 0.95, 1.15)155 of developing any type of cancer among this clinical population, 
while a population-based register study found an increased risk of cancer across both 
sexes for people with schizophrenia, as compared to controls.156 There are two conflicting 
hypotheses that support these sets of results, and involve elucidation of risk factors that 
 
14 
 
may underlie specific types of cancer.157 People with psychosis are at risk of developing 
breast, colorectal and other obesity-related cancers, for which weight gain is a significant 
determinant and may result from use of SGAs. This has been supported by reviews 
demonstrating increased risk of breast cancer (SIR = 1.12, 95% CI 1.02, 1.23) among 
people with psychosis compared to controls.155 Furthermore, use of SGAs result in 
increased prolactin levels, which further increases risk for breast cancer.158,159 
Additionally, smoking is more common among people with psychotic disorders11,12,98,99 
and serves as a risk factor for cervical, lung and other types of cancers,101,160 which may 
explain why those with psychosis are at increased risk of developing cancer. Alternately, 
SGAs may have anti-proliferative effects on cells161 or schizophrenia itself may have a 
protective effect against cancer, due to increased natural killer cell activity162 or its 
association with a tumour suppressor gene.163 This is supported by findings from other 
meta-analyses which demonstrate a decreased risk of even obesity-related cancers, such 
as colorectal (RR = 0.82, 95% CI 0.69, 0.98)154 and liver cancer (SIR = 0.76, 95% CI 
0.61, 0.96)164 among patients compared to controls. Another review found that people 
with schizophrenia do not necessarily have an increased risk of developing cancer, but 
increased cancer-related mortality (HR = 1.51, 95% CI 1.13, 2.03),165 which may be 
explained by delays in cancer screening and treatment initiation among this clinical 
population.166–169  
2.3.4 Diseases of the Respiratory System 
People with psychosis may also experience diseases affecting the respiratory system such 
as asthma, chronic obstructive pulmonary disease, and bronchitis. These have been 
summarized below. 
2.3.4.1 Asthma  
Extra production of mucus resulting from narrowed airways in the respiratory tract is 
called asthma. Risk factors for asthma include lifestyle factors (e.g. smoking, being 
overweight, and exposure to air pollution), as well as family history and respiratory 
infections.18 Given that the use of SGAs results in weight gain, and people with psychosis 
have a higher prevalence of smoking compared to the general population,11,12 they also 
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have an increased risk of developing asthma. A nation-wide cohort study using data from 
the National Health and Nutrition Examination Survey (NHANES) found that people 
with schizophrenia had a higher odds of developing asthma compared to age-, sex-, and 
race-matched controls, after adjustment for smoking (OR = 2.23, 95% CI 1.25, 3.97).170  
2.3.4.2 Chronic Obstructive Pulmonary Disease  
Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease resulting in 
reduced airflow to the lungs.171 Risk factors for COPD include smoking and exposure to 
air pollution and other irritants. Given that people with psychosis have a higher 
prevalence of smoking compared to the general population,11,12 which is considered the 
primary cause of developing COPD,172 it is unsurprising that prevalence of COPD is 
higher among this clinical population.4,141,173 A long-term follow-up study of health care 
billings in the United States found an 88% higher odds of people with schizophrenia 
developing COPD compared to controls (OR = 1.88, 95% CI 1.51, 2.32).174 These 
findings were also supported by a population-based study evaluating the odds of 
developing various respiratory illnesses, including COPD, among people with psychosis 
compared to controls (COPD-specific OR adjusted for age and sex = 4.23, 95% CI 1.61, 
11.10).175 
2.3.4.3 Bronchitis 
Bronchitis characterizes an inflammation of the bronchial tube lining, resulting in 
expelling of mucous, and can be a chronic condition. Primary risk factors for bronchitis 
include smoking and exposure to air pollution.176 People with psychosis have a higher 
prevalence of smoking compared to the general population11,12 and consequently 
experience a higher odds of developing chronic bronchitis compared to controls (chronic 
bronchitis-specific OR adjusted for age and sex = 3.75, 95% CI 1.64, 8.55), as 
demonstrated by a population-based study.175 
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2.3.5 Diseases of the Musculoskeletal System 
People with schizophrenia and other psychotic disorders are also prone to developing 
diseases which affect the musculoskeletal system, such as arthritis and osteoporosis. 
These have been briefly summarized below. 
2.3.5.1 Arthritis  
Arthritis refers to swelling of the body’s joints, resulting in joint pain and stiffness, and 
includes both rheumatoid arthritis and osteoarthritis. Risk factors for both sub-types 
include: obesity, family history, increased age, and the female sex.177–181 The body’s 
immune system attacks the joint lining, and may eventually destroy cartilage through an 
auto-immune condition known as rheumatoid arthritis,182 whereas osteoarthritis results 
from wear and tear of the body’s cartilage.183 There is mixed evidence on the association 
between schizophrenia and rheumatoid arthritis,184 with some studies suggesting a 
reduced risk for the condition among this clinical population (HR = 0.69, 95% CI 0.59, 
0.80),185 whereas others suggest no significant association (OR = 1.88, 95% CI 0.79, 
4.49, compared to age-, sex-, and race-matched controls).170 Research suggests that the 
relationship between these two chronic conditions may be the result of an overlap 
between genetic factors for both diseases which are located in the Human Leukocyte 
Antigen (HLA) region,186 as polymorphisms in HLA-C may be associated with a 
decreased risk of rheumatoid arthritis and an increased risk of schizophrenia.187–189 A 
recent meta-analysis found that people with schizophrenia have a lower odds of 
rheumatoid arthritis as compared to those without schizophrenia (OR = 0.48, 95% CI 
0.34, 0.67).190 Conversely, the weight gain caused by SGA use may lead to more strain 
on the body’s joints and an increased risk of osteoarthritis (OR = 1.40, 95% CI 1.04, 
1.89).174  
2.3.5.2 Osteoporosis 
Weakening of bones which may lead to fractures is characterized as osteoporosis. Risk 
factors for this condition include: increased age, female sex, and low calcium 
intake.191,192 Given that use of SGAs is associated with elevated prolactin levels92 which 
may result in loss of bone mineral density,79,93–97 it is biologically plausible that people 
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with psychosis could have an increased incidence of this chronic condition. This is 
supported by a recent meta-analysis which found a significant greater odds of people with 
schizophrenia developing osteoporosis, as compared to controls (OR = 2.86, 95% CI 
1.27, 6.42).193 
2.3.6 Neurological and Other Mental Health Conditions 
People with schizophrenia and other psychotic disorders are also prone to developing 
diseases which affect neurological systems (e.g. dementia) and other mental health 
conditions (e.g. mood and anxiety disorders). These have been briefly summarized 
below. 
2.3.6.1 Dementia 
Dementia is characterized by a cluster of symptoms which includes memory loss and 
difficulty in tasks involving coordination, problem-solving, and communication. Damage 
to nerve cells in the brain and increased age may result in dementia.194,195 The association 
between psychosis and dementia is unclear, but two hypotheses have been postulated. 
Firstly, people with schizophrenia have a higher incidence of several cardiometabolic 
comorbidities, including diabetes196 and CHF,197 which are known risk factors for 
dementia.198 Secondly, those with chronic schizophrenia, in particular geriatric 
populations, show cognitive decline,199–202 which may be the result of cumulative 
exposure to the anti-cholinergic effects of SGAs.203 Although further elucidation of this 
association is necessary, findings from a meta-analysis, which included 4 prospective and 
2 retrospective cohort studies, highlight the increased risk of dementia among people 
with schizophrenia (RR = 2.29, 95% CI 1.35, 3.88).204 
2.3.6.2 Mood and Anxiety Disorders 
Mood disorders (e.g. depression, bipolar disorders) characterize one’s mood being 
lowered or elevated, whereas anxiety disorders describe persistent feelings of fear or 
worry.205,206 These two types of mental disorders often occur concurrently.207,208 Blunted 
affect characterizes the negative symptoms of psychosis, and is also associated with 
depression and other mood disorders.209 Alternately, changes in mood may also be a 
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consequence of a diagnosis of psychotic disorder, or both conditions may be rooted in 
historical childhood trauma.210 It is postulated that anhedonia, a feature of schizophrenia, 
results in associated anxiety.211 People with schizophrenia and other psychotic disorders 
often have comorbid mood and anxiety disorders. Meta-analyses have demonstrated 
pooled prevalence of depressive and anxiety disorders were respectively 26.0% (95% CI 
22.1, 30.3)212 and 10.9% (95% CI 2.9, 18.8)213 among those with schizophrenia, whereas 
reviews have found that the prevalence of these conditions among the general population 
are as high as 6.7% (95% CI 4.2, 10.1)214 and 4.0% (95% CI 3.7, 4.2).215 
2.3.7 Other Chronic Conditions 
People with schizophrenia and other psychotic disorders may also develop other chronic 
conditions, such as HIV, inflammatory bowel disease, chronic kidney disease, chronic 
liver disease, and urinary incontinence.  
HIV is spread by contact with infected bodily fluids and characterizes the damage caused 
to the body’s immune system and subsequent impaired ability to fight infections.216 A 
meta-analysis found that people with psychotic disorders have a high prevalence of HIV 
infection (6.0%, 95% CI 4.3%, 8.3%),217 which may be explained by risky sexual 
behaviours and reduced knowledge about HIV transmission.218,219  
Inflammatory bowel disease (IBD) characterizes chronic inflammation of the digestive 
system and includes ulcerative colitis and Crohn’s Disease.220,221 Genetic overlap of 
alleles that give rise to both schizophrenia and Crohn’s Disease may explain the strong 
association between the two conditions.222 Two population-based Canadian studies using 
administrative health data found an increased risk of schizophrenia among people with 
IBD (IRR = 1.64, 95% CI 0.95, 2.84;223 IRR = 1.51 95% CI 0.99, 2.30224).  
Gradual loss of kidney function or kidney failure is known as Chronic Kidney Disease 
(CKD)225,226 whereas Chronic Liver Disease (CLD) characterizes the slow destruction of 
the liver.227 Use of SGAs are associated with an increased risk of developing 
cardiometabolic comorbidities such as diabetes, hypertension and CVD, which are risk 
factors for both CKD and CLD.228,229 People with schizophrenia therefore have a marked 
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increase in the odds or risk of CKD compared to controls, as demonstrated by population-
based studies in Israel (OR = 1.62, 95% CI 1.45, 1.82)230 and Taiwan (HR = 1.25, 95% CI 
1.04, 1.50).231 A Taiwanese-based national cohort study found that people with 
schizophrenia also have increased risk of developing CLD as compared to controls (RR = 
1.15, 95% CI 1.07, 1.24).232  
Loss of bladder control is formally known as urinary incontinence. Risk factors for this 
condition include: female sex, increased age, smoking, obesity, and diabetes.233–235 
Detrusor overactivity resulting from use of SGAs236,237 may explain why people with 
schizophrenia have an increased odds of urinary incontinence, as compared to controls, as 
shown in a recent population-based study (OR adjusted for comorbidity and SGA type = 
1.78, 95% CI 1.26, 2.50).238 
2.4 Multimorbidity 
Chronic conditions may co-occur - the definition, measurement, prevalence, and risk 
factors for this phenomenon will be discussed in this section. 
2.4.1 Multimorbidity: Overview and Definition 
The existence of multiple co-occurring chronic conditions is formally known as 
multimorbidity.65,239–241 There is confusion regarding the use of the term multimorbidity 
versus comorbidity across academic, public health, and clinical settings, as well as 
extensive heterogeneity in its operational definition with respect to the number and types 
of conditions included, the cut-offs and tools used to measure multiple co-occurring 
conditions, and prevalence estimates for multimorbidity. These issues will be discussed 
below. 
2.4.1.1 Comorbidity vs. Multimorbidity 
There are two terms used to refer to people with multiple co-occurring chronic 
conditions. Use of the term multimorbidity indicates no priority or precedence of any 
single chronic condition for the patient, clinician, or researcher, whereas comorbidity is 
used to describe the combined effects of additional chronic conditions when considering 
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one index condition.239,241,242 For instance, we may state that a patient with 
multimorbidity has diabetes mellitus, cancer, and HIV, or that a patient with diabetes 
mellitus has the comorbid conditions cancer and HIV, the latter of which is in reference 
to diabetes mellitus as the index condition. Given the extensive research published on 
multiple chronic conditions in the last two decades239 and previous confusion regarding 
interchangeable use of these terms, there are now separate designated Medical Subject 
Headings (MeSH) for comorbidity and multimorbidity.243  
It is also important to note that the term multimorbidity has not been used extensively to-
date. In 1996, van den Akker and colleagues formally documented the inconsistency and 
ambiguity used to describe the existence of multiple chronic conditions, and called for a 
conceptual organization and distinction from comorbidity.241 A bibliometric analysis of 
publications indexed in the MEDLINE database from 1970 to 2012 demonstrated that 
only 434 publications mentioned multimorbidity, as compared to the 67,557 articles 
which referenced comorbidity.244 The motivation behind its increased use in recent years 
is thought be a response to a call for more holistic, person-centered care in contrast to the 
existing single-disease approach.245,246 Nonetheless, relatively few studies formally 
mention this term in their titles and abstracts,244 including those included in our 
systematic review and meta-analysis (Chapter 3). Authors may be reluctant to use this 
term due to its inability to capture patients’ symptoms and functionality due to chronic 
conditions beyond disease counts, in addition to the heterogeneity associated with its 
definition,245 the latter of which is described below. 
2.4.1.2 Heterogeneity in Operational Definition 
There is extensive heterogeneity with respect to defining the types of chronic conditions 
which constitute multimorbidity, as well the number of conditions required to be 
considered multimorbidity.  
A systematic review on multimorbidity indices247 found that the number of different 
conditions included in various definitions of multimorbidity ranged from four248 to 
102.249 It is postulated that variation in included conditions arises due to different data 
sources and study populations. Data sources may pose limitations due to availability of 
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information on particular conditions.250 Furthermore, definitions of multimorbidity often 
fail to differentiate between diseases (e.g. diabetes) and risk states (e.g. obesity) or 
symptoms (e.g. urinary incontinence) of chronic conditions, thereby creating even greater 
discrepancies in the types of included conditions.251  
In addition to the aforementioned heterogeneity, the cut-offs used to determine 
multimorbidity are also unclear across study contexts. For instance, a person may be 
considered to have multimorbidity with cut-offs ranging from two or more (2+) to five or 
more (5+) co-occurring conditions. This variation may be due to concern about 
prevention and management for research conducted to inform capacity planning and use 
of health services, which warrants a cut-off at 2+ conditions, whereas health care 
providers who are focussed on providing care to patients with more complex needs may 
only consider co-occurrence of conditions as multimorbid after the third, fourth, or fifth 
diagnosis.252–254 However, 2+ and three or more (3+) conditions are the most widely used 
cut-offs when measuring multimorbidity.250,255,256  
2.4.1.3 Operational Definitions of Multimorbidity in Canada 
Definitions of multimorbidity vary both across and within jurisdictions due to differences 
in data sources and target audience, i.e. public health vs. clinical. Fortin and colleagues 
(2010) evaluated multimorbidity using Canadian Community Health Survey (CCHS) data 
for the general population and data abstraction of electronic medical records (EMRs) 
from primary care practices, and compared these prevalence estimates in Quebec for 
adults aged 25 and older. This study found that prevalence estimates of multimorbidity 
were higher in primary care practices, due to the greater number of conditions considered 
and due to patients seeking care for chronic health needs.257  
Primary care definitions of multimorbidity include a greater number of conditions, as 
providers examine a wider number of chronic conditions due to: 
1. The impact of chronic conditions on patients; 
2. The relevance of chronic conditions to health services for primary care; 
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3. The prevalence of chronic conditions among patients who present to primary 
care providers.250 
Conversely, public health professionals, who are concerned about population-level 
impact select conditions based on their duration, population prevalence in the region in 
question, impact on society and the economy, and ability to be targeted by primary 
prevention strategies.65,258,259  
As such, we have several definitions of multimorbidity across Canadian contexts, which 
are detailed in the table below, along with a definition of multimorbidity used by studies 
to assess the burden of multiple co-occurring chronic conditions the province of Ontario 
across different data sources.260,261
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Table 2.1: Included chronic conditions in definitions of multimorbidity across Canadian contexts 
Feature 
Context 
Public Health 
Agency of Canada 
(PHAC) 
PHAC – Canadian Chronic 
Disease Surveillance System 
Primary care context ICES (Ontario) 
Data 
Source 
CCHS65 
Administrative data from 7 
provinces, 3 territories262 
n/a (scoping review)250 ICES data holdings260 
Number of 
conditions 
9 5 20 17 
Included 
conditions 
Arthritis - Arthritis and/or rheumatoid arthritis Rheumatoid arthritis, Osteoarthritis 
Mental disorders Mental illness (omnibus) Depression or anxiety Mood disorder (depression, anxiety, phobia, bipolar disorder) 
Asthma 
Respiratory (Asthma, COPD) Asthma, COPD or chronic bronchitis 
Asthma 
COPD COPD including bronchitis 
Heart disease Cardiovascular (Ischemic heart 
disease, heart failure) 
Cardiovascular disease (angina, MI, atrial fibrillation, 
poor circulation in lower limbs) 
Cardiovascular disease (coronary artery disease, MI, angina, 
peripheral vascular disease, arrythmia) 
- Heart failure Congestive heart failure 
Diabetes mellitus Diabetes Diabetes Diabetes 
Cancer - Cancer Cancer 
Stroke - Stroke/ transient ischemic attack Stroke/ transient ischemic attack 
Alzheimer’s and 
related dementias 
- Dementia or Alzheimer’s Dementia 
- Hypertension Hypertension Hypertension 
- - Chronic musculoskeletal conditions  - 
- - Osteoporosis Osteoporosis 
- - Stomach problems -- 
- - 
Colon problems (IBS, Crohn’s, ulcerative colitis, 
diverticulosis) 
IBD 
- - Chronic hepatitis - 
- - Thyroid disorder - 
- - Kidney disease or failure Chronic kidney disease 
- - Chronic urinary problem Urinary incontinence 
- - Hyperlipidemia - 
- - Obesity - 
- - - HIV 
- - - Chronic liver disease 
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As Table 2.1 illustrates, although there is variation in the types of chronic conditions 
across definitions of multimorbidity, conditions which appear across all contexts include: 
diabetes, mental illness of some form, asthma, COPD, and CVD, owing to their 
prevalence and impact on the Canadian population. There are also broad groupings of 
chronic conditions for disease categories; for example, CVD refers to angina, MI, atrial 
fibrillation, and poor power limb circulation in the definition of Fortin and colleagues 
(2017), and includes coronary artery disease, MI, angina, peripheral vascular disease, and 
arrythmia in the definition of Ryan and colleagues (2018). Mental disorders or mental 
illness also broadly captures a range of mental health conditions in both definitions of 
multimorbidity used by the Public Health Agency of Canada (PHAC).65,262 
2.4.2 Tools used to Measure Multimorbidity 
The variation across definitions of multimorbidity also extends to differences in 
measurement tools or instruments. Systematic reviews of the literature on measures of 
multimorbidity across primary care and community health settings revealed that as many 
as 35 different tools may be employed.263–265 Measures include: disease counts, Adjusted 
Clinical Groups (ACG) System, the Charlson Comorbidity Index, and administrative 
data. The use of different measures reflects variation in the outcome of interest. For 
instance, the Charlson Comorbidity Index or disease counts are best used to assess health 
care utilization and quality of life, whereas the ACG system is best suited for health care 
utilization and costs.263 Furthermore, health administrative data, e.g. medical billings, is 
best used to provide information about large numbers of people.266 Although measures 
may also be combined to increase validity, simple disease counts, complex measures, and 
billings from administrative data are considered accurate in predictive value.263,267 Four 
of these measures are briefly described below. 
Disease counts can be derived from patient self-reports to questionnaires or interviews. 
Alternately, they may reflect clinician diagnoses or disease counts from EMRs and health 
administrative data.263 Fortin and colleagues (2017) developed a questionnaire for 
patients to document 20 self-reported chronic conditions or categories in primary care 
settings. The Charlson Comorbidity Index is another tool used to measure multiple co-
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occurring chronic conditions, and is often considered the most widely-studied validated 
measure of multimorbidity.263 It was intended to evaluate prognosis based on age and 
weight for specific comorbid conditions.268 Alternately, the ACG System is an 
adjustment system which groups diagnosed conditions from EMRs or insurance billings. 
Its development was intended for prediction of morbidity and health care resource 
utilization.269 Finally, health administrative data, e.g. medical billings, are collected for 
administrative and billing purposes, but may be utilized to inform healthcare decision-
making on chronic diseases and risk factors.270,271 A Canadian study found that as many 
as 30 chronic conditions could be identified using health administrative data with 
moderate to high validity.272  
2.4.3 Prevalence of Multimorbidity 
It is difficult to compare prevalence estimates of multimorbidity across settings due to the 
heterogeneity in the types, included conditions, and cut-offs and tools used for 
measurement, as discussed above. As such, estimates of multimorbidity which have been 
presented below are considered with note to their definition, data sources, and 
populations.  
The pooled global prevalence of multimorbidity was estimated as 33.1% (95% CI 30.0–
36.3%) in a systematic review and meta-analysis which evaluated patients of varying 
ages (mean age ranging from 36-75 years) in community-based settings across 18 high-
income countries (HICs) and 31 low-income countries.273 A report from the Academy of 
Medical Sciences, which identifies multimorbidity as a priority for global health research, 
further details that its prevalence is the norm among HICs, but is also becoming 
increasingly prevalent across low- and middle-income countries (LMICs) due to the 
aging population and increasing prevalence of non-communicable diseases.104 
In Canada, the PHAC found that 12.9% and 3.9% of Canadians aged 20 and older had 2+ 
and 3+ chronic conditions, respectively, from a list of 9 conditions and utilizing data from 
the CCHS.65 Another Canadian analysis by the PHAC found that 26.5% and 10.2% of 
Canadians aged 40 and older had 2+ and 3+ chronic conditions, respectively from a list 
of 5 conditions and utilizing provincial and territorial health administrative data holdings 
 
26 
 
in accordance with Canadian Chronic Disease Surveillance System (CCDSS) 
methodology (see Table 2.1 for list of included conditions).262  
Here in Ontario, a retrospective cohort study utilizing ICES data holdings across all age 
groups found that the prevalence of 2+ chronic conditions from a list of 16 increased 
from 17.4% to 24.3% in 2003 and 2009 respectively.274 A more recent cross-sectional 
study using the same data source and a list of 17 conditions revealed an overall 
prevalence of 15.2% (3+ conditions) among Ontario residents of all age groups.260 
2.4.4 Risk Factors for Multimorbidity 
Factors associated with the development of multiple chronic conditions include both 
behavioural and sociodemographic factors. Prior research has demonstrated that 
behavioural risk factors including tobacco use, diet, and physical activity,  and 
sociodemographic characteristics such as sex, age, and SES or material deprivation may 
be associated with multimorbidity.104 Lifestyle factors are particularly important in 
influencing risk for developing multiple co-occurring chronic conditions. Although 
various studies have found conflicting evidence on the association between tobacco use 
and multimorbidity,21,22,275 smoking remains a risk factor for several chronic conditions, 
including CVD and diabetes.19 Low rates of physical activity have also been found to be 
associated with multimorbidity20,21 due to the mediating effects of high BMI and 
obesity,104 which are in turn risk factors for cardiometabolic conditions.  
Sex is a known risk factor for multimorbidity, as demonstrated across studies in both 
LMICs276–278 and HICs279–282. It is postulated that females are more likely than males to 
experience income inequality and be of low SES, and are consequently at higher risk for 
developing multimorbidity.104 Mental-physical comorbidity is also more prevalent among 
females than males.281 Alternately, sex may serve as a proxy for the differential 
recognition of physical symptoms across males and females by health care providers, in 
particular for coronary heart disease283–285 and/or comparatively greater health-seeking 
behaviour by females.281,286–289 
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A systematic review and meta-analysis found that age is a significant determinant of 
multimorbidity, with ORs ranging from 1.26 to 227.46 across 39 studies.290 This finding 
has been replicated by several observational studies where increasing age is associated 
with greater prevalence or increased odds of developing multiple co-occurring chronic 
conditions.65,279,291  
SES or material deprivation has also been identified as a risk factor for multimorbidity, 
but it has a differential impact on the development of multimorbidity in HICs compared 
to LMICs. An inverse relationship between SES and multimorbidity has been 
demonstrated in HICs, with multimorbidity being more prevalent among those of low 
SES or high deprivation.246,279,291 This may be due to the fact that SES underlies access to 
health care, environmental exposure to risk factors for chronic conditions (e.g. smoke and 
pollution), and health behaviours.292 Conversely, affluent residents of LMICs have 
greater access to substances such as tobacco and alcohol and high-calorie foods, which 
contribute to increased risk for developing multiple co-occurring chronic conditions. 
Alternately, they may also have increased access to healthcare and be more likely than 
those from lower income brackets to be diagnosed with chronic diseases.104  
Multimorbidity may also be associated with other sociodemographic characteristics, 
including: ethnicity, level of education, and migration status. A long-term follow-up 
study analyzing data from the Health and Retirement Study found that Non-Hispanic 
Blacks had higher initial chronic disease counts than non-Hispanic Whites (IRR = 1.28, 
95% CI 1.20, 1.36).293 Another US population-based study found that non-Hispanic 
Blacks had greater odds of developing multimorbidity compared to non-Hispanic Whites, 
after adjustment for family income level, employment status, and home ownership.294 
Another risk factor for multimorbidity is level of education. People who did not complete 
high school  (OR = 1.58, 95% CI 1.50, 1.66) and those who completed high school or 
college (OR = 1.32, 95% CI 1.27, 1.37) had a higher odds of developing multiple chronic 
conditions compared to those who had at least a baccalaureate degree.294 Lastly, migrant 
status is also associated with developing multiple chronic conditions. Refugees and 
immigrants may experience deteriorations in their health status after arrival in their host 
countries, due to barriers in accessing health care services, and poorer education and 
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employment prospects. As such, migrant status may be a proxy for other social 
determinants, including education level and SES.295–297 A cohort study found that Danish 
refugee groups were at 20% higher risk of developing multimorbidity as compared to 
native Danes (HR = 1.20, 95% CI 1.15, 1.25).298  
2.4.5 Impact of Multimorbidity 
A recent study called multimorbidity “the most common chronic condition worldwide” 
299, due to its impact on patients, clinicians, and health care systems. Findings from a 
recent systematic review and meta-analysis demonstrate that  multimorbidity is 
significantly associated with a decrease in both mental (−1.55%, 95% CI −2.97, −0.13) 
and physical (−4.37%, 95% CI −7.13, −1.61) health-related quality of life with each 
added disease.300 Clinicians who care for patients with multiple chronic conditions 
experience difficulties in adjusting treatments based on other conditions.104 They also 
face challenges in navigating healthcare services and systems which are fragmented by 
specialty, and in collaborating with other health care providers in shared-decision 
making.301 People with multimorbidity use health care services at a disproportionately 
high rate, contributing to increased use of primary care and hospital admissions.279,280,286 
Furthermore, the cost of care for people with multimorbidity is exponentially greater than 
that for those with individual chronic conditions, as found by a systematic review 
evaluating health care costs across HICs.302 
2.5 Study Rationale and Objectives 
Findings from several studies indicate that there is a widening mortality gap between 
people with schizophrenia and the general population69,303–305 and that these people 
experience longer hospital stays and increased healthcare costs,2,306,307 both of which are 
due to other chronic health conditions. There has been extensive research conducted on 
the types of conditions experienced by people suffering from psychotic disorders,2,3,69,70 
and estimation of the prevalence of multiple co-occurring chronic conditions across the 
general population in global,104,273 Canadian,65,262 and Ontario contexts.260,274 However, 
there is a paucity of research on the excess prevalence of multimorbidity experienced by 
those with psychotic disorders, despite the presence of common risk factors which 
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underlie both psychosis and multimorbidity, such as low SES, ethnic background, and 
migrant status. These shared risk factors may be interrelated and form a unique pattern of 
conditions associated with psychotic disorders.3 
2.5.1 Study Objectives 
There is a gap in research and a need to evaluate the burden of multimorbidity among 
people with psychotic disorders. The overall objective of this thesis was to quantify the 
excess risk or prevalence of multimorbidity experienced by people with psychotic 
disorders. This was achieved through a systematic review and meta-analysis of the 
existing literature (Chapter 3), as well as an analysis of data from a retrospective cohort 
study. The latter assessed whether there was an excess prevalence of multiple chronic 
health conditions 10-years after a first episode of psychosis, compared to people without 
psychotic disorders (Chapter 4). To meet these objectives, our thesis answered the 
following questions:  
1. Is there a significant difference between the risk of multimorbidity for people with 
psychotic disorders and the general population? (Chapter 3) 
2. What is the prevalence of multimorbidity 10-years after a first diagnosis of 
psychotic disorder for people treated by an early intervention program? Do people 
with psychosis have a higher prevalence of multimorbidity as compared to those 
without psychotic disorders? (Chapter 4) 
3. Are increased severity of psychotic symptoms and persistence of impaired 
functioning associated with increased prevalence of multimorbid conditions? 
(Chapter 4) 
4. What are common risk factors for multimorbid health conditions among people 
with psychotic disorders (e.g. age, sex, neighbourhood income level, SES)? 
(Chapter 4) 
We hypothesized that people with psychotic disorders would have a higher risk of 
multimorbidity after first diagnosis, and that certain socioeconomic, lifestyle, and clinical 
factors may have rendered particular subgroups of people more susceptible to the 
development of multiple chronic health conditions. We hope that the findings from this 
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study will facilitate increased surveillance and recognition of the common chronic 
conditions faced by people with psychotic disorders, including those contributing to 
premature mortality. This information will assist decision-makers in creating tailored 
intervention plans to improve the physical health of people with psychotic disorders, and 
integrate care across multiple specialties to reduce the growing burden of disease on the 
Canadian health system. 
2.6 Thesis Format 
This thesis was written in integrated-article style and consists of two independent studies 
in Chapters 3 and 4. 
Chapter 3 presents a systematic review and meta-analysis to summarize the relationship 
between psychotic disorders and multimorbidity. It specifically examines the excess risk 
of multimorbidity experienced by people with psychosis, compared to those without 
psychotic disorders, and presents pooled prevalence estimates of multimorbidity for 
people with psychosis. 
Chapter 4 assesses the excess prevalence of multimorbidity experienced by people with 
psychotic disorders, compared to those without psychosis, using health administrative 
data in Ontario, Canada.  
Chapter 5 summarizes the findings from the integrated articles and describes the 
implications of these findings for patients, clinicians, and policy-makers. It concludes 
with a brief discussion of areas for future research. 
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Chapter 3  
 The Risk of Physical Multimorbidity in People with 
Psychotic Disorders: A Systematic Review and Meta-
Analysis 
3.1 Abstract 
Background: The occurrence of multiple co-occurring chronic health conditions, known 
as multimorbidity, is associated with decreases in quality of life for patients and poses 
unique challenges for healthcare systems. Since people with psychotic disorders have an 
excess of physical health conditions compared to the general population, they may also 
be at a higher risk for multimorbidity. We conducted a systematic review and meta-
analysis to quantify the prevalence and excess risk of multimorbidity among people with 
psychotic disorders, relative to those without psychosis. Methods: We searched the 
MEDLINE, EMBASE, and PsycINFO databases, and conducted forward and backward 
citation tracing of included studies. Studies published after 1990 were included if they 
reported the prevalence of multiple chronic physical health conditions among people with 
psychotic disorders. Data on the prevalence and relative risk of multimorbidity were 
meta-analyzed using random effects models.  Results: Fourteen studies met the inclusion 
criteria, and eight were included in the meta-analysis. Each study used a different 
operational definition of multimorbidity, both for the number and types of chronic 
conditions, which resulted in a wide range in prevalence estimates (16% to 91%). People 
with psychotic disorders had an increased risk of multimorbidity (RR=1.69, 95%CI=1.37, 
2.08), relative to those without psychosis. Conclusions: People with psychotic disorders 
are more likely to experience multimorbidity than those without psychotic disorders. 
Clinicians treating people with psychosis should closely monitor for a range of physical 
health conditions. Future research examining multimorbidity among people with 
psychiatric illness should employ consistent definitions to better enable cross-study 
comparisons.  
Keywords: comorbidity, multimorbidity, multiple chronic conditions, physical health, 
psychotic disorders, systematic review 
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3.2 Introduction 
Chronic conditions are those that require long-term ongoing management,61 and the co-
existence of multiple co-occurring chronic conditions is known as multimorbidity.65 
There is currently no consensus on what constitutes the appropriate number of co-existing 
conditions, nor which particular conditions are to be considered in the operational 
definition of multimorbidity. Across the literature, there is considerable variation in the 
types of included conditions, and cut-offs include two (2+), three (3+), and four (4+) or 
more co-occurring conditions.252,253 This heterogeneity is perceived to be the result of 
contextual variation in the consideration of multimorbidity across clinical and public 
health settings; whereas clinical management of multiple diagnoses is considered 
challenging only after the third diagnosis, concerns about prevention and management for 
public health professionals warrants a cut-off of two co-occurring 
conditions.239,252,253,257,308  
Despite these inconsistencies, however, it is clear that the prevalence of multimorbidity 
has increased. One-third of Canadians live with at least one chronic condition, with 2+ 
and 3+ conditions affecting over 12% and 3% of Canadians, respectively.65,66 The 
prevalence of multimorbidity is expected to increase with the aging population and 
increased exposure to risk factors for chronic conditions.309 The co-occurrence of 
multiple chronic conditions poses a unique set of challenges for healthcare systems, 
clinicians, and patients. People with multimorbidity contribute to exponentially greater 
costs for health care systems as compared to those with individual chronic conditions due 
to increased use of primary care and hospital admissions. 302 Furthermore, health care 
providers must make adjustments to treatments based on other conditions, and liaise with 
other clinicians for shared decision-making in healthcare systems that are fragmented by 
specialty.301 Findings from a recent systematic review and meta-analysis also show that 
multimorbidity is significantly associated with a decrease in mental and physical health-
related quality of life with each additional chronic condition.300 
People with psychotic disorders have a reduced life expectancy of 14.5 years (95% 
CI=11.2, 17.8) compared to the general population.68,310 This premature mortality is 
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primarily due to differences in physical health and preventable physical conditions.2,3 
Prior systematic reviews suggest that people with schizophrenia and other psychotic 
disorders have a higher prevalence of several chronic physical health conditions, 
including HIV, diabetes mellitus, as well as gastrointestinal, cardiovascular, and 
respiratory diseases.4,141 There is also evidence of an three-fold gap in standardized all-
cause mortality rates (SMR) between people with schizophrenia and the general 
population (SMR=3.0%, 95%CI=0.1,6.0).71,303  
The increased risk of chronic health conditions among people with psychosis may be due 
to ongoing treatment with second-generation antipsychotic medications, which are 
associated with cardiometabolic side effects such as weight gain and impaired glucose 
metabolism.4–7 These side effects may predispose patients to chronic physical health 
conditions, including cardiovascular disease and diabetes mellitus.8–10 People with 
psychotic disorders also have a higher prevalence of smoking,11,12 poor nutritional 
habits,14,15 disrupted sleep patterns,111 and sedentary behaviour13 compared to the general 
population. These lifestyle factors are particularly important in influencing the risk of 
various chronic conditions,19–21 including cardiometabolic8–10,16,17,109,110,113 and 
respiratory18 diseases. Moreover, sociodemographic characteristics, including ethnic 
background and socioeconomic status (SES) are associated with psychosis and 
multimorbidity;33 people from non-White backgrounds and materially-deprived areas 
experience a higher incidence of both psychotic disorders40–44 and 
multimorbidity.246,279,291,293,294 
Despite extensive evidence on the increased risk of chronic physical conditions among 
people with psychotic disorders, there has been a paucity of research on the risk of 
multimorbidity3 and no prior systematic review and meta-analysis on this topic. The 
objective of our review was to quantify the prevalence of multimorbidity among people 
with psychotic disorders, and to assess the risk of multimorbidity relative to people 
without psychotic disorders. 
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3.3 Methods 
3.3.1 Protocol 
Our systematic review and meta-analysis followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) statement311 (Supplementary 
Appendix 3A). The protocol for our review was registered in PROSPERO 
(CRD42019112512).312 
3.3.2 Search Strategy and Study Selection 
We searched the MEDLINE, EMBASE, and PsycINFO electronic databases in 
September 2019 using the Ovid platform.  An academic librarian assisted with the 
development of the search strategy, which involved a combination of keywords and 
controlled vocabulary that were specific to each database (Supplementary Appendix 3B). 
We limited the search to human subjects, and restricted records to the English language 
and to those published after 1990, which was the year when second-generation 
antipsychotic medications came onto the market.75 Forward and backward citation tracing 
of included articles was also used to identify relevant studies that may have been missed 
by the main search strategy.   
Both level 1 (title and abstract) and level 2 (full-text) screening were performed 
independently by two reviewers (MR & JCW), with discrepancies resolved by discussion 
and consensus, and conflicts resolved by a third reviewer (KKA) as necessary. Studies of 
all designs, including both experimental and observational, were considered for inclusion. 
Studies were included if: (i) the study population was limited to people with psychotic 
disorders, or stratified data were presented for people with psychosis; and (ii) the study 
assessed the prevalence of multimorbidity, defined as the presence of 2+ and/or 3+ 
conditions from a defined list of chronic physical health conditions; or (iii) the study 
presented proportions or data which enabled computation of proportions of 
multimorbidity among people with psychotic disorders. The cut-offs for the number of 
conditions was based on commonly-used definitions of multimorbidity in public health 
and clinical settings, respectively.252,253,257 We excluded studies that focused exclusively 
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on co-morbid mental and substance use disorders, due to our principal focus on physical 
health conditions among people with psychosis. 
3.3.3 Data Extraction and Risk of Bias Assessment 
Data extraction was completed independently by two reviewers (MR & JCW) using 
standardized tools developed a priori. We extracted data on characteristics of the study 
(e.g. design, country) and sample (e.g. case composition), ascertainment of exposure (i.e., 
psychosis) and outcome (i.e., multimorbidity), the considered risk factors for 
multimorbidity, and the proportions of people with 2+ and 3+ chronic conditions among 
the exposed group and comparison group. Risk of bias assessments were also conducted 
independently by two reviewers using the CLARITY tools for case-control313 and 
cohort314 studies, which we adapted for cross-sectional studies (Supplementary Appendix 
3C).  
3.3.4 Data Synthesis  
We synthesized the characteristics and findings of included studies in a summary table, 
including the number and types of conditions across the multimorbidity definitions, as 
well as findings regarding the prevalence and risk of multimorbidity for people with 
psychotic disorders.   
All meta-analyses were conducted using Stata version 13.0315 with random effects models 
to account for heterogeneity in the study methodology (e.g. number and type of chronic 
conditions) and sample characteristics.316,317 We stratified the analyses by study design 
where applicable, and also computed a common pooled effect estimate. For both 
stratified and pooled estimates, we assessed statistical heterogeneity using the I2 statistic, 
which can be interpreted as low (>25%), moderate (>50%), or high (>75%) 
heterogeneity.317,318  
First, we conducted meta-analyses to compute a pooled estimate of the prevalence of 
multimorbidity among people with psychotic disorder using the metaprop command; 
study-specific confidence intervals (CIs) were computed using the exact method to yield 
the most conservative estimates.319 The analysis for the prevalence of multimorbidity (2+ 
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and 3+ chronic conditions) was stratified by study design, and then combined to obtain a 
common pooled estimate with 95% CI.  
Second, we pooled study effect estimates to assess the risk of multimorbidity (2+ chronic 
conditions) among people with psychotic disorder (exposed group), relative to those 
without psychosis (unexposed group), using the metan command.320 We pooled 
prevalence ratios (PR) with 95% CI for cross-sectional studies where incidence could not 
be assessed, and risk ratios (RR) with 95% CIs for cohort studies where the incidence of 
multimorbidity was estimated. PRs can be pooled with RRs to obtain a common risk 
estimate,321 which may be interpreted as a RR, when the exposure (i.e. psychosis) does 
not impact the duration of the outcome (i.e. multimorbidity). We used this approach 
rather than a pooled odds ratios (OR), given that the OR overestimates the RR when the 
outcome is common (i.e. prevalence of multimorbidity > 5% to 10%).318,322–325  
We conducted sensitivity analyses to assess: (i) the excess risk of 3+ chronic conditions 
among those with psychotic disorders; and (ii) the impact of study quality on estimates, 
after removing studies that scored ‘intermediate’ or ‘high’ on any risk of bias domains. 
We also performed an exploratory analysis to assess the impact of excluding substance 
use disorders and mental health conditions from multimorbidity definitions by separately 
pooling studies that only examined physical health conditions. Given that we had fewer 
than 10 studies for our meta-analysis, we were unable to perform meta-regression to 
explore sources of heterogeneity or assess publication bias through funnel plots.318  
3.4 Results 
Our search strategy retrieved 4,141 records, and we reviewed 81 full-text studies for 
inclusion (Figure 3.1). Fourteen studies met our inclusion criteria, and a detailed list of 
reasons for exclusion is presented in Figure 1. The included studies reported data on the 
proportion of people with psychosis who had 2+ and/or 3+ chronic physical conditions, 
or enabled us to calculate the prevalence or risk of multimorbidity (2+ and 3+ conditions) 
for patients with psychosis.  
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The characteristics of included studies are summarized in Table 3.1. Studies were 
conducted in various settings, including the UK (n=2),326,327 USA (n=4),174,328–330 Europe 
(n=5),331–335 and Middle East/South Asia (n=2),336,337 with one study338 reporting data on 
48 low- and middle-income countries. Studies also varied in methodological design, 
including cross-sectional (n=6),326–328,332,337,338 case-control (n=1),336 and both prospective 
(n=1)334 and retrospective (n=6)174,329–331,333,335 cohort studies. The presence of a 
psychotic disorder was determined through administrative data, chart reviews, and patient 
self-reports, whereas the multimorbidity outcome was ascertained through administrative 
data, patient self-reports, physician claims, pharmacy records, and various comorbidity 
indices. Case definition of psychosis was restricted to people with non-affective 
psychotic disorders (e.g. schizophrenia, schizoaffective disorder) in twelve174,326,328–337 
studies, and was not reported in the remaining two327,338 studies.  The mean age of people 
with psychotic disorders ranged from 28 to 52 years across the studies, and the 
percentage of males ranged from 16% to 76%. 
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Figure 3.1: PRISMA diagram of study identification and selection for systematic 
review and meta-analysis 
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Table 3.1: Summary of the characteristics of included studies (n=14) 
Study Country Study Design Sample Size 
Mean Age of 
Cases in years (sd) 
Number of 
Males in Case 
Sample (%) 
Diagnostic 
Criteria for 
Psychosis 
Source of 
Psychosis 
Diagnosis 
Multimorbidity 
definition: 
number of 
included 
conditions 
Inclusion of 
mental health in 
definition of 
multimorbidity 
Source of Multimorbidity 
conditions 
Bhalla et al., 2018 USA Cross-Sectional 843,583 NR NR ICD-9 
Registry/Admin 
data 
40 ✓ Charlson Comorbidity Index 
Bouza et al., 2010 Spain Retrospective Cohort 16,776 43.5 (16) 10,952 (65%) ICD-9 
Registry/Admin 
data 
12 (clusters)  ICD-9 Codes 
Carney et al., 
2006* 
USA Retrospective Cohort 727,336 40.2 (11.9) 505 (47%) ICD-9 
Registry/Admin 
data 
46 ✓ Elixhauser Comorbidity Index 
Correll et al., 
2017* 
USA Retrospective Cohort 182,309 49.8 (NR) 103,916 (57%) ICD-9 CM codes 
Registry/Admin 
data 
6  ICD-9 CM codes 
Domino et al., 
2014 
USA Retrospective Cohort 188,531 
stratified results 
presented only 
stratified 
results 
presented only 
Claims Diagnoses 
Registry/Admin 
data 
6  Claims diagnoses 
Filipcic et al., 
2019 
Croatia Cross-Sectional 1,166 NR 184 (16%) None described Self-Reports 15  Self-reports 
Gabilondo et al., 
2017 
Spain Retrospective Cohort 2,255,406 48.6 (NR) 
4,429 (60.4%) 
 
None described 
Registry/Admin 
data 
47  
Diagnoses in chart reviews - 
not specified 
Islam et al., 2017* 
Netherlan
ds and 
Belgium 
Prospective Cohort 2,584 27.8 (8.2) 
1,951 
(75.50%) 
ICD-10 Chart Reviews 121 ✓ 
Self-reports + Pharmacy 
records 
Jahrami et al., 
2017 
Bahrain Case-Control 240 41.69 (13) 66 (55%) None described 
Registry/Admin 
data 
4  
National Health Information 
System Bahrain 
Kugathasan et al., 
2019 
Denmark Retrospective Cohort 5,432,821 32.59 (11.42) 17,288 (57%) ICD-8 or ICD-10 
Registry/Admin 
data 
10 (clusters)  ICD-10 codes 
Nishanth et al., 
2017 
India Cross-Sectional 100 35.12 (10.7) 55 (55%) DSM-IV Not Described Not Described Not described Not described 
Smith et al., 2013 UK Cross-Sectional 1,424,378 51.6 (16.5) 4,961 (51.5%) Read codes 
Registry/Admin 
data 
32  Not described 
Stubbs et al., 2016 
Internatio
nal 
Cross-Sectional 207,146 NR NR 
WHO Composite 
International 
Diagnostic 
Interview  
Self-Reports 9  Self-reported 
Woodhead et al., 
2014* 
UK Cross-Sectional 308,643 48.7 (NR) 2,432 (56%) None described EHRs 12  
Binary (Y/N) variables in 
EHRs 
Notes:  
*Baseline characteristics for these studies are based on the sample sizes reported in this table, and do not account for loss to follow-up. Meta-analyses have been conducted on the observed number of cases and controls, accounting 
for loss to follow-up. 
Abbreviations: 
DSM = Diagnostic and Statistical Manual of Mental Disorders; EHR = electronic health record; ICD = International Classification of Diseases; NR = not reported; SD = standard deviation; Y/N = yes/no variables 
Legend: 
✓Mental health condition(s) included in study definition of multimorbidity  
 No mental health condition(s) included in study definition of multimorbidity 
 
40 
 
The studies varied with respect to the number (range: 6 to 121) and types of chronic 
conditions included in definitions of multimorbidity (see Supplementary Appendices 3D-
3E for the conditions examined by individual studies). All studies included both diabetes 
mellitus and some form of chronic cardiovascular disease, such as hypertension, coronary 
heart disease, myocardial infarction, ischemic stroke, or atrial fibrillation. Eleven studies 
counted individual conditions,174,326–330,332–334,336,338 whereas two studies organized 
conditions into disease clusters (e.g. infectious diseases, respiratory diseases) and 
conditions within the same cluster counted as one chronic condition.331,335 Three studies 
considered substance use and/or mental disorders in their definitions of multimorbidity, 
and counted each distinct type of substance use or mental disorder as a separate 
condition. Psychotic disorder was not included in these definitions, as it was considered 
the exposure variable.174,328,334  
Studies investigated sociodemographic (e.g. age, sex, SES), clinical (e.g. healthcare use, 
medication use), and lifestyle (e.g. smoking, alcohol use, body mass index (BMI)) factors 
associated with multimorbidity. Five studies investigated age as a risk factor for 
multimorbidity,331,332,334,337,338 and three of these studies found older age to be 
significantly associated with multimorbidity.331,334,337 One of the studies noted an 
interaction between age and sex, where female cases under 35 years of age had a higher 
prevalence of multimorbidity compared to same-aged female controls.332 Five of 
six326,331–334,337 studies which examined sex as a risk factor found that females with 
psychotic disorders were significantly more likely to experience multimorbidity than 
males. One study investigated quality of care metrics for people with schizophrenia who 
had other co-occurring chronic health conditions, and observed a positive association 
between adherence to antipsychotic medications and number of medical conditions.330 
Both studies that investigated smoking and alcohol consumption found that alcohol was 
associated with multimorbidity, and that smoking accounted for excess physical 
morbidity related to specific chronic conditions (e.g. heart failure, COPD, epilepsy).327,336  
Findings for other risk factors for multimorbidity among people with psychotic disorders 
are summarized in Table 3.2 and Supplementary Appendix 3F. 
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The findings from the risk of bias assessment for included studies are presented in Figure 
3.2 and Supplementary Appendix 3C. We found that only two studies completely satisfied 
all domains.329,330 Common issues included: selection of the source population and 
exposed or unexposed cohorts; assessment of exposure, outcome, and confounding 
factors; and missing data. 
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Table 3.2: Brief summary of findings from included studies on factors associated with multimorbidity among people with 
psychosis (n=14) 
Notes: 
1Studied factors related to mortality among patients with schizophrenia due to 2+/3+ physical health conditions 
2Studied quality care metrics among patients with schizophrenia with co-occurring 2+/3+ physical health conditions 
3Smoking and alcohol use studied as a risk factor for multimorbidity, not included in counts of chronic conditions  
Legend: 
✓Positive association between risk factor and prevalence/ odds/ incidence of multimorbidity 
↓Inverse association between risk factor and prevalence/ odds/ incidence of multimorbidity 
 No significant association between risk factor and prevalence/ odds/ incidence of multimorbidity 
- Association not studied 
Study Case Sample 
Low 
SES 
Homelessness 
High BMI or 
Excessive Dietary 
Intake 
Increased 
Age 
Female 
Sex 
Rural 
Settings 
Healthcare 
Use 
Mortality 
Medication 
Use and 
Adherence 
Smoking and 
Alcohol Use3 
Bhalla et al., 
2018 
Veterans in mental health specialty 
clinics 
✓ ✓ ✓ - - - - - - - 
Bouza et al., 
20101 
Inpatients in hospitals across country - - - ✓  - - - - - 
Carney et al., 
2006 
Outpatients in practices across state - - - - -  ✓ - - - 
Correll et al., 
20171 
Inpatients in hospitals across country - - - - - - ↓ ✓ - - 
Domino et al., 
20142 
Outpatients and inpatients among 
Medicaid enrollees 
- - - - - - - - ✓ - 
Filipcic et al., 
2019 
Stable outpatients who were once 
treated as inpatients at 1 academic 
psychiatric institution 
- - -  ✓ - - - - - 
Gabilondo et 
al., 2017 
Outpatients and inpatients in 
practices across county 
- - - - ✓ - - - - - 
Islam et al., 
2017 
Outpatients of academic psychiatric 
institutions across country 
- - - ✓ ✓ - - - - - 
Jahrami et al., 
2017 
Outpatients of 1 academic psychiatric 
institution 
- - ✓ - - - - - - ✓ 
Kugathasan et 
al., 20191 
Outpatients and inpatients of 
psychiatric hospitals across country 
- - - - - - - ✓ - - 
Nishanth et 
al., 2017 
Outpatients of 1 academic psychiatric 
institution 
- - - ✓ ✓ - - - ✓ - 
Smith et al., 
2013 
Outpatients of primary care practices 
across country 
- - - - ✓ - - - - - 
Stubbs et al., 
2016 
Persons with psychosis across 48 
low- and middle-income countries 
- - - ↓ - - - - - - 
Woodhead et 
al., 2014 
Outpatients of family physicians’ 
practices across borough 
- - ✓ - - - - - - ✓ 
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Figure 3.2: Risk of bias assessment across included studies (n=14) 
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3.4.1 Meta-Analyses  
Across the thirteen studies included in our quantitative synthesis of 2+ chronic physical 
health conditions (pooled n=211,093), the pooled prevalence of multimorbidity among 
people with psychotic disorders was 43% (95%CI=25%,60%; I2=99.9%). Prevalence 
estimates across individual studies varied with the number of conditions included in 
multimorbidity definitions, ranging from 16% to 91% (Supplementary Appendix 3G). 
Across the nine studies reporting data on 3+ chronic physical health conditions (pooled 
n=142,568), the pooled prevalence among people with psychotic disorders was 22% 
(95%CI=14%,30%; I2=99.9%; Supplementary Appendix 3H).  
Our meta-analysis of eight studies (pooled n=10,253,920) reporting risk of 2+ chronic 
conditions found that the risk of multimorbidity was 69% higher among people with 
psychotic disorders, relative to people without psychosis (RR=1.69, 95%CI=1.37,2.08; 
I2=99.7%). The magnitude of effect was similar for the pooled estimates from the four 
cross-sectional studies (pooled n=1,915,810; PR=1.77, 95%CI=1.15,2.74; I2=99.5%) and 
the four cohort studies (pooled n=8,338,110; RR=1.60, 95%CI=1.14,2.24; I2=99.7%) 
(Figure 3.3). 
3.4.1.1 Sensitivity Analyses 
We found a larger magnitude of effect for our sensitivity analysis of 3+ chronic 
conditions, where people with psychotic disorders had a nearly three times greater risk of 
multimorbidity (RR=2.68, 95%CI=1.45,5.10; I2=99.9%) relative to those without 
psychosis (Supplementary Appendix 3I). Sensitivity analyses restricted to studies which 
met all criteria in our risk of bias assessment yielded similar effect estimates as the main 
analysis (Supplementary Appendix 3J). An exploratory analysis of six studies (pooled 
n=9,604,037) which only considered physical health conditions in their definitions of 
multimorbidity also yielded similar findings as the main analysis (RR=1.62, 
95%CI=1.36,1.94; I2=99.4%; Supplementary Appendix 3K). 
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Figure 3.3: Risk of multimorbidity (2+ conditions) for people with psychosis compared to people who do not have psychotic disorders (n=8) 
 
 
Abbreviations:  
CI = confidence interval; RR = risk ratio 
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3.5 Discussion 
The findings from our systematic review and meta-analysis suggest an increased risk of 
multimorbidity among people with psychotic disorders. The excess risk of having 2+ 
chronic health conditions was found to be 69% higher among people with psychotic 
disorders, relative to people without psychosis. Furthermore, people with psychosis had a 
nearly three times greater risk of developing 3+ chronic conditions. This finding may 
potentially be due to the cardio-metabolic disturbances caused by antipsychotic 
medications, as well as behavioural risk factors such as smoking, physical inactivity, and 
poor dietary patterns, which increase the risk of several chronic health conditions.4,141 
Our exploratory analysis of studies which did not consider substance use and other 
mental health conditions in definitions of multimorbidity found similar effect sizes. We 
expected to see a smaller magnitude of effect for this analysis due to the comorbidity 
between mental health conditions, but this may be explained by diagnostic 
overshadowing of psychosis over other mental health conditions with psychotic-like 
symptoms.339,340  
Factors associated with multimorbidity among people with psychotic disorders included 
sociodemographic characteristics such as female sex and older age, and behavioural risk 
factors such as substance use, sedentary behaviour, high caloric intake, and high BMI. 
Several studies of the general population have documented higher risk of multimorbidity 
among females,246,257,341–343 potentially owing to lower healthcare utilization by men and 
consequent under-recognition of chronic medical conditions.288,289 Primary studies in our 
review found that older age was a risk factor for development of multiple chronic 
conditions, but two studies noted high odds or prevalence of multimorbidity among 
younger persons with psychosis relative to those without psychotic disorders. Other 
population-based studies have also found that although older cohorts have the highest risk 
of developing multiple chronic conditions,246,260 there is a high prevalence of 
multimorbidity across all age groups, including those in the youngest cohorts.274 
Excessive dietary intake, low physical activity, and substance use are risk factors for 
several cardiometabolic conditions such as diabetes and hypertension.344 These lifestyle 
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factors are prevalent among both younger people345,346 and those with psychosis,11–13 
which may explain the high prevalence of multimorbidity observed among younger 
people with psychotic disorders.  
Our systematic review and meta-analysis findings also highlight the extensive 
heterogeneity associated with operational definitions of multimorbidity across the 
literature, both in the number and types of included chronic conditions, which is a 
common issue in multimorbidity research.252,253 The implications of this issue were 
evident in the wide range of prevalence estimates (16% to 91%) across studies included 
in our review. The variation in the number of conditions stems from considerations for 
the prevention and management of chronic conditions across public health (2+) and 
clinical (3+) settings,252,253,257 but may also reflect regional differences regarding chronic 
conditions which merit consideration.257,300 However, conditions in the metabolic 
syndrome, such as diabetes and cardiovascular disease were included in the definition for 
all studies owing to the high prevalence of these conditions, both among the general 
population and people with psychotic disorders.4,141,347–349 Furthermore, the majority of 
studies in our review (n=11/14) did not consider substance use or mental health 
conditions in their definitions of multimorbidity. This raises important questions 
regarding the inclusion of mental health conditions generally, and psychotic disorders 
specifically, in the definitions of multimorbidity when attempting to assess the risk 
among people with psychosis. The Public Health Agency of Canada considers mental 
health conditions as a broad category,65,262 such that people with any number of mental 
disorders are counted only once according to their definition of multimorbidity. Although 
this approach takes into account the high degree of comorbidity among diverse mental 
health conditions,339 effect estimates would be of even greater magnitude if we were to 
consider each psychiatric disorder separately in defining multimorbidity. Further, if we 
were to consider the exposure condition of psychotic disorder in definitions of 
multimorbidity, such that people with schizophrenia and other psychotic disorders 
already have one chronic health condition, effect estimates for the observed excess risk of 
multimorbidity would be even higher. 
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Our risk of bias assessment indicated that several studies failed to consider confounding 
factors beyond age, sex, and SES. In the future, studies should account for notable 
confounders such as duration of antipsychotic medication use139  and common 
behavioural risk factors (e.g. smoking, low physical activity),19–21 which is a limitation of 
using health administrative data.350 Future studies should also use similar operational 
definitions for multimorbidity, in terms of both the number and types of chronic 
conditions included, in order to better enable cross-study comparisons. Moreover, further 
investigation of specific clusters of chronic conditions commonly experienced by this 
clinical population is warranted.  
3.5.1 Limitations 
Our findings should be interpreted with consideration of the limitations of included 
studies. Several studies were cross-sectional, which makes it challenging to establish 
temporality between psychosis and multimorbidity,351 as people with psychotic disorders  
may have chronic health conditions prior to the onset of psychosis.352 Assessment of 
chronic conditions also occurred by self-report in some studies. Although this method has 
been shown to have a high degree of reliability in ascertaining chronic health conditions 
among patients with mental illness,353 it is a potential source of misclassification for the 
studies included in our review. 
The methodological limitations of our review should also be noted. First, most included 
studies were not designed with a primary objective of examining the risk of 
multimorbidity among people with psychotic disorders, and our search strategy may have 
missed studies that did not use the terms “multimorbidity” or “comorbidity” in their titles 
or abstracts. Second, risk of bias assessment was conducted using the CLARITY tools, 
which were originally designed for case-control313 and cohort314 studies, but were adapted 
for the cross-sectional studies in our review. Third, we pooled PR and RR into a common 
estimate under the assumption that psychotic disorders do not impact the duration of 
multimorbidity,321 which may not be valid for conditions where the presence of psychotic 
symptoms may impact illness duration. Fourth, we cannot rule out systematic 
underreporting by studies with null findings, as we had fewer than the number of studies 
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required to assess this publication bias.318 Finally, we found a high degree of statistical 
heterogeneity in our pooled estimates, which made it difficult to compare prevalence 
estimates across studies. This heterogeneity may be partially explained by the wide 
variation in definitions of multimorbidity and different compositions of samples. Neither 
the severity of illness nor the subsequent duration of antipsychotic treatment were 
considered when evaluating the risk of multimorbidity, which may differ greatly among 
people with more severe psychoses, affective psychotic disorders, or longer duration of 
treatment with antipsychotic medications.139 However, we were unable to examine the 
sources of heterogeneity using meta-regression, given that we had fewer than 10 studies 
for our meta-analysis.318  
3.5.2 Conclusions 
Our systematic review and meta-analysis highlight a greater risk of physical 
multimorbidity among people with psychotic disorder. This burden of illness is likely to 
reflect both exposure to antipsychotic medications as well as a higher prevalence of 
behavioural risk factors. Clinicians who care for patients with psychosis should routinely 
assess for risk of physical health conditions and work to integrate care across medical 
specialties to better manage the unique needs of this population. 
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Chapter 4  
 The Prevalence of Multimorbidity among People with 
Non-Affective Psychotic Disorders 10-Years after First 
Diagnosis 
4.1 Abstract 
Background: An excess risk of physical health conditions among people with psychotic 
disorders may result in a reduced life expectancy, as compared to those without 
psychosis. It is unknown whether those with psychotic disorders also have a higher risk 
of multiple co-occurring chronic health conditions, known as multimorbidity. We 
conducted a retrospective matched cohort study to quantify the prevalence of 
multimorbidity and associated factors among people with psychotic disorders over the 
10-year period following first diagnosis, relative to those without psychosis. Methods: 
Data from the Prevention and Early Intervention Program for Psychoses in London, 
Canada were linked to population-based health administrative data to identify patients 
with first-episode of psychosis (n=439), and a comparison group from the general 
population (n=1,759) matched on age, sex, and neighbourhood. We followed the cohort 
for ten years to ascertain the prevalence of multimorbidity. We compared people with and 
without psychosis using modified Poisson regression models, and explored risk factors 
for multimorbidity among those with psychotic disorder. Results: People with psychotic 
disorders may have a 26% higher prevalence of multimorbidity ten years following first 
diagnosis, although our findings include the possibility of a null effect (PR=1.26, 
95%=CI 0.96,1.66). Twenty-six to thirty-year olds with psychosis had a higher 
prevalence of multimorbidity than those aged 16-20 years (PR=1.77, 95%CI=0.98,3.21). 
People with psychotic disorders living in areas with the highest levels of material 
deprivation had a three-fold higher prevalence of multimorbidity as compared to those in 
the lowest areas of material deprivation (PR=3.09, 95%CI=1.21,7.90). Conclusions: 
More research is needed to better understand multimorbidity among people with serious 
mental illness, particularly studies using larger sample sizes and longer follow-up 
periods.  
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Keywords: comorbidity, multimorbidity, multiple chronic conditions, physical health, 
psychotic disorders  
 
4.2 Introduction 
People with schizophrenia and other psychotic disorders have a reduced life expectancy 
of up to 20 years compared to the general population,1 primarily due to differences in 
physical health and preventable physical illnesses.2,3 Several studies have found that 
people with schizophrenia experience longer hospital stays and increased healthcare costs 
for chronic health conditions, relative to the general population.2,306 Furthermore, 
mortality gaps are widening between those with and without psychotic disorders,303,305 
largely due to presence of chronic health conditions. Diabetes mellitus, infection with 
human immunodeficiency virus (HIV), and cardiovascular and respiratory diseases are 
several chronic conditions found to be highly prevalent among people with psychosis.4 
The differences in the risk of chronic conditions for this clinical population may be 
explained by ongoing treatment with second-generation antipsychotic medications. These 
interventions may result in metabolic side effects such as weight gain and impaired 
glucose metabolism,4–7 which are associated with an increased risk of cardiovascular 
disease and diabetes mellitus.8–10  Furthermore, the high prevalence of lifestyle factors 
such as risky sexual behaviours218 and smoking11–13 among people with psychotic 
disorders may explain why the relative risk of HIV infection and respiratory illness is 
higher among this clinical population.4  
Although there is a vast body of evidence on the increased risk of individual chronic 
physical conditions among people with schizophrenia and other psychotic disorders, 
research on the co-existence of multiple co-occurring chronic conditions – known as 
multimorbidity – is more limited.3 Operational definitions of multimorbidity vary 
extensively across studies with respect to the types of chronic conditions included and 
cut-offs for the number of co-existing conditions, ranging from two to four co-occurring 
conditions.252 Considerations of multimorbidity across public health and clinical settings 
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may explain this heterogeneity, as prevention and management of chronic diseases is 
concerning for public health professionals at two co-occurring conditions, whereas 
clinical management of multiple diagnoses typically pose a challenge for clinicians after 
the third diagnosis.252,253  
Evidence to date suggests that both psychosis and multimorbidity share common risk 
factors. Lifestyle factors, such as smoking and sedentary behaviour, influence risk for 
cardiometabolic,16,17 respiratory,18 and other chronic conditions19–21 and are more 
prevalent both among people with multimorbidity20–22 and those with psychotic 
disorders.11–13 Furthermore, studies indicate that people from non-White ethnic 
backgrounds and materially-deprived areas experience a higher incidence of both 
psychosis33,40–44 and multimorbidity.246,279,291,293,294 Risk factors underlying the co-
existence of multiple chronic conditions and psychotic disorders may be interrelated and 
form unique clusters of conditions.3 
There have been few large-scale studies to date quantifying the excess prevalence of 
multimorbidity experienced by people with schizophrenia and other psychotic disorders. 
The objective of our study was to estimate the excess prevalence of multiple chronic 
conditions 10-years after a first episode of psychosis, compared to people without 
psychotic disorders matched on age, sex, and neighbourhood. Although psychosis is a 
chronic condition,61 we excluded it as a count towards multimorbidity in our main model, 
given that it was the exposure of interest and it is not typically included in standard 
multimorbidity definitions.250,260  
We sought to: (i) estimate the prevalence of multimorbidity 10-years after a first 
diagnosis of non-affective psychotic disorder, and assess whether it was significantly 
different relative to people without psychotic disorders; (ii) evaluate the effect of age, sex 
and material deprivation on the prevalence of multimorbidity separately for people with 
and without psychotic disorders; and (iii) investigate whether severity of psychotic 
symptoms and persistence of functioning impairments were associated with a higher 
prevalence of multimorbidity among people with psychotic disorders. We hypothesized 
that people with psychotic disorders would have a higher prevalence of multimorbidity, 
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and that sociodemographic and clinical factors may render subgroups of this clinical 
population particularly susceptible to the development of multiple chronic health 
conditions. 
4.3 Methods 
We followed the REporting of studies Conducted using Observational Routinely-
collected health Data (RECORD) guidelines for observational studies (see Supplementary 
Appendix 4L).354 We obtained approval using an existing Health Sciences Research 
Ethics Board application at Western University (protocol #112446) to link the primary 
data from the early psychosis intervention program, described below. 
4.3.1 Data Sources 
We used the following population-based databases housed at ICES, which compiles 
health administrative data for the province of Ontario:355 According to Ontario’s Personal 
Health Information Privacy Act,356 ICES is a prescribed entity, and permitted to collect 
personal health information on Ontario’s patients from physicians, hospitals and long-
term care homes without prior patient consent. Information used by ICES is for 
evaluation and monitoring of Ontario’s health care system and approved research. Data 
sharing agreements between ICES and data partners who access ICES data detail security 
measures which ensures privacy of sensitive patient health data.357 
• Demographic information about people registered for the Ontario Health 
Insurance Plan (OHIP), such as date of birth, sex, and neighbourhood-level indicators of 
deprivation, is collected and stored in the Registered Persons Database by the Ontario 
Ministry of Health and Long-Term Care. Nearly the entire population of Ontario (98.5%) 
is covered for medically necessary health services by OHIP.358–361 
• The Ontario Mental Health Reporting System (OMHRS), which contains 
standardized information on clinical and administrative mental health data for all patients 
admitted to designated adult psychiatric inpatient beds.  
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• The Discharge Abstract Database (DAD) maintains administrative, clinical, and 
demographic information from acute care settings for people discharged from other 
hospital inpatient units, and for psychiatric hospitalization not covered by OMHRS.  
• The OHIP Claims Database contains data on physician billing claims, including 
information on the type, date, and the diagnosis made during the provision of services.362  
• The National Ambulatory Care Reporting System (NACRS) stores administrative, 
clinical, and demographic information for emergency departments, day surgeries, and 
hospital and community-based ambulatory care.362  
• Information about prescription drugs issued under the Ontario Drug Benefit 
(ODB) program is routinely collected and stored in the ODB Claims Database, which 
excludes the majority of drugs prescribed in Ontario that are not issued under this 
program.362 The ODB covers Ontario residents with a valid health card who are either 
below 25 or over 65 years of age, or those who live in a Long-Term Care Home, are 
enrolled in the Home Care Program, are low income residents registered in the Trillium 
Drug Program due to inability to pay for prescription drugs, or receive governmental 
social assistance.363 
These ICES databases were also linked to primary data from the Prevention and Early 
Intervention Program for Psychoses (PEPP) using health insurance numbers (96% of 
clinical sample). This primary data linkage was needed to identify PEPP clients within 
the health administrative data holdings. Unique encoded identifiers were used to link all 
datasets by analysts at ICES, and remote data access was made available through the 
ICES Data & Analytic Services division.364 
4.3.2 Study Design and Sample 
We used a retrospective cohort design to investigate the association between psychosis 
and multimorbidity over a ten-year follow-up period, the duration for which we had 
follow-up data.  
People with first-episode psychosis treated at PEPP in London, Ontario between April 1, 
1997 and March 31, 2007 formed our exposed group.45 PEPP provides early psychosis 
intervention services for young people with psychosis (aged 16 to 50) in London and the 
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surrounding catchment area,365–368 including tailored treatment plans consisting of 
pharmacological and psychosocial interventions.367–369 The index date was defined as the 
date when exposed participants were admitted to the PEPP program. 
We randomly selected an unexposed comparison group from the general population, 
matched to exposed participants with psychosis on age (3 years), sex, and postal code. 
Up to four unexposed participants were selected for each exposed participant, and those 
who were unexposed assumed the same index date as the exposed participant to whom 
they were matched. We excluded people from the comparison group who had a diagnosis 
of schizophrenia, schizoaffective disorder, or psychotic disorder not-otherwise-specified 
at any point in their medical records. Both exposed and unexposed participants were 
followed up for ten years in the health administrative data to ascertain the onset of 
chronic health conditions.  
4.3.3 Definition of Multimorbidity 
Our primary outcome of interest – multimorbidity – was defined as the co-occurrence of 
two or more (2+) chronic health conditions from a list of 17 conditions, which included 
16 physical conditions and 1 mental health condition (comprised of either of two mental 
disorders). Multimorbidity has been previously identified using ICES databases,260 and 
we used the same definitions and time frames for chronic conditions which were used by 
this prior study. These conditions were also selected based on a research tool developed 
to document the presence of chronic conditions.250 The conditions included: arthritis 
(either osteoarthritis or rheumatoid arthritis), asthma, cancer, congestive heart failure, 
chronic obstructive pulmonary disease, cardiovascular disease, dementia, diabetes, HIV, 
hypertension, inflammatory bowel disease, chronic kidney disease, chronic liver disease, 
osteoporosis, stroke/ transient ischemic attack, urinary incontinence, and either mood or 
anxiety disorder. 
All conditions included in our definition have been validated for use in health 
administrative data, and the presence of these conditions was ascertained from predefined 
cohorts where available, or with the use of standardized algorithms. We identified 
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conditions present at the index date using a lookback window of 5, 8, or 10 years 
(condition-dependent), as well as the presence of conditions that developed over the 10-
year follow-up period. Both the predefined cohorts as well as the algorithms use 
diagnostic codes from the International Classification of Diseases, 9th and 10th Revisions 
(ICD-9 and ICD-10), and a complete list of the relevant codes and lookback windows is 
presented in Supplementary Appendix 4M.  
For all physical health conditions, we included both prevalent conditions (present before 
study entry) and incident conditions over the 10-year follow-up period (i.e. within 3,650 
days of follow-up) in our definition of multimorbidity. We chose to employ this approach 
due to the long-standing nature of chronic conditions,62 and the fact people with 
psychotic disorders may have a higher burden of chronic health conditions even prior to 
the onset of psychosis.352 For mental health conditions included in the multimorbidity 
definition, specifically mood and/or anxiety disorders, we excluded diagnoses that were 
present before cohort entry given that changes in mood and anxiety symptoms (e.g. 
depression, anxiety, mood swings) often characterize the prodrome to psychosis,370 which 
we did not want to capture in our outcome definition.   
We first created a summary variable to capture the sum of all chronic conditions in each 
person. We then created binary variables to capture presence or absence of 
multimorbidity using two ore more (2+) and three or more (3+) chronic conditions as cut-
offs, in line with public health and clinical definitions of multimorbidity, respectively. 
For exploratory analyses, we also created a binary variable aligned with the Public Health 
Agency of Canada’s (PHAC) definition,65,262 which considers psychosis as a “count” 
towards multimorbidity due to its chronic nature.61 For this variable, we used an omnibus 
mental health condition that included both psychotic and mood/anxiety disorders, in 
keeping with the PHAC definition, such that people with psychotic disorders were 
required to have only 1 or more (1+) chronic physical condition from our list to meet the 
definition for multimorbidity.  
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4.3.4 Factors associated with Multimorbidity  
We examined sociodemographic factors potentially associated with multimorbidity 
separately among people with and without psychotic disorders. These included sex, age at 
index date, and neighbourhood-level indicators of material deprivation. Sex was used as a 
binary variable (Male, Female), whereas age was captured through ordinal variables 
representing distinct age groups (26 to 30, 31 to 35, 36 to 40, 41 to 45, 46 to 50 years of 
age). We used the Ontario Marginalization Index (ON-Marg) to obtain information on 
neighbourhood-level material deprivation.371 ON-Marg is a multi-dimensional scale 
based on census data that captures components of marginalization and has been validated 
as a geographically-based index.372,373 Material deprivation broadly encompasses the 
inability to access and attain basic material needs, and includes indicators of income, 
educational attainment, family structure, and quality of housing.371,374 Neighbourhood-
level material deprivation scores were divided into quintiles based on the provincial 
distribution ranging from one (least marginalized) to five (most marginalized).  
Among people with psychotic disorders, we used proxy measures as indicators of the 
severity of psychotic symptoms and persistence of impaired functioning. Total 
psychiatric hospital days over the follow-up period was used as a proxy measure to assess 
psychosis severity, which has been validated in a recent study which found a dose-
response association between psychosis severity and total days spent in the hospital.375 
For persistence of impaired functioning, we used the length of time on the Ontario Drug 
Benefit Program (ODB) as a proxy measure, as people who experience psychosis for 
prolonged periods may be unable to partake in gainful employment and consequently 
depend on social assistance for their income.376–378 The face validity of our measure has 
been demonstrated in a study where length of time on social assistance programs 
increased with poorer functioning of psychotic patients.379 Social assistance is provided 
by the Ontario government through either Ontario Works for people in temporary 
financial need, or through the Ontario Disability Support Program as a form of long-term 
income support for people with disabilities.380 We used the ODB program as a proxy 
measure of social assistance in our study, given that the ODB is a comprehensive public 
drug funding program which covers Ontario residents with a valid health card who 
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receive social assistance through these programs.363 We used a continuous measure of 
length of time a patient has received ODB over the follow-up period, calculated as the 
time between the earliest and latest prescription dispensing date. 
4.3.5 Data Analysis 
All analyses were conducted using Stata MP version 16.1.315 Descriptive statistics were 
summarized using frequencies and proportions for categorical data.  
First, we estimated the proportion of people who experienced multimorbidity within 10-
years of a first diagnosis of psychotic disorder. We also estimated the proportion of 
people without psychotic disorders who experienced multimorbidity within this time 
period. Second, we compared these proportions using modified Poisson regression 
models with robust variance estimators through the xtpoisson command in Stata MP 
version 16.1. This command enabled us to produce a prevalence ratio with an associated 
95% confidence interval conditioned on the matched study design where cohort members 
of the same set were identified by a common group identification number.381,382 
Third, we limited the sample to those with psychotic disorders in order to examine the 
effect of sociodemographic and clinical factors (age, sex, neighbourhood-level material 
deprivation, psychosis severity, persistence of impaired functioning) on the prevalence of 
multimorbidity among people with psychotic disorders, computing prevalence ratios 
(PRs) with associated 95% confidence intervals for each variable. To explore the 
association between psychosis severity and multimorbidity, we used the proxy measure 
of total hospital days (number of days in 30-day intervals) for severity. We used length of 
time on ODB in years as a proxy measure for persistence of impaired functioning to 
explore its association with prevalence of multimorbidity in our Poisson regression 
model. We also explored the effect of age, sex, and neighbourhood-level material 
deprivation on prevalence of multimorbidity among people without psychotic disorders. 
We conducted complete-case analyses given our small to moderate sample size and 
limited missingness (<4%) of data.383,384 We also performed sensitivity analyses for all 
objectives using 3+ conditions as a cut-off for our definition of multimorbidity, which is 
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in line with clinical definitions. Lastly, we performed exploratory analyses that included 
psychosis as a “count” towards multimorbidity, meaning that 1+ physical health 
condition would be the cut-off for multimorbidity among our exposed group, whereas 2+ 
conditions would be the cut-off for the unexposed comparison group.  Further details 
describing our methods can be found in Supplementary Appendices 4M-4N. 
4.4 Results 
Out of 455 people with first-episode psychosis and 1,783 controls, we excluded 16 
exposed participants and their unexposed matched counterparts from our final sample due 
to missing information for neighbourhood-level deprivation as a result of missing postal 
codes. Thus, our final sample consisted of 439 people with psychotic disorders and 1,759 
age-, sex-, and neighbourhood-matched comparisons (total n = 2,198). The 
sociodemographic characteristics of the cohort are presented in Table 4.1.  
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Table 4.1: Sociodemographic characteristics in people with and without psychotic 
disorders at baseline (n=2,198) 
Sociodemographic 
characteristics 
People with Psychotic Disorders 
(n=439) 
N (%) 
People without Psychotic 
Disorders (n=1,759) 
N (%) 
Age group 
16-20 years 172 (39.2) 677 (38.5) 
21-25 years 128 (29.2) 525 (29.9) 
26-30 years 139 (31.7) 557 (31.7) 
Sex 
Males 330 (75.2) 1,322 (75.2) 
Females 109 (24.8) 437 (24.8) 
Material Deprivation1 
Quintile 1 82 (18.7) 324 (18.4) 
Quintile 2 77 (17.5) 332 (18.9) 
Quintile 3 66 (15.0) 313 (17.8) 
Quintile 4 114 (26.0) 393 (22.3) 
Quintile 5 100 (22.8) 397 (22.6) 
Notes:  
1Material deprivation was assessed in quintiles ranging from one (least marginalized) to 
five (most marginalized). 
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Two hundred and fifty-five people with psychosis were admitted to the hospital for 
psychiatric reasons over the follow-up period, with hospital stays ranging from one to 
fifteen (median = 2 counts; Interquartile Range, IQR = 1, 3 counts). The total number of 
hospital days ranged from 0 to 735 days, with a median of 40 days (IQR = 16, 68 days). 
The ODB was administered to 304 people with psychosis over the follow-up period, and 
the length of coverage ranged from 100 to 3650 days. The median length of time on ODB 
was 3622 days (IQR = 2879, 3644 days). 
The number of chronic conditions for people with and without psychotic disorders is 
presented in Supplementary Appendix 4O, and range from 0 to 7 counts, with a median 
count of 1 condition. Nearly 75% of people with psychotic disorders were already living 
with one chronic condition prior to study entry (see Supplementary Appendix 4P). Over 
14.1% of people (95%CI = 11.2%, 17.7) with psychosis had 2+ chronic conditions, 
compared to 11.2% (95%CI = 9.8%, 12.8) of the matched comparison group. The 
prevalence ratio suggests that people with psychotic disorders may have a 26% higher 
prevalence of multimorbidity, although the 95% CI includes the possibility of a null 
effect (PR=1.26, 95% CI 0.96, 1.66).  
Prevalence ratios summarizing the effect of sociodemographic and clinical factors on the 
prevalence of multimorbidity (2+ conditions) at 10-year follow-up for those with 
psychotic disorders are presented in Tables 4.2 and 4.3. People with psychotic disorders 
aged 21-25 at first diagnosis had a 33% higher prevalence of 2+ chronic conditions at 10-
year follow-up (PR=1.33, 95%CI = 0.72, 2.46), and those aged 26-30 years had a 77% 
higher prevalence of multimorbidity (PR=1.77, 95%CI = 0.98, 3.21), as compared to 
people with psychosis aged 16-20 years, although our 95% CI for both estimates included 
the null value. Females with psychotic disorders did not have a higher prevalence of 2+ 
chronic conditions as compared to males (PR=1.01, 95%CI = 0.59, 1.73). There was also 
evidence of a gradient effect for neighbourhood-level material deprivation, with exposed 
participants in the second-highest level of deprivation having a two-fold greater 
prevalence of multimorbidity (PR=2.46, 95%CI = 0.99, 6.12), and exposed participants at 
the highest deprivation level having a three times greater prevalence of multimorbidity, 
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when compared to those with psychotic disorders at the lowest deprivation level 
(PR=3.09, 95%CI = 1.21, 7.90). We observed similar findings for the effects of age, sex 
and material deprivation on prevalence of 2+ chronic conditions among people without 
psychotic disorders (see Supplementary Appendix 4Q). The prevalence of multimorbidity 
among people with psychotic disorders increased by 5% for each 30-day increase in total 
length of psychiatric hospitalization (PR = 1.05, 95%CI=0.96, 1.13), although this 
included the possibility of a null effect. Furthermore, the prevalence of 2+ chronic 
conditions among people with psychotic disorders increased by 6% for each year spent 
receiving social assistance through ODB (PR = 1.06, 95%CI=1.00, 1.12).  
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Table 4.2: Prevalence ratios of sociodemographic factors and their association with 
multimorbidity among people with psychotic disorders at 10-year follow-up (n=439) 
Sociodemographic characteristics 2+ conditions 
PR (95% CI)1 
Age group2 
26-30 years Reference 
31-35 years 1.33 (0.72, 2.46) 
36-40 years 1.77 (0.98, 3.21) 
Sex 
Males Reference 
Females 1.01 (0.59, 1.73) 
Material Deprivation 
Quintile 1 (Least Deprived) Reference 
Quintile 2 1.69 (0.57, 5.07) 
Quintile 3 2.14 (0.76, 6.05) 
Quintile 4 2.46 (0.99, 6.12)* 
Quintile 5 (Most Deprived) 3.09 (1.21, 7.90)** 
Abbreviations: 
CI = confidence interval; PR = prevalence ratios 
Notes:  
1Prevalence ratios have been adjusted for total hospital days (severity of psychotic 
symptoms) and length of time on the Ontario Drug Benefit (proxy measure of social 
assistance; persistence of impaired functioning). 
2Age categories at follow-up reflect age of participants 10 years after baseline. 
*Prevalence ratio may be considered significant at α=0.05  
**Prevalence ratio is significant at α=0.05  
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Table 4.3: Severity of psychotic symptoms and persistence of impaired functioning, 
and their association with multimorbidity among people with psychotic disorders at 
10-year follow-up (n=439) 
Psychotic Symptoms 2+ conditions 
PR (95% CI)1 
Severity 
Total hospital days (30-day intervals) 1.05 (0.96, 1.13) 
Persistence 
Length of time on ODB (365-day intervals) 1.06 (1.00, 1.12)* 
Abbreviations: 
CI = confidence interval; ODB = Ontario Drug Benefit; PR = prevalence ratio 
Notes: 
1Prevalence ratios have been adjusted for age, sex and material deprivation. 
*Prevalence ratio is significant at α=0.05. 
 
 
  
 
66 
 
4.4.1 Sensitivity Analyses 
When using 3+ conditions as the cut-off for multimorbidity, in keeping with clinical 
definitions, 3.0% (95%CI = 1.7%, 5.0) of people with psychosis had multiple co-
occurring chronic conditions, compared to 2.7% (95%CI = 2.1%, 3.6) of those without 
psychotic disorders. People with psychotic disorders did not have a higher prevalence of 
3+ co-occurring chronic conditions as compared to those without psychotic disorders 
(PR=1.08, 95%CI = 0.60, 1.96). The findings from our other sensitivity analyses were 
similar to those from our main analysis (see Supplementary Appendices 4R-4T). 
4.4.2 Exploratory Analyses 
Our exploratory analyses which considered psychosis and mood and anxiety disorders as 
an omnibus mental health chronic condition, as used in the PHAC definition, found that 
33.7% of people with psychosis had multimorbidity (95%CI = 29.4%, 38.3) compared to 
11.2% (95%CI = 9.8%, 12.8) of the unexposed comparison group. When including 
mental health disorders in the multimorbidity definition, people with psychotic disorders 
had a prevalence that was over three times greater than those without psychotic disorders 
(PR=3.01, 95%CI = 2.47, 3.67).  
4.5 Discussion 
Our findings suggest that people with schizophrenia and other psychotic disorders had a 
higher prevalence of 2+ co-occurring chronic conditions although our 95% CI also 
included the possibility of a null effect. This may be explained by characteristics of our 
cohort and study methodology. Firstly, several population-based studies have 
demonstrated that the onset of multiple chronic conditions peaks after 45 years of 
age.65,246,279,291,385,386 Given that the oldest people in our cohort were only between 36-40 
years of age at the end of the follow-up period, it is likely that we would need a longer 
follow-up time to see an even higher prevalence of multimorbidity among those with 
psychotic disorders. Additionally, our use of physician billing claims to identify chronic 
conditions may be subject to diagnostic overshadowing. Since physicians may only 
submit one diagnostic code per patient encounter, it is likely that billings for psychosis 
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take precedence over other conditions,339,340 particularly mental health conditions that 
were included in our definition of multimorbidity, thus resulting in an underestimation of 
prevalence estimates. Furthermore, prior research suggests that the use of a single data 
source, in particular health administrative data, may result in an underestimate of the 
prevalence of multimorbidity as compared to studies which used multiple data sources, 
e.g. health administrative and self-report data.350 Lastly, chronic health conditions are 
underdiagnosed among people with mental illness who navigate fragmented healthcare 
systems in accessing treatment,387 which may explain why our study did not find a larger 
difference in the prevalence of multimorbidity between those with and without psychosis. 
Our study did not find evidence that females with psychotic disorders had a greater 
prevalence of multimorbidity than males 10 years after a first-episode of psychosis, 
which may be explained by our small exposed group and relatively short follow-up 
period.388 In contrast, other studies examining people with psychotic disorders have 
found that multimorbidity is higher among females326,332 than males potentially due to 
comparatively greater help-seeking behaviour by females.288 Although our 95% CIs 
included the possibility of a null effect, we found that age was associated with 
multimorbidity among people with psychotic disorders, particularly for people with 
psychotic disorders who were 36-40 years at 10-year follow-up. Other studies which 
examined people with psychotic disorders have also found that age is associated with a 
higher prevalence of multimorbidity,331,334,337 since older age is often associated with 
greater prevalence of multiple co-occurring chronic conditions.65 Additionally, we found 
evidence of a gradient effect for material deprivation on the prevalence of 
multimorbidity. Given that socioeconomic status may facilitate or hinder access to health 
care, health promoting behaviours, and environmental exposures (e.g. smoke, 
pollution),292 it is unsurprising that the prevalence of multimorbidity increases with 
increasing deprivation levels, as demonstrated by findings from several 
studies.246,279,291,385   
Although our findings included the possibility of a null effect, we found evidence for an 
association between severity of psychotic symptoms and prevalence of multimorbidity, 
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using the proxy measure of number of days spent in the hospital. Several meta-analyses 
have found that the prevalence of chronic cardiometabolic conditions, e.g. 
hypertension,139 cardiovascular diseases,142 diabetes,139 is higher among people with 
chronic schizophrenia as compared to those immediately after the onset of psychosis, 
potentially owing to longer duration of antipsychotic medications, which may increase 
the risk of various illnesses139 and consequently, multimorbidity among people with 
psychotic disorders. Although the face validity of our proxy measure has been 
demonstrated in prior research where patients with more severe psychotic symptoms 
spend more time in the hospital,375 our sample may have been underpowered to reveal a 
stronger association between psychosis severity and prevalence of multiple chronic 
conditions due to our relatively small exposed group.388 Furthermore, our study followed 
people treated by an early psychosis intervention program immediately after a first 
episode of psychosis, where the risk for developing chronic conditions may be lower as 
compared to later in the course of psychotic illness.139,142 Alternately, other measures of 
severity to which we did not have access may have a stronger relationship with chronic 
health conditions. For example, prior research has found a dose-response relationship 
between the number of psychotic symptoms and a higher number of chronic physical 
conditions.389  
We also found evidence for an association between persistence of impaired functioning 
and prevalence of multimorbidity, using the proxy measure of years on social assistance. 
The interplay between metabolic side effects associated with the use of antipsychotic 
medication and behavioural risk factors among people with psychotic disorders may 
underlie this association, which is consistent with findings from other studies.390–393 
Diminished physiological capacity which characterizes functional impairment may 
directly impede the ability of those with psychotic disorders to engage in physical fitness 
and may lead to sedentary behaviour,390,394,395 which is known to influence risk for 
various cardiometabolic chronic conditions.103 Furthermore, there is already an excess of 
behavioural risk factors among chronic sufferers of psychotic disorders, such as poor 
nutritional habits and high rates of smoking,11–13 which are associated with respiratory 
and other chronic diseases.16–21 Finally, use of antipsychotic medications is also 
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associated with weight gain and other metabolic side effects which influence risk for 
various chronic conditions.4–7 Thus, functional impairment, when combined with poor 
physical fitness, behavioural risk factors, and medication use may explain the observed 
association between impaired functioning and prevalence of multimorbidity among those 
with psychotic disorders in our study. 
It is important to note that variation in the type and number of chronic conditions used to 
define multimorbidity will affect prevalence estimates. When the cut-off was increased to 
3+ conditions in our sensitivity analysis, we found a lower prevalence of multimorbidity 
among those with psychotic disorders, which has been demonstrated in the broader 
literature where higher cut-offs result in lower prevalence estimates.253 In contrast, 
inclusion of psychosis as a count towards multimorbidity resulted in over a three-fold 
greater prevalence of multimorbidity among this clinical population, as compared to 
those without psychotic disorders. Using this definition, we found that over 30% of those 
with psychosis met the definition for multimorbidity compared to 11.2% of the 
comparison group. Furthermore, nearly three-quarters of people with psychotic disorders 
in our study had at least one other chronic condition even prior to the onset of psychosis. 
When we consider the presence of this condition, in addition to the burden posed by 
psychosis, the public health cut-offs for multimorbidity are met. This finding also 
illustrates the phenomenon commonly seen in multimorbidity research – that inclusion of 
additional risk factors, symptoms, or conditions influences prevalence estimates.253,396 
Psychotic disorders are broadly grouped with other mental health conditions in 
definitions of multimorbidity used by the PHAC,65,262 and psychosis does not factor into 
definitions suggested for use in primary care settings250 and ICES data holdings,260 which 
only consider mood and anxiety disorders. Use of these definitions that do not include 
psychotic disorders may therefore result in an underestimation of the true prevalence of 
multimorbidity.  
Our study follows people with psychotic disorders treated by an early psychosis 
intervention program who have been followed immediately after the onset of symptoms 
for 10 years, which is novel for multimorbidity research conducted on this population309 
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and enabled us to see development of multiple chronic conditions early in the course of 
psychotic illness. However, future studies examining multimorbidity should use larger 
sample sizes with longer follow-up periods to ascertain the true burden of multiple 
chronic conditions among those with psychotic disorders, which our study may have been 
underpowered to detect. We found that those with psychotic disorders have chronic 
conditions even prior to the onset of the study, and future research with longer follow-up 
periods would enable us to gauge the development of chronic conditions over the 
trajectory of psychotic illness. Furthermore, our study linked data from an early psychosis 
intervention program to health administrative databases to examine multimorbidity 
among people with psychotic disorders. Participants in our study therefore had access to 
care for psychotic symptoms through the PEPP program and furthermore access to other 
forms of healthcare through OHIP, as we were able to track their health outcomes. 
However, people with psychotic disorders often lack consistent access to care both for 
psychotic illness as well as physical health needs.397 There is therefore a need for broader 
population-based studies to examine the association between psychosis and 
multimorbidity and capture people with psychotic disorders who may not have consistent 
access to care in order for prevalence estimates of the burden of multimorbidity to be 
more reflective of this clinical population.  
Researchers should also consider cross-validation of multiple data sources when 
assessing multimorbidity – such as chart reviews, administrative data, and patient self-
reports – to obtain more accurate estimates.350 Furthermore, they should also explore how 
variation in definitions influences prevalence estimates.396 Finally, they should consider 
the association between severity of psychotic symptoms and prevalence of 
multimorbidity using better proxy measures, such as the number of psychotic 
symptoms,389 or a direct measurement of psychosis severity using the Positive and 
Negative Syndrome Scale.25  
4.5.1 Limitations 
Our use of pre-existing health administrative data limits our analyses to the variables 
captured by this database. In particular, we do not have information on obesity or 
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hyperlipidemia,350 which were identified for inclusion in operational definitions of 
multimorbidity by a recent scoping review.250 We may also be missing information on 
key variables integral to our analysis, such as ethnicity293,294 and duration of treatment 
with antipsychotic medications,139,142 which may serve as confounders in the association 
between psychosis and multimorbidity. Additionally, lack of standardization in data 
collection procedures across health care providers or institutions may result in missing or 
inconsistent data. Furthermore, we lack information on the duration of untreated 
psychosis (DUP) for people with psychotic disorders in our study, which is known to 
affect prognosis of psychotic illness.398 The association between DUP and chronic health 
conditions is unknown, but DUP may serve as a confounder in our study, for which we 
could not account.  
The use of proxy measures for psychosis severity and impaired functioning may result in 
the presence of residual confounding in our study. The ODB includes low-income 
residents of Ontario, as well as those who receive social assistance through disability 
support programs, which may have resulted in misclassification. Furthermore, since we 
used dispensing dates of prescriptions issued under only the ODB program as a proxy to 
calculate the length of time on social assistance, our study may be subject to 
measurement error in underestimating the length of time on social assistance. Use of 
neighbourhood-level indicators of marginalization may also have resulted in 
misclassification, particularly as this was assigned at baseline, and this may have changed 
throughout the follow-up period. Social drift is often documented among people with 
serious mental illness due to deteriorations in functioning over the course of psychotic 
illness and consequent difficulties in securing gainful employment.399 As such, 
marginalization of those with psychotic disorders is likely to increase over the follow-up 
period. Finally, given that our sample is limited to people with psychosis treated by an 
early psychosis intervention program, we cannot generalize our findings to people with 
psychotic disorders treated elsewhere in the mental health system.369  
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4.5.2 Conclusions 
Our matched retrospective cohort study highlights that people with psychotic disorders 
treated by an early psychosis intervention program may have a 26% higher prevalence of 
multimorbidity over a 10-year follow-up period from first-episode psychosis, although 
our findings also include the possibility of a null effect. Future studies should use larger 
sample sizes with longer follow-up periods to better ascertain the development of chronic 
conditions over the lifespan of those with psychotic disorders, and the influence of 
behavioural, sociodemographic and clinical risk factors on the prevalence of 
multimorbidity. Clinicians who care for patients with psychosis should routinely assess 
for risk of chronic health conditions to better capture the extent of multimorbidity among 
this clinical population. 
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Chapter 5  
 Synthesis and Conclusion 
The overall objective of this chapter is to synthesize and contextualize the findings 
presented in the two manuscripts in this thesis within the larger body of literature on 
multimorbidity among people with psychotic disorders. The research contributions and 
limitations of our analyses will be noted. Finally, this chapter will discuss the 
implications of our findings for policy makers and clinicians, and future directions for 
research in this area. 
5.1 Summary of Studies 
The principal aim of this thesis was to contribute to the growing body of literature on 
multimorbidity among people with schizophrenia and other psychotic disorders using two 
complementary but independent analyses. First, we synthesized the existing literature to 
quantify the prevalence and excess risk of multimorbidity among people with psychotic 
disorders, relative to those without psychotic disorders, using a systematic review and 
meta-analysis (Chapter 3). This review provided context for the subsequent assessment of 
the excess prevalence of multimorbidity experienced by people with psychotic disorders, 
compared to those without psychosis, using health administrative data in Ontario, Canada 
in a retrospective matched cohort study (Chapter 4). 
Our systematic review and meta-analysis found that people with psychotic disorders had 
an increased risk of 2+ chronic conditions (RR=1.69, 95%CI=1.37,2.08), relative to those 
without psychosis. Furthermore, every study used different operational definitions of 
multimorbidity, with respect to both the number and types of included chronic conditions, 
which resulted in a wide range of prevalence estimates (16% to 91%). Included studies 
identified older age,331,334,337  low SES,328 and female sex326,331–334,337 as risk factors for 
multimorbidity among people with psychotic disorders. 
Our retrospective cohort study found that people who were treated for psychotic disorders 
at an early intervention program in London, Ontario have a greater prevalence of 
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multimorbidity (2+ chronic conditions) (PR=1.26, 95%CI=0.96,1.66) than controls 
matched on age, sex, and postal code, however the confidence interval includes the 
possibility of a null effect. We did not find that females with psychotic disorders had a 
greater prevalence of multimorbidity than males. However, we found that age was 
associated with multimorbidity among people with psychotic disorders, although our 
findings included the null value. Furthermore, among people with psychosis, living in 
areas with the highest levels of material deprivation was associated with multimorbidity 
(PR=3.09, 95%CI=1.21, 7.90). Most importantly, we found that the operational definition 
of multimorbidity had a profound impact on prevalence estimates. When we conducted 
an exploratory analysis which included mental illness as an omnibus condition and 
‘count’ towards multiple chronic conditions, we found that people with psychotic 
disorders had a significantly greater prevalence of 2+ chronic conditions than those 
without psychotic disorders (PR=3.01, 95% CI=2.47, 3.67).   
5.2 Research Contributions  
This thesis fits in with the growing body of literature on the increased risk of many 
physical health conditions experienced by people with psychosis. To our knowledge, we 
conducted the first systematic review and meta-analysis quantifying the excess risk of 
multimorbidity among people with psychotic disorders relative to those without 
psychosis (Chapter 3). Furthermore, our retrospective cohort study using health 
administrative data to assess the prevalence of multimorbidity among people treated by 
an early psychosis intervention program is the first Canadian data on this topic (Chapter 
4). Additionally, our study is novel among research which examines the association 
between psychosis and multimorbidity given that we follow people with psychotic 
disorders immediately after the onset of psychosis, and our follow-up period is 10 
years.309 We note limitations of our retrospective cohort study and additional 
considerations for interpretation in the following section.  
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5.3 Limitations  
The primary limitation of our retrospective cohort study was the small sample size,388 
which may explain why our study did not find similar trends in the prevalence of 
multimorbidity among people with psychotic disorders as found in prior studies.326,327,338 
Furthermore, our use of health administrative data limited our definition of 
multimorbidity to conditions solely captured by this database. Several studies have found 
that the identification of people as having “multimorbidity” increases as the outcome 
definition expands, i.e. as the number of included co-morbidities in operational 
definitions increase.256,257,400 In particular, we used a list of 17 chronic conditions for our 
operational definition of multimorbidity, which may not be an exhaustive list of all 
chronic conditions experienced by patients in our study. For instance, we do not have 
access to information on hyperlipidemia or obesity,350 which are very common conditions 
as well as predictors of cardiometabolic chronic conditions,8–10 and also serve as chronic 
conditions on their own that were identified for inclusion in operational definitions of 
multimorbidity by a recent scoping review250 (see Table 2.1). Additionally, we could not 
control for behavioural risk factors such as smoking and poorer nutritional habits, which 
may have confounded our findings, since these are known to be associated with 
multimorbidity19–21 and highly prevalent among people with psychotic disorders.11,12,14,15 
Finally, health care providers may not recognize chronic health conditions among those 
with serious mental illness, compared to those without mental health conditions,401 which 
may have resulted in an underestimation of the excess prevalence of multimorbidity in 
our study.  
5.4 Additional Considerations 
There are additional considerations which may help to contextualize our findings within 
the larger body of literature. First, it must be noted that our analysis of the association 
between age and multimorbidity among people with psychotic disorders included the 
possibility of a null effect. In contrast, age is a well-replicated risk factor for 
multimorbidity in the broader literature both among the general population290 and in 
studies examining people with psychotic disorders.331,334,337 However, a recent study by 
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Filipcic and colleagues (2019) found that age was not significantly associated with the 
prevalence of multiple chronic physical conditions among people with psychotic 
disorders.332 These findings may indicate that the patterns of risk for multiple chronic 
conditions are different for those with and without psychotic disorders. Alterations in 
immune system responses have been identified in people with schizophrenia who have 
several chronic physical conditions, such as diabetes mellitus and cancer.402 It is therefore 
possible that those with schizophrenia already have a vulnerability to developing certain 
chronic conditions,403 and that the risk of multimorbidity is heightened across all age 
groups for this clinical population.332 
Second, we found that females with psychotic disorders did not have a higher prevalence 
of 2+ co-occurring chronic conditions than males (PR=1.01, 95%CI = 0.59, 1.73. This is 
in contrast with studies included in our systematic review, which have found a much 
greater prevalence of multimorbidity among females with psychosis compared to 
males.326,332–334,337 General population studies have similarly identified that females have 
a higher prevalence of multimorbidity,257,282,342,404 whereas more males than females are 
observed to have multimorbidity in studies which focus on primary care/ family practice 
settings.386 Differential patterns of help-seeking behaviour may explain these findings, as 
females are more likely than males to visit health care providers for concerns about 
potential illness.288 Furthermore, sex may also interact with age and practice setting, such 
that younger males and older females have higher prevalence of multimorbidity in the 
general population.405,406 Given that our study focussed on younger people with psychotic 
disorders, we may have been unable to find an association between female sex and 
multimorbidity. The association between sex and multimorbidity is unclear among people 
with psychotic disorders, and needs to be further studied across both family practice and 
general population contexts.  
5.5 Implications for Policy and Practice 
Although psychosis is not present in widely-used definitions of multimorbidity, our study 
highlights that consideration of this chronic condition merits recognition. Furthermore, 
our study demonstrated that people with psychotic disorders have a higher prevalence of 
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multimorbidity as compared to people without psychotic disorders. These findings have 
important implications for health policy and clinical practice. 
Our exploratory analysis, which considered people with psychotic disorders and other 
mental health conditions to already have one ‘count’ towards chronic conditions found 
that prevalence of 2+ chronic conditions was significantly higher among this population 
than same age, sex, and neighbourhood-matched controls. Although our analysis was 
exploratory in nature, it aligns with the definitions of multimorbidity set forth by PHAC; 
i.e., consideration of any mental health diagnosis as one chronic condition in 
multimorbidity counts.65,262 By contrast, psychotic disorders were not identified for 
inclusion in operational definitions of multimorbidity by a recent scoping review,250 nor 
considered in the ICES definition260 (see Table 2.1).  
Using the definitions suggested by the scoping review and ICES, policy makers require 
people with psychotic disorders to have 2+ chronic conditions in order to meet the cut-off 
for multimorbidity. This is problematic because it fails to capture younger populations 
with psychotic disorders in counts of multimorbidity who may have one other co-
occurring chronic condition, and therefore do not meet the criteria. Furthermore, it 
underestimates the burden of multiple co-occurring chronic conditions experienced by 
this clinical population, and understates the impact of psychosis as a chronic condition 
which in itself has a prolonged course of illness53–58 and multiple risk factors33,62,63 and 
requires long-term ongoing management.61 Inclusion of schizophrenia and psychotic 
disorders in definitions of multimorbidity is pivotal to capacity planning for health 
services and systems. People with multimorbidity are frequent service users279,280,286 and 
incur greater costs of care than those with single chronic conditions.302 Thus, including 
people with psychotic disorders in conventionally-used definitions of multimorbidity 
would better capture the extent of service use for their chronic health conditions,2,306,307 
and assist policy-makers in planning to meet the needs of patients. 
Additionally, clinicians caring for people with schizophrenia and other psychotic 
disorders need to routinely probe for the risk of other chronic conditions to inform 
treatment planning. Concerns about polypharmacy, or the prescription of multiple 
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medications used to treat more than one chronic illness,407 are often noted among 
providers who care for patients with multimorbidity.408,409 This is of particular 
importance for those who care for people with psychotic disorders who also have other 
co-occurring chronic conditions, as SGAs may interact with other medications, including 
those used to treat cancer, HIV, and CVD.410 Multimorbidity should therefore be 
documented in patients’ health records so that providers are aware of other co-existing 
conditions and are better able to adjust treatment planning.104 
5.6 Future Studies 
Future research is needed to better assess the extent of multimorbidity among people with 
psychotic disorders. Integration of health administrative records with patient-level data, 
such as clinical charts and pharmacy records, would provide information on behavioural 
risk factors such as smoking and nutritional habits,11,12,14,15,19–21 and duration of 
antipsychotic use.139,142 These aforementioned factors may have confounded the 
association between psychosis and multimorbidity in our study, and require adjustment in 
statistical models in future studies. Furthermore, the use of multiple data sources, in 
particular the integration of population- and patient-level data, has been demonstrated to 
increase accuracy when assessing the prevalence of multimorbidity.350 Future research 
should also consider inclusion of schizophrenia in operational definitions of 
multimorbidity.  
Moreover, longer term studies with larger sample sizes are needed to better estimate 
excess prevalence and risk of multimorbidity among this clinical population, as well as 
understand factors associated with occurrence of multiple co-occurring chronic health 
conditions. Studies with larger sample sizes and longer follow-up periods would enable 
us to better see trajectories of illness onset over the lifespan. It would be useful for 
treatment and capacity planning to assess whether there is a critical timeframe after onset 
of psychotic symptoms during which people with psychotic disorders develop other 
chronic health conditions.  
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5.7 Conclusions 
The primary objective of this thesis was to explore the association between psychotic 
disorders and multimorbidity using two independent studies. Our systematic review and 
meta-analysis found that people with psychosis had a 69% excess risk of multiple co-
occurring chronic conditions compared to those without psychotic disorders. Our 
retrospective cohort study found that those treated for psychotic disorders at an early 
intervention program in London, Ontario experienced a higher prevalence of 
multimorbidity than controls matched for age, sex, and postal code; however, our 
findings included the possibility of a null effect. Our subsequent analysis which included 
psychotic disorders in multimorbidity counts did find a statistically significant greater 
relative prevalence of multiple co-occurring chronic conditions among this clinical 
population. Although our main analysis did not find a statistically significant association 
between psychotic disorders and multimorbidity, our thesis overall echoes the findings of 
several studies which have evaluated multimorbidity, and reinforces the idea that 
multimorbidity frameworks greatly impact prevalence estimates. The findings from this 
thesis serve to highlight the consideration of psychotic disorders as a chronic condition in 
all definitions of multimorbidity, which has important implications for patients, clinicians 
and health systems.    
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Appendices 
Appendix 3A: PRISMA Checklist 
  
 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  31 
ABSTRACT  
 
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  
31 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  32-33 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  33 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration 
number.  
34 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for 
eligibility, giving rationale.  
34 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last 
searched.  
34 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Supplementary 
Appendix 3B 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  34-35 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from 
investigators.  
35 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  35 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
35 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  35-36 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  35-36 
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Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  35 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  36 
RESULTS  
 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  36, Fig 3.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  36-37, Table 
3.1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Supplementary 
Appendix 3C 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
36-41, 
Supplementary 
Appendices 
3D-3F, Table 
3.2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  44, Fig 3.3 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Fig 3.2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  44, 
Supplementary 
Appendices 
3G-3K 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
46-48 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  48-49 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  49 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  49-50 
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Appendix 3B: Search Strategy 
Concept MEDLINE EMBASE PsycINFO Keywords 
Psychosis 
1.(Psychosis OR psychotic OR psychotic disorder* OR schizophreni* OR 
sever* mental ill* OR sever* mental disorder*).ti,ab  
1. (Psychosis OR psychotic OR psychotic disorder* OR schizophreni* OR sever* 
mental ill* OR sever* mental disorder*).ti,ab  
1. ti,ab(Psychosis OR 
psychotic OR psychotic 
disorder* OR 
schizophreni* OR sever* 
mental ill* OR sever* 
mental disorder*) 
1. exp schizophrenia/ or schizophreni*.ti,ab. 
2. exp psychosis/ or disorders with psychotic features.ti,ab.
  
3. Affective Disorders, Psychotic.mp. or affective 
psychosis.ti,ab.  
4. acute psychosis/ or schizoaffective psychosis/ or manic 
psychosis.ti,ab. 
5. psychotic disorder.ti,ab.  
6. mental disease/ or sever* mental ill*.ti,ab. 
7. (sever* mental disorder* or Mental Disorders).ti,ab. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
Comorbidity 
2. (Comorbidity OR associated condition* OR associated diagnos* OR 
associated disease* OR associated health problem* OR associated 
illness* OR associated morbidit* OR associated patholog* OR coexisting 
condition* OR co-existing condition* OR coexisting diagnos* OR 
co?existing diagnos* OR coexisting disease* OR co-existing disease* OR 
coexisting health problem* OR co-existing health problem* OR 
coexisting illness* OR co-existing illness* OR coexisting pathology* OR 
co-existing pathology* OR comorbid condition* OR co-morbid 
condition* OR comorbid diagnos* OR co-morbid diagnos* OR comorbid 
disease* OR co-morbid disease* OR comorbid health problem* OR co-
morbid health problem* OR comorbid illness* OR co-morbid illness* OR 
comorbid patholog* OR co-morbid patholog* OR concurrent condition* 
OR concurrent diagnos* OR concurrent disease* OR concurrent health 
problem* OR concurrent illness* OR concurrent patholog* OR 
cooccurring condition* OR co-occurring condition* OR cooccurring 
diagnos* OR co-occurring diagnos* OR cooccurring disease* OR co-
occurring disease* OR cooccurring health problem* OR co-occurring 
health problem* OR cooccurring illness* OR co-occurring illness* OR 
cooccurring patholog* OR co-occuring patholog* OR comorbidities OR 
co-morbidity OR co-morbidities OR chronic illness* OR chronic 
disease*).ti,ab 
2. (Comorbidity OR comorbidities OR co-morbidity OR co-morbidities OR associated 
condition* OR associated diagnos* OR associated disease* OR associated health 
problem* OR associated illness* OR associated morbidity OR associated morbidities 
OR associated pathology OR associated pathologies OR comorbid condition* OR co-
morbid condition* OR comorbid diagnos* OR co-morbid diagnos* OR comorbid 
disease* OR co-morbid disease* OR comorbid health problem* OR co-morbid health 
problem* OR comorbid illness* OR co-morbid illness* OR comorbid patholog* OR co-
morbid patholog* OR coexisting condition* OR co-existing condition OR coexisting 
diagnos* OR co-existing diagnos* OR coexisting disease* OR co-existing disease* OR 
coexisting health problem* OR co-existing health problem* OR coexisting illness* OR 
co-existing illness* OR coexisting patholog* OR co-existing patholog* OR concurrent 
condition OR concurrent conditions OR concurrent diagnos* OR concurrent disease* 
OR concurrent health problem* OR concurrent illness* OR concurrent morbid* OR 
concurrent patholog* OR cooccurring condition* OR cooccurring disease* OR 
cooccurring diagnos* OR co-occurring diagnos* OR cooccurring disease* OR co-
occurring disease* OR cooccurring health problem* OR co-occurring health problem* 
OR cooccurring illness* OR co-occurring illness* OR cooccurring morbid* OR co-
occurring morbid* OR cooccurring patholog* OR co-occurring pathology*).ti,ab 
2. ti,ab(Comorbidity OR 
Comorbid disorders OR 
medical comorbidity) 
9. comorbidit*.kw.  
10. co?existing diagnos*.ti,ab.  
11. comorbid condition*.ti.  
12. co-morbid condition*.ti.  
13. comorbid illness*.ti. 
14. co-morbid illness*.ti. 
15. concurrent condition*.ti,ab.  
16. concurrent diagnos*.ti,ab.  
17. concurrent disease*.ti,ab.  
18. concurrent health problem*.ti,ab. 
19. concurrent illness*.ti,ab.  
20. cooccurring condition*.ti,ab.  
21. co-occurring condition*.ti,ab.  
22. co-occurring diagnos*.ti,ab.  
23. cooccurring disease*.ti,ab.  
24. co-occurring disease*.ti,ab.  
25. cooccurring illness*.ti,ab.  
26. co-occurring illness*.ti,ab.  
27. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 or 23 or 24 or 25 or 26 
Multimorbidity 
3. (Multimorbidit* OR multiple chronic condition* OR Multiple 
condition* OR multiple diagnos* OR multiple disease* OR multiple 
health problem* OR multiple illness* OR multiple patholog* OR 
multidisease* OR multi-disease* OR multi-morbidit* OR multiple 
chronic condition* OR multipatholog* OR multi-patholog* OR 
pluripatholog* OR polypatholog* OR poly-patholog*).ti,ab 
3. (Multiple chronic condition OR multiple chronic conditions OR multimorbidity OR 
multiple chronic disease OR multiple chronic diseases OR Multiple chronic disorders 
OR multiple chronic illnesses OR multiple chronic health conditions OR multiple 
condition OR multiple conditions OR multiple diagnosis OR multiple diagnoses OR 
multiple disease OR multiple diseases OR multiple health problem* OR multiple 
illness* OR multiple morbid* OR multiple pathology OR multiple pathologies OR 
multidisease OR multi disease OR multi diseases OR multimorbidity OR 
multimorbidities OR multi morbidity OR multi morbidities OR multipathology OR 
multipathologies OR multi pathology OR multi pathologies OR pluripathology or 
pluripathologies OR polypathology OR polypathologies OR poly pathology or 
polypathologies).ti,ab 
3. ti,ab(Multiple health 
conditions OR Multiple 
morbid conditions) 
28. multimorbidity/ or multimorbidit*.ti,ab.  
29. multiple chronic condition*.ti,ab. 
30. multiple condition*.ti,ab.  
31. multiple diagnos*.ti,ab.  
32. multiple disease*.ti,ab.  
33. multiple illness*.ti,ab. 
34. multi-morbidit*.ti,ab. 
35. multiple chronic condition*.ti,ab. 
36. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 
Linking Concepts 
4. 1 AND 2 
5. 1 AND 3 
6. 4 OR 5 
4. 1 AND 2 
5. 1 AND 3 
6. 4 OR 5 
4. 1 AND 2 
5. 1 AND 3 
6. 4 OR 5 
37. 8 and 27  
38. 8 and 36  
39. 37 or 38 
Limits 
7. limit 6 to (human and english and yr="1990 -Current") 7. limit 6 to (human and english and yr="1990 -Current") 7. limit 6 to (human and 
english and yr="1990 -
Current") 
40. limit 39 to (human and english and yr="1990 -Current") 
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Appendix 3C: Risk of bias assessment for individual studies (n=14) 
Domain Quality criteria 
Assessment of included studies 
Bhalla 
et al., 
2018 
Bouza 
et al., 
2010 
Carney 
et al., 
2006 
Correll 
et al., 
2017 
Domino 
et al., 
2014 
Filipcic 
et al., 
2019 
Gabilondo 
et al., 
2017 
Islam 
et al., 
2017 
Jahrami 
et al., 
2017 
Kugathasan 
et al., 2019 
Nishanth 
et al., 
2017 
Smith 
et al., 
2013 
Stubbs 
et al., 
2016 
Woodhead 
et al., 
2014 
1. Is the source 
population 
representative of the 
general population? 
Population-based roster (+) 
Community-based study (*) 
Hospital-based patient records or undefined source population (-) 
No description (-) 
* + * + + * + + - + - * + * 
2. Was selection of 
exposed (people with 
psychosis) and non-
exposed (people 
without psychosis) 
cohorts drawn from 
the same population? 
Same roster (+) 
Similar roster (*) 
Different points of care for exposed and unexposed populations (-) 
No description (-) 
NA NA + NA NA * + + * + NA + + + 
3. Can we be 
confident in the 
assessment of 
exposure (psychosis)? 
Secure record or repeated ascertainment (+) 
Single interview or retrospective recall (*) 
Uncertain (-) 
No description (-) 
+ + + + + + + * + + + + * + 
4. Can we be 
confident in the 
assessment of the 
outcome 
(multimorbidity)? 
Independent blind assessment or validated instrument (+) 
Instrument with limited validity assessment or self-report (*) 
Clinical interview or chart diagnoses or unvalidated instruments (-) 
No description (-) 
+ + + + + * + * - + + + * + 
5. Did the design or 
analysis account for 
important 
confounding factors? 
Participant interview or survey, or reproducible chart review or 
accurate database (+) 
Chart review without reproducibility or database with uncertain 
accuracies (*) 
Database with no available information on accuracy of confounding 
factors (-) 
No description (-) 
NA * + + + + * * * * * * * * 
6. Can we be 
confident in the 
assessment of the 
confounding factors? 
Matching or adjustment for sociodemographic and clinical factors 
(+) 
Matching or adjustment for age, sex, and other sociodemographic 
factors (*) 
Matching or adjustment for age and sex (-) 
No description (-) 
NA + + + + * + * + + * + + + 
7. Is there little 
missing data? 
High responses and little missing data (+) 
Moderate responses and some missing data (*) 
Low responses and substantial missing data (-) 
No description (-) 
+ + + + + NA + + NA + NA + + + 
Legend: 
+ criteria satisfied 
* criteria partially met 
- criteria not met 
NA criteria not applicable to study design 
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Appendix 3D: Conditions included in multimorbidity definitions (n=14) 
Study 
Number of included 
conditions 
Types of included conditions 
Bhalla et al., 2018 40 Psychiatric; Substance Abuse; Medical disorders: hypertension, diabetes mellitus, chronic obstructive airway disease, miscellaneous 
Bouza et al., 2010 12 (clusters) 
Infectious Diseases; Neoplasms; Endocrine Diseases; Hematological Diseases; Neurological Diseases; Diseases of the Circulatory 
System; Respiratory Diseases; Diseases of the Digestive System; Diseases of the genitourinary tract; Complications of pregnancy, 
childbirth and the puerperium; Diseases of the musculoskeletal system and connective tissue; Injury and Poisoning 
Carney et al., 2006* 46 
Cardiovascular; Neurological; Pulmonary; Endocrine; Renal; Gastrointestinal; Viral/infectious; Hematology/oncology; Musculoskeletal; 
Other - accidents and injuries; Genital; Inflammatory disease of ovary; Drug abuse/dependence; Other – miscellaneous 
Correll et al., 2017* 6 Cerebrovascular disease; Coronary or ischemic heart disease; Diabetes mellitus; Hyperglycemia; Hyperlipidemia; Hypertension 
Domino et al., 2014 6 Asthma; COPD; Diabetes; Hypertension; Hyperlipidemia; Seizure disorder 
Filipcic et al., 2019 15 
Asthma (including allergic asthma); Chronic bronchitis, COPD and emphysema; Myocardial infarction or chronic consequences of MI; 
Coronary heart disease or angina pectoris; Hypertension; Cerebrovascular insult (cerebral haemorrhage, cerebral thrombosis) or chronic 
consequences of stroke; Arthrosis (excluding arthritis); Low back disorder or other chronic back defects; Neck disorder or other chronic 
neck defects; Diabetes mellitus; Allergy (rhinitis, hay fever, eye inflammation, dermatitis, food allergy or other allergy/ asthma allergy 
excluded); Liver cirrhosis; Urinary incontinence; Kidney disease; Obesity 
Gabilondo et al., 2017 47 
Clusters: Neurological; Cardiovascular 1 - Hypertension, diabetes, ischemic heart disease, chronic kidney disease; Cardiovascular 2 – 
cardiovascular disease, atrial fibrillation, heart failure; Chronic liver disease or pancreatic disease, viral hepatitis; Dementia, COPD, low 
back pain, cancer, asthma, osteoporosis, peripheral neuropathy; Miscellaneous: bone disorders or chromosomal abnormalities or 
glaucoma or gout 
Islam et al., 2017* 121 
Clusters: Mental and behavioural disorders; Diseases of the circulatory system; Endocrine, nutritional and metabolic diseases; Diseases 
of the respiratory system; Neoplasms; Diseases of the musculoskeletal system and connective tissue; Diseases of the digestive system; 
Pregnancy, childbirth and the puerperium; Diseases of the genitourinary system; Certain infectious and parasitic diseases; Diseases of 
the skin and subcutaneous tissue; Diseases of the eye and adnexa; Diseases of the ear and mastoid process; Diseases of the nervous 
system (+ due to injury); Diseases of blood & blood-forming organs and certain disorders involving the immune mechanism; Congenital 
malformations, deformations and chromosomal abnormalities 
Jahrami et al., 2017 4 Diabetes Type 2; Hypertension; Cardiovascular disease; Musculoskeletal disorders 
Kugathasan et al., 2019 10 (clusters) Infection; Cancer; Endocrine; Neurologic; Cardiovascular; Respiratory; Digestive; Skin; Musculoskeletal; Urogenital 
Nishanth et al., 2017 Not Described Not described 
Smith et al., 2013 32 Cardiovascular diseases; COPD; Cancer; Neurological; Gastrointestinal issues; Diabetes; Hypertension; Miscellaneous 
Stubbs et al., 2016 9 
Arthritis; Asthma; Diabetes mellitus; Angina pectoris; Chronic back pain; Tuberculosis; Visual impairment; Hearing problems; 
Edentulism 
Woodhead et al., 2014* 12 
Hypertension; Epilepsy; Diabetes mellitus; Coronary heart disease; Chronic kidney disease; COPD; Cancer (non specified); Atrial 
fibrillation; Heart failure; Stroke; Hypothyroidism; Asthma 
Abbreviations: 
COPD = chronic obstructive pulmonary disease; MI = myocardial infarction 
  
 
134 
 
Appendix 3E: Risk of specific chronic conditions among people with psychosis in included studies (n=14) 
 
Legend: 
↓ Decreased prevalence, incidence or odds among persons with psychosis relative to those without psychosis 
↑ Increased prevalence, incidence or odds among persons with psychosis relative to those without psychosis 
 Study did not examine prevalence, incidence or odds of specific condition experienced by persons with psychosis  
Study 
Diseases of the 
Cardiovascular 
and/or 
Circulatory 
Systems 
Diabetes 
Mellitus 
Respiratory 
Diseases 
Substance 
Abuse 
and 
Addiction 
Disorders 
Endocrine 
Diseases 
Chronic 
Pain or 
Arthritis 
Obesity 
Infectious 
Diseases 
Neuropsychiatric 
Diseases 
Digestive 
Diseases 
Bhalla et al., 
2018 
          
Bouza et al., 
2010 
↑ ↑ ↑ ↑      ↑ 
Carney et al., 
2006 
 ↑ ↑ ↑ ↑   ↑   
Correll et al., 
2017 
↑ ↑         
Domino et al., 
2014 
          
Filipcic et al., 
2019 
↑     ↑ ↑    
Gabilondo et al., 
2017 
↓ ↑      ↑ ↑  
Islam et al., 2017           
Jahrami et al., 
2017 
          
Kugathasan et 
al., 2019 
↑  ↑       ↑ 
Nishanth et al., 
2017 
↑ ↑         
Smith et al., 
2013 
↓       ↑ ↑ ↑ 
Stubbs et al., 
2016 
↑ ↑    ↑     
Woodhead et al., 
2014 
↑ ↑         
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Appendix 3F: Detailed summary of findings from included studies on factors associated with multimorbidity among 
people with psychosis (n=14) 
 
Notes: 
1Studied factors related to mortality among patients with schizophrenia due to 2+/3+ physical health conditions 
2Studied quality care metrics among patients with schizophrenia with co-occurring 2+/3+ physical health conditions 
3Smoking and alcohol use studied as a risk factor for multimorbidity, not included in counts of chronic conditions 
  
Study Summary of Findings 
Bhalla et al., 2018 Veterans with multimorbidity had a substantial increase in all examined risk factors (low SES, homelessness, BMI >30) 
Bouza et al., 20101 Age >53 years was significantly related to in-hospital mortality among cases with multimorbidity 
Carney et al., 2006 
Persons with schizophrenia were only slightly more likely to live in urban settings than controls; Cases had significantly more 
months of follow-up and healthcare visits than controls 
Correll et al., 20171 
Inverse association between cardiometabolic comorbidity burden and length of stay for patients; Patients with schizophrenia 
had twice the rate of mortality due to cardiometabolic multimorbidities as compared to patients with bipolar disorder 
Domino et al., 20142 Positive association between adherence to antipsychotic medications and number of medical conditions 
Filipcic et al., 2019 
Age was not significantly associated with multimorbidity among cases; Female cases had a higher prevalence of 
multimorbidity than males; Interaction between age and sex – female cases under 35 years of age had a higher prevalence of 
multimorbidity than same-aged controls 
Gabilondo et al., 2017 Female cases had a higher prevalence of multimorbidity than males 
Islam et al., 2017 
Sex (females > males) and age (older adults > 40 years) were significantly associated with multimorbidity independently, but 
interaction was not significant 
Jahrami et al., 20173 
Cases with multimorbidity had excessive dietary intake, decreased physical activity and higher prevalence of smoking and 
alcohol intake, as compared to controls 
Kugathasan et al., 
20191 
Patients with schizophrenia had an increased mortality rate compared to controls, independent of the number of somatic 
diseases; Cases had more than double hazard rate for all individual disease categories 
Nishanth et al., 2017 Cases with multimorbidity were older, married, and female, and had longer duration of illness and longer duration of treatment 
Smith et al., 2013 Higher proportions of female cases had multimorbidity (2+ and 3+ conditions) as compared to male cases 
Stubbs et al., 2016 
Multimorbidity present across all age groups; Highest odds of multimorbidity in younger age groups (those aged 18-44 years) 
for those with psychosis 
Woodhead et al., 
20143 
Smoking and high BMI accounted for excess physical morbidity among cases 
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Appendix 3G: Prevalence of multimorbidity (2+ conditions) among people with psychosis (n=13) 
 
 Notes:  
*Studies which examined clusters of conditions  
Nishanth et al. (2017) did not describe included conditions in the definition of multimorbidity  
Abbreviations: 
CI = confidence interval; ES = effect size  
Heterogeneity between groups: p = 0.136
Overall  (I^2 = 99.99%, p = 0.00);
Cohort
Kugathasan et al., 2019*
Islam et al., 2017
Bhalla et al., 2018
Carney et al., 2006
Bouza et al., 2010*
Woodhead et al., 2014
Gabilondo et al., 2017
Study
Nishanth et al., 2017
Cross-Sectional
Domino et al., 2014
Filipcic et al., 2019
Stubbs et al., 2016
Smith et al., 2013
Correll et al., 2017
10
included
121
40
46
12
12
47
conditions
6
15
9
32
6
Number of
0.43 (0.25, 0.60)
0.63 (0.63, 0.64)
0.46 (0.43, 0.49)
0.91 (0.91, 0.91)
0.51 (0.48, 0.54)
0.32 (0.31, 0.32)
0.16 (0.15, 0.17)
0.29 (0.28, 0.30)
ES (95% CI)
0.38 (0.28, 0.48)
0.41 (0.40, 0.41)
0.40 (0.35, 0.46)
0.32 (0.31, 0.34)
0.34 (0.33, 0.34)
0.39 (0.39, 0.40)
100.00
7.71
%
7.70
7.71
7.70
7.71
7.71
7.71
Weight
7.54
7.71
7.66
7.71
7.71
7.71
  
-.5 0 .5 1 1.5
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Appendix 3H: Prevalence of multimorbidity (3+ conditions) among people with psychosis (n=9) 
 
Notes:  
*Studies which examined clusters of conditions  
Nishanth et al. (2017) did not describe included conditions in the definition of multimorbidity  
Abbreviations: 
CI = confidence interval; ES = effect size  
Heterogeneity between groups: p = 0.136
Overall  (I^2 = 99.92%, p = 0.00);
Smith et al., 2013
Domino et al., 2014
Gabilondo et al., 2017
Correll et al., 2017
Bouza et al., 2010*
Cross-Sectional
Kugathasan et al., 2019*
Study
Cohort
Nishanth et al., 2017
Carney et al., 2006
Woodhead et al., 2014
32
6
47
6
12
10
conditions
46
12
included
Number of
0.22 (0.14, 0.30)
0.18 (0.17, 0.19)
0.21 (0.21, 0.22)
0.15 (0.14, 0.16)
0.19 (0.19, 0.20)
0.17 (0.16, 0.17)
0.47 (0.46, 0.47)
ES (95% CI)
0.17 (0.10, 0.26)
0.33 (0.30, 0.36)
0.06 (0.06, 0.07)
100.00
11.23
11.24
11.23
11.24
11.24
11.24
Weight
10.26
11.09
11.23
%
  
-.2 0 .2 .4 .6
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Appendix 3I: Sensitivity analysis: Risk of multimorbidity (3+ conditions) for people with psychosis compared to people 
who do not have psychotic disorders (n=5) 
 
Abbreviations: 
CI = confidence interval; RR = risk ratio  
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Appendix 3J: Sensitivity analyses for risk of bias assessment 
Risk of multimorbidity (2+ conditions) for people with psychosis compared to those who do not have psychotic disorders 
Notes:  
*I2 (heterogeneity) values are not applicable for sub-group analyses with only one study 
Abbreviations: 
CI = confidence interval; RR = risk ratio 
  
Domain 
Cross-sectional Studies Cohort Studies Pooled Estimate 
Number 
of 
Studies 
Sample 
Size 
RR 
(95%CI) 
I2* 
Number 
of 
Studies 
Sample 
Size 
RR 
(95%CI) 
I2 
Number 
of 
Studies 
Sample 
Size 
RR 
(95%CI) 
I2 
Representativeness 
of source 
population 
1 181,653 
3.02 
(2.84,3.21) 
N/A 3 7,689,817 
1.24 
(1.11,1.40) 
96.7% 4 7,871,470 
1.54 
(1.16,2.03) 
99.5% 
Selection of 
exposed and non-
exposed cohorts 
3 1,914,644 
2.18 
(1.33,3.59) 
99.6% 4 8,338,110 
1.60 
(1.14,2.24) 
99.7% 7 10,252,754 
1.83 
(1.46,2.28) 
99.7% 
Assessment of 
exposure 
3 1,734,157 
1.48 
(0.99,2.23) 
99.0% 3 8,336,520 
1.85 
(1.25,2.76) 
99.8% 6 10,070,677 
1.66 
(1.35,2.05) 
99.6% 
Assessment of 
outcome 
2 1,732,991 
1.86 
(1.14,3.03) 
99.4% 3 8,336,520 
1.85 
(1.25,2.76) 
99.8% 5 10,069,511 
1.85 
(1.48,2.32) 
99.7% 
Accounting for 
confounding 
factors 
1 1,166 
0.93 
(0.80,1.08) 
N/A 1 648,293 
3.53 
(3.33,3.74) 
N/A 2 649,459 
1.81 
(0.49,6.71) 
99.6% 
Assessment for 
confounding 
factors 
3 1,914,644 
2.18 
(1.33,3.59) 
99.6% 3 8,336,520 
1.85 
(1.25,2.76) 
99.8% 6 10,251,164 
2.01 
(1.58,2.55) 
99.7% 
Missing Data 4 1,915,810 
1.77 
(1.15,2.74) 
99.5% 4 8,338,110 
1.60 
(1.14,2.24) 
99.7% 8 10,253,920 
1.69 
(1.37,2.08) 
99.6% 
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Appendix 3K: Exploratory analysis: Risk of physical health multimorbidity (2+ conditions) for people with psychosis 
compared to people who do not have psychotic disorders (n=6) 
 
Abbreviations: 
CI = confidence interval; RR = risk ratio 
.
.
Overall  (I-squared = 99.4%, p = 0.000)
Subtotal  (I-squared = 99.5%, p = 0.000)
Cohort
Kugathasan et al., 2019
Subtotal  (I-squared = 96.4%, p = 0.000)
Study
Gabilondo et al., 2017
Cross-Sectional
Filipcic et al., 2019
Woodhead et al., 2014
Stubbs et al., 2016
Smith et al., 2013
Denmark
Country
Spain
Croatia
UK
International
UK
1.62 (1.36, 1.94)
1.77 (1.15, 2.74)
1.41 (1.40, 1.43)
1.35 (1.22, 1.48)
RR (95% CI)
1.28 (1.24, 1.33)
0.93 (0.80, 1.08)
2.38 (2.22, 2.56)
3.02 (2.84, 3.21)
1.45 (1.41, 1.49)
100.00
65.82
17.14
34.18
Weight
17.03
15.24
16.70
16.81
17.08
%
  
1 2 3 4 5 6
Risk Ratio
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Appendix 4L: The RECORD statement – checklist of items, extended from the STROBE statement, that should be 
reported in observational studies using routinely collected health data  
 Item No. STROBE items Location in manuscript where items 
are reported (page numbers) 
RECORD items Location in manuscript where items 
are reported (page numbers) 
Title and abstract  
 1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract (b) Provide in 
the abstract an informative and balanced summary 
of what was done and what was found 
a. 51 
b. 51 
RECORD 1.1: The type of data used should be specified in the 
title or abstract. When possible, the name of the databases used 
should be included. 
RECORD 1.2: If applicable, the geographic region and 
timeframe within which the study took place should be 
reported in the title or abstract. 
RECORD 1.3: If linkage between databases was conducted for 
the study, this should be clearly stated in the title or abstract. 
51 
Introduction 
Background 
rationale 
2 Explain the scientific background and rationale for 
the investigation being reported 
52-53   
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
53-54   
Methods 
Study Design 4 Present key elements of study design early in the 
paper 
54-56   
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
55-56   
Participants 6 (a) Cohort study - Give the eligibility criteria, and 
the sources and methods of selection of 
participants. Describe methods of follow-up 
Case-control study - Give the eligibility criteria, 
and the sources and methods of case ascertainment 
and control selection. Give the rationale for the 
choice of cases and controls 
Cross-sectional study - Give the eligibility criteria, 
and the sources and methods of selection of 
participants 
 
(b) Cohort study - For matched studies, give 
matching criteria and number of exposed and 
unexposed 
Case-control study - For matched studies, give 
matching criteria and the number of controls per 
case 
55-56 RECORD 6.1: The methods of study population selection 
(such as codes or algorithms used to identify subjects) should 
be listed in detail. If this is not possible, an explanation should 
be provided.  
RECORD 6.2: Any validation studies of the codes or 
algorithms used to select the population should be referenced. 
If validation was conducted for this study and not published 
elsewhere, detailed methods and results should be provided. 
RECORD 6.3: If the study involved linkage of databases, 
consider use of a flow diagram or other graphical display to 
demonstrate the data linkage process, including the number of 
individuals with linked data at each stage. 
Supplementary Appendix 4M, 55-56 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable. 
56-58 RECORD 7.1: A complete list of codes and algorithms used to 
classify exposures, outcomes, confounders, and effect 
modifiers should be provided. If these cannot be reported, an 
explanation should be provided. 
Supplementary Appendix 4M 
Data sources/ 
measurement 
8 For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). 
Describe comparability of assessment methods if 
there is more than one group 
56-58   
Bias 9 Describe any efforts to address potential sources of 
bias 
59   
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Study size 10 Explain how the study size was arrived at 59   
Quantitative 
variables 
11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which 
groupings were chosen, and why 
56-60   
Statistical 
methods 
12 (a) Describe all statistical methods, including those 
used to control for confounding 
(b) Describe any methods used to examine 
subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study - If applicable, explain how loss to 
follow-up was addressed 
Case-control study - If applicable, explain how 
matching of cases and controls was addressed 
Cross-sectional study - If applicable, describe 
analytical methods taking account of sampling 
strategy 
(e) Describe any sensitivity analyses 
59-60    
Data access and 
cleaning 
methods 
 .. 54. 59 RECORD 12.1: Authors should describe the extent to which 
the investigators had access to the database population used to 
create the study population. 
RECORD 12.2: Authors should provide information on the 
data cleaning methods used in the study. 
54. 59 
Linkage  .. 54-55 RECORD 12.3: State whether the study included person-level, 
institutional-level, or other data linkage across two or more 
databases. The methods of linkage and methods of linkage 
quality evaluation should be provided. 
54-55 
Results 
Participants 13 (a) Report the numbers of individuals at each stage 
of the study (e.g., numbers potentially eligible, 
examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and 
analysed) 
(b) Give reasons for non-participation at each 
stage. 
(c) Consider use of a flow diagram 
60 RECORD 13.1: Describe in detail the selection of the persons 
included in the study (i.e., study population selection) 
including filtering based on data quality, data availability and 
linkage. The selection of included persons can be described in 
the text and/or by means of the study flow diagram. 
60 
Descriptive data 14 (a) Give characteristics of study participants (e.g., 
demographic, clinical, social) and information on 
exposures and potential confounders 
(b) Indicate the number of participants with 
missing data for each variable of interest 
(c) Cohort study - summarise follow-up time (e.g., 
average and total amount) 
Table 4.1, 62   
Outcome data 15 Cohort study - Report numbers of outcome events 
or summary measures over time 
Case-control study - Report numbers in each 
exposure category, or summary measures of 
exposure 
Cross-sectional study - Report numbers of outcome 
events or summary measures 
62-63   
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g., 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
Tables 4.2 and 4.3, 62-63   
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(b) Report category boundaries when continuous 
variables were categorized 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful 
time period 
Other analyses 17 Report other analyses done—e.g., analyses of 
subgroups and interactions, and sensitivity analyses 
66   
Discussion 
Key results 18 Summarise key results with reference to study 
objectives 
66-69   
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any 
potential bias 
70-71 RECORD 19.1: Discuss the implications of using data that 
were not created or collected to answer the specific research 
question(s). Include discussion of misclassification bias, 
unmeasured confounding, missing data, and changing 
eligibility over time, as they pertain to the study being 
reported. 
70-71 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
70-71   
Generalisability 21 Discuss the generalisability (external validity) of 
the study results 
70-71   
Other Information 
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
71   
Accessibility of 
protocol, raw 
data, and 
programming 
code 
 ..  RECORD 22.1: Authors should provide information on how to 
access any supplemental information such as the study 
protocol, raw data, or programming code. 
N/A 
*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD 
Working Committee.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement.  
PLoS Medicine 2015; in press. 
*Checklist is protected under Creative Commons Attribution (CC BY) license.  
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Appendix 4M: Chronic conditions included in definition of multimorbidity 
 
Notes: 
1Rheumatoid arthritis and osteoarthritis were captured by two variables in the administrative data holdings, but presence of either condition counted as one chronic condition for our definition of multimorbidity. 
2Mood and anxiety disorders were captured by two variables in the administrative data holdings, but presence of one or both conditions counted as one chronic condition for our definition of multimorbidity. 
3ICES-derived cohort 
Abbreviations: 
CIHI-DAD: Canadian Institute for Health Information Discharge Abstract Database; CIHI-SDS: Canadian Institute for Health Information Same Day Surgery Database; NACRS: National Ambulatory Care Reporting System; ODB: Ontario Drug 
Benefit Claims; OHIP: Ontario Health Insurance Plan Claims Database; OMHRS: Ontario Mental Health Reporting System; RPDB: Registered Persons Database 
References: 
Ryan BL, Jenkyn KB, Shariff SZ, et al. Beyond the grey tsunami: a cross-sectional population-based study of multimorbidity in Ontario. Can J Public Heal. 2018;109(5-6):845-854. 
Conditions in 
Multimorbidity 
Definition 
Variables in administrative data 
holdings 
Database
260
 Diagnosis of condition  Lookback Window Source 
Arthritis
1
 
Rheumatoid arthritis ORAD2016 database
3
 
≥1 Hospitalization with RA diagnosis code (ICD-9 or ICD-10), or ≥3 OHIP visits with RA diagnosis code 
within 2 years with ≥1 of the claims made by musculoskeletal specialist 
*Only patients over the age of 15 included 
DAD: 28 years; OHIP: 24 years, 9 months 
5-year washout/lookback for incidence 
CIHI-DAD, OHIP, RPDB 
Osteoarthritis Algorithm Diagnosis of OA based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 10 years CIHI-DAD, OHIP, RPDB 
Asthma Asthma ASTHMA2016 database
3
 ≥1 Hospitalization or ≥2 OHIP visits within 2 years 
DAD: 25 years; OHIP: 24 years, 9 months; SDS: 25 years 
5-year washout/lookback for incidence 
CIHI-DAD, OHIP, CIHI-SDS, RPDB 
Cancer Cancer OCR database 
1 acute care diagnosis present on admission in the look-back window, or 2 OHIP visit diagnoses within 
two years, with the first of the two visit dates defined as the diagnosis date, in the look-back window  
5 years CIHI-DAD, OHIP, RPDB 
Congestive heart 
failure 
Congestive heart failure CHF2016 database
3
 
≥1 Hospitalization or ≥1 OHIP/ED visit, followed by ≥1 Hospitalization/ ED/ OHIP visit within 1 year 
*Only patients over the age of 40 included 
DAD: 28 years; OHIP: 25 years; SDS: 25 years; OMHRS: 11 years 
3-year washout/lookback for incidence 
CIHI-DAD, OHIP, NACRS, OMHRS, 
RPDB  
COPD (including 
bronchitis) 
COPD (including bronchitis) COPD2016 database
3
 
≥1 Hospitalization or ≥1 OHIP visit within 2 years 
*Only patients over the age of 35 included 
DAD: 25 years; OHIP: 24 years, 9 months; SDS: 25 years  
5-year washout/lookback for incidence 
CIHI-DAD, OHIP, CIHI-SDS, RPDB 
Cardiovascular 
disease  
Cardiovascular disease  Algorithm 
Flag if diagnosis of any of these conditions: 
5 years CIHI-DAD, OHIP, RPDB 
Coronary Artery 
Disease (including 
MI and angina) 
1 acute care diagnosis present on admission or 2 OHIP visit diagnoses within 2 
years, with the first of the two visit dates defined as the diagnosis date 
Peripheral vascular 
disease 
1 acute care diagnosis present on admission in the lookback window (5 years), or 
2 OHIP visit diagnoses within 2 years, with the first of the two visit dates defined 
as the diagnosis date in the look-back window (5 years) 
Arrhythmia 
1 acute care diagnosis present on admission in the lookback window (5 years), or 
2 OHIP visit diagnoses within 2 years, with the first of the two visit dates defined 
as the diagnosis date in the look-back window (5 years) 
Dementia Dementia DEMENTIA2016 database 
≥1 Hospitalization, or ≥1 ODB claim for cholinesterase inhibitors, or ≥3 OHIP visits at least 30 days apart 
within 2 years 
*Only patients over the age of 40 included 
10 years CIHI-DAD, OHIP, ODB, RPDB 
Diabetes Diabetes ODD2016 database
3
 
≥2 OHIP diagnosis 250 within 2 years, or ≥1 Hospitalization within 2 years, or ≥1 OHIP fee code 
(Q040/K020/K030) within 2 years 
*Patients over 19 years of age 
DAD: 28 years; OHIP: 24 years, 9 months; SDS: 25 years  
3-year washout/lookback for incidence 
CIHI-DAD, OHIP CIHI-SDS, NACRS, 
RPDB 
HIV HIV HIV2016 database
3
 
≥3 OHIP visits within 3 years 
*Only patients over the age of 18 included 
DAD:  25 years; OHIP: 24 years 
2-year washout/lookback for incidence 
OHIP, RPDB 
Hypertension Hypertension HYPER2016 database
3
 
≥1 Hospitalization or ≥2 OHIP visits within 2 years, or 1 OHIP visit followed by Hospitalization/ OHIP 
visit within 2 years, or Hospitalization (<1991) followed by 1 Hospitalization (>1991) 
*Only patients over the age of 20 included 
DAD: 28 years; OHIP: 24 years, 9 months; SDS: 25 years  
3-year washout/lookback for incidence 
CIHI-DAD, OHIP, RPDB 
Inflammatory Bowel 
Disease 
Inflammatory Bowel Disease OCCC2016 database
3
 
2 Years of OHIP eligibility and ≥5 Hospitalization/ OHIP visits within 4 years, or ≥3 Hospitalization/ ED/ 
OHIP visits within 4 years with no 2-year OHIP eligibility 
*Patients between 18 and 64 years of age 
8 years 
 
CIHI-DAD, OHIP, NACRS, ODB, 
RPDB 
Chronic kidney 
disease 
Chronic kidney disease Algorithm 
Diagnosis of CKD based on one of the ICD-9 or ICD-10 codes in DAD or two in OHIP within a 2-year 
period  
10 years CIHI-DAD, OHIP, RPDB 
Chronic liver disease Chronic liver disease Algorithm Diagnosis of CLD based on 1 hospitalization or 2 OHIP visit diagnoses or fee codes within 2 years 10 years CIHI-DAD, OHIP, RPDB 
Mood or Anxiety 
Disorder
2
 
Anxiety Algorithm Diagnosis of anxiety based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 5 years CIHI-DAD, OHIP, OMHRS, RPDB 
Mood disorder Algorithm Diagnosis of MD based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 5 years CIHI-DAD, OHIP, OMHRS, RPDB 
Osteoporosis Osteoporosis Algorithm Diagnosis of osteoporosis based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 10 years CIHI-DAD, OHIP, RPDB 
Stroke/ transient 
ischemic attack 
Stroke/ transient ischemic attack Algorithm Diagnosis of stroke based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 10 years CIHI-DAD, OHIP, RPDB 
Urinary incontinence Urinary incontinence Algorithm Diagnosis of UI based on 1 hospitalization or 2 OHIP visit diagnoses within 2 years 5 years CIHI-DAD, OHIP, RPDB 
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Appendix 4N: Detailed methods 
PEPP program 
Suspected cases are screened by a psychiatric nurse or social worker within 24 hours of 
referral, and are followed up by a full psychiatric assessment within one week, as needed. 
Patients between the ages of 16 and 50 who reside in the defined catchment area, have 
been diagnosed with nonaffective psychotic disorder, have not received treatment with 
antipsychotic medications for over 1 month, do not have a developmental disability or 
organic psychosis, and do not have ongoing criminal charges potentially resulting in 
contact with the criminal justice system are accepted into the PEPP program.367–369 The 
PEPP program is similar to its US counterpart, the National Institute of Mental Health 
Recovery After an Initial Schizophrenia Episode-Early Treatment Program (NAVIGATE 
RAISE-ETP).411 
Severity of psychotic symptoms and persistence of impaired functioning 
Typically, the severity of psychosis is assessed using an eight-item Likert-type scale in 
the DSM-V which measures the severity of symptoms which define schizophrenia 
spectrum disorders (e.g. hallucinations, disorganized speech, abnormal psychomotor 
behaviour, negative symptoms, delusions), and cognitive, depressive, and manic 
symptoms from 0 (absent) to 4 (severe).25 However, this information is not available to us 
in the health administrative data, therefore we will use a proxy measure of total number 
of hospital days to assess psychosis severity. A recent study demonstrated the validity of 
this proxy measure through a dose-response association between psychosis severity and 
number of hospital days.375 
People who experience psychosis for prolonged periods may face impairment in activities 
of daily living. This includes inability to partake in gainful employment, and 
consequently, these people may depend on social assistance for their income.376,377 A 
recent study in the U.S. found that time to receipt of social assistance benefits for patients 
with psychosis treated by the NAVIGATE RAISE-ETP could be significantly predicted 
by higher positive symptom scores (on the Positive and Negative Syndrome Scale 
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(PANSS) used to measure psychosis severity) (HR= 1.06, 95% CI 1.01, 1.11, p= 
0.021).379 In other words, patients who had impaired functioning, as identified by 
PANSS, received income from social assistance earlier. Because we lack information on 
persistence of impaired functioning, we will use a proxy measure of time on social 
assistance, i.e. length of time a patient has received the Ontario Drug Benefit (ODB) over 
the follow-up period. This measure has been calculated from the time between the earliest 
and latest prescription dispensing date for patients receiving ODB. Furthermore, as noted 
above, the NAVIGATE RAISE-ETP and PEPP programs are similar in the provision of 
early intervention services for young people with psychosis.  
Poisson regression model 
We used the xtpoisson command in Stata MP version 16.1 to compute prevalence ratios. 
This command is appropriate for producing estimates from matched-cohort data.382 We 
specifically used a robust variance estimator given that use of conventional variance 
estimators may produce standard errors, p-values, and confidence intervals which are too 
large. Furthermore, the robust variance estimator results in more accurate 
coverage,381,382,412,413 and may account for the outcome being a poor fit for the Poisson 
distribution.414 
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Appendix 4O: Counts of chronic conditions for people with and without psychotic 
disorders at 10-year follow-up (n=2,198) 
 
Number of 
Chronic 
Conditions 
People with Psychotic 
Disorders (n=439) 
N (%) 
People without Psychotic 
Disorders (n=1,759) 
N (%) 
0 207 (47.2) 1,032 (58. 7) 
1 170 (38.7) 530 (30.1) 
2 49 (11.2) 149 (8.5) 
3+* 13 (3.0) 48 (2.7) 
Notes:  
*The number of chronic conditions in this category range from 3 to 7. Exact counts have 
been suppressed due to ICES privacy regulations. 
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Appendix 4P: Counts of chronic conditions for people with psychotic disorders 
before study entry and during the follow-up period (n=439) 
 
Number of 
Chronic 
Conditions 
Before study entry  
N (%) 
During the follow-up period  
N (%) 
0 53 (12.1) 242 (55.1) 
1 327 (74.5) 161 (36. 7) 
2+* 59 (13.4) 36 (8.2) 
Notes:  
*The number of chronic conditions in this category range from 2 to 7. Exact counts have 
been suppressed due to ICES privacy regulations. 
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Appendix 4Q: Prevalence ratios of sociodemographic factors and their association 
with multimorbidity among people without psychotic disorders at 10-year follow-up 
(n=1,759) 
Abbreviations: 
CI = confidence interval; PR = prevalence ratios 
Notes:  
1Age categories at follow-up reflect age of participants 10 years after baseline. 
*Prevalence ratio is significant at α=0.05 
 
 
  
Sociodemographic characteristics 2+ conditions 
PR (95% CI) 
Age group1 
26-30 years Reference 
31-35 years 0.81 (0.54, 1.20) 
36-40 years 1.86 (1.34, 2.57)* 
Sex 
Males Reference 
Females 2.03 (1.59, 2.73)* 
Material Deprivation 
Quintile 1 (Least Deprived) Reference 
Quintile 2 1.00 (0.64, 1.58) 
Quintile 3 1.02 (0.68, 1.52) 
Quintile 4 0.86 (0.57, 1.29) 
Quintile 5 (Most Deprived) 1.10 (0.74, 1.67) 
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Appendix 4R: Prevalence ratios of sociodemographic factors and their association 
with multimorbidity among people with psychotic disorders at 10-year follow-up 
(n=439) 
 
Abbreviations: 
CI = confidence interval; PR = prevalence ratios 
Notes:  
11+ physical health condition for people with psychosis and mood/anxiety disorders (an 
omnibus mental health condition). 
2Prevalence ratios have been adjusted for total hospital days (severity of psychotic 
symptoms) and length of time on the Ontario Drug Benefit (proxy measure of social 
assistance; persistence of impaired functioning). 
3Age categories at follow-up reflect age of participants 10 years after baseline. 
*Prevalence ratio is significant at α=0.05  
 
 
 
  
Sociodemographic 
characteristics 
3+ conditions 
PR (95% CI) 
1+ condition1 
PR (95% CI)2 
Age group3 
26-30 years Reference Reference 
31-35 years 1.20 (0.15, 9.37) 1.25 (0.89, 1.76) 
36-40 years 3.72 (0.59, 23.41) 1.54 (1.11, 2.13)* 
Sex 
Males Reference Reference 
Females 1.82 (0.59, 5.60) 1.17 (0.88, 1.55) 
Material Deprivation 
Quintile 1 (Least Deprived) Reference Reference 
Quintile 2 0.78 (0.02, 26.4) 1.60 (0.94, 2.74) 
Quintile 3 2.42 (0.24, 24.6) 1.32 (0.74, 2.35) 
Quintile 4 3.20 (0.50, 20.5) 1.80 (1.11, 2.93)* 
Quintile 5 (Most Deprived) 3.13 (0.38, 25.6) 2.08 (1.28, 3.37)* 
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Appendix 4S: Prevalence ratios of sociodemographic factors and their association 
with multimorbidity among people without psychotic disorders at 10-year follow-up 
(n=1,759) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
CI = confidence interval; PR = prevalence ratios 
Notes:  
1Age categories at follow-up reflect age of participants 10 years after baseline. 
*Prevalence ratio is significant at α=0.05  
 
 
 
  
Sociodemographic characteristics 3+ conditions 
PR (95% CI) 
Age group1 
26-30 years Reference 
31-35 years 1.19 (0.41, 3.42) 
36-40 years 5.35 (2.31, 12.34)* 
Sex 
Males Reference 
Females 2.03 (1.06, 3.89)* 
Material Deprivation 
Quintile 1 (Least Deprived) Reference 
Quintile 2 0.48 (0.16. 1.42) 
Quintile 3 0.60 (0.22, 1.68) 
Quintile 4 1.06 (0.50, 2.24) 
Quintile 5 (Most Deprived) 1.13 (0.50, 2.55) 
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Appendix 4T: Severity of psychotic symptoms and persistence of impaired 
functioning, and their association with multimorbidity among people with psychotic 
disorders at 10-year follow-up (n=439) 
Psychotic Symptoms 3+ conditions  
PR (95% CI) 
1+ conditions1  
PR (95% CI)2 
Severity 
Total hospital days (30-day intervals) 1.17 (0.95, 1.44) 1.01 (0.95, 1.07) 
Persistence 
Length of time on ODB (365-day intervals) 0.98 (0.87, 1.10) 1.06 (1.02, 1.09)* 
Abbreviations: 
CI = confidence interval; ODB = Ontario Drug Benefit; PR = prevalence ratio 
Notes:  
11+ physical health condition for people with psychosis and mood/anxiety disorders (an 
omnibus mental health condition). 
2Prevalence ratios have been adjusted for age, sex, and material deprivation. 
*Prevalence ratio is significant at α=0.05. 
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Appendix U: ICES Dataset Creation Plan 
Project Initiation 
This Section must be Completed Prior to Project Dataset(s) Creation 
Project Title: Long-Term Outcomes of First-Episode Psychosis: 10-Years After Admission to an Early 
Psychosis Intervention Program 
Project TRIM number: 2018 0906 327 000 (ICES Western), 2018-465 (DAS) 
Research Program: MHA 
Site: DAS 
Project Objectives: Insert Project Objectives as listed in the approved ICES Project PIA 
1.) To identify socio-demographic and clinical factors at admission that are associated 
with long-term trajectories of mental health service use among people with first-episode 
psychosis, including mental health related emergency department visits, psychiatric 
hospitalizations, and involuntary admissions 
2.) To identify socio-demographic and clinical factors at admission that are associated 
with other outcome indicators at 10-year follow-up, including use of social assistance 
programs, contact for alcohol- and substance-use problems, self-harm attempts, and 
mortality 
3.) To describe the incidence of physical co-morbidities and multimorbidity after a first 
episode of psychosis  
ICES Project PIA Initial Approval 
Date: 
The ICES Employee or agent who is responsible for creating the Project Dataset(s) is responsible for ensuring 
there is an approved ICES Project PIA and verifying the date of approval prior to creating the Project Dataset(s) 
2018-Mar-22  
Principal Investigator (PI): Kelly Anderson 
Check the applicable box if the PI 
is an ICES Student/Trainee 
☐ ICES Student ☐ ICES Fellow ☐ ICES Post-Doctoral Trainee     ☐ Visiting Scholar 
Responsible ICES Scientist: Name the Responsible ICES Scientist if the PI is not a Full Status ICES Scientist 
N/A 
Project Team Member(s) 
Responsible for Project Dataset 
Creation and/or Statistical 
Analysis and date joined (list all): 
All person(s) (ICES Analyst, Appointed Analyst, Analytic Epidemiologist, PI, and/or Student) responsible for 
creating the Project Dataset(s) and/or statistical analysis on the Research Analytics Environment (RAE) and the 
date they joined the project must be recorded 
 yyyy-mon-dd 
Other ICES Project Team 
Members and date joined (list all): 
All other Research Project Team Members (e.g., Research Administrative Assistants, Research Assistants, 
Project Managers, Epidemiologists) and the date they joined the project must be recorded 
 yyyy-mon-dd 
Confirmation that DCP is 
consistent with Project 
Objectives: 
The following individuals must confirm that the ICES Data provided for in this DCP is relevant (e.g., with respect 
to cohort, timeframe, and variables) and required to achieve the Project Objectives stated in the ICES Project 
PIA prior to initial Project Dataset creation: 1) PI; 2) Responsible ICES Scientist if the PI is not a Full Status ICES 
Scientist, or a second ICES Scientist or the Scientific Program Lead if the PI is creating both the DCP and the 
Project Dataset[s]; 3) ICES Research and Analysis Staff creating the DCP; and 4) ICES Analytic Staff (ICES 
Employee or agent responsible for creating the Project Dataset[s]). This may be delegated either verbally or via 
e-mail. 
Principal Investigator ☒ 2018-Aug-13 
Responsible ICES Scientist or Second ICES Scientist/Lead ☐ yyyy-mon-dd 
ICES Research and Analysis Staff Creating the DCP ☐ yyyy-mon-dd 
ICES Analytic Staff ☐ yyyy-mon-dd 
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Designated ICES Research and 
Analysis Staff accountable for 
Project Documentation: 
The person named (ICES staff) is accountable for ensuring that the approved ICES Project PIA, ICES Project PIA 
Amendments, and DCP are saved on the T Drive, ensuring ICES Project PIA Amendments are submitted as 
required, ensuring DCP Amendments are documented, and sharing the final DCP with the PI/Responsible ICES 
Scientist at project completion 
 
DCP Creation Date and Author: Date DCP was finalized prior to Project 
Dataset(s) creation Name of person who created the DCP 
Date Name 
2018-Aug-01 Kelly Anderson 
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ICES Data 
This Section must be Completed Prior to Project Dataset(s) Creation 
The ICES Employee or agent who is responsible for creating the Project Dataset(s) must ensure that 
this list includes only data listed in the ICES Project PIA 
Changes to this list after initial ICES Project PIA approval require an ICES Project PIA Amendment 
Mandatory for all datasets that are available by 
individual year 
General Use Datasets – Health Services Years (where applicable) 
CCRS 1997 – 2016 
CIHI DAD  1992 – 2016 
CIHI SDS 1992 – 2016 
CONTACT 1997 – 2016 
NACRS 1992 – 2016 
ODB 1997 – 2016 
OHIP 1992 – 2016 
OMHRS 1992 – 2016 
General Use Datasets – Population  
RPDB 1997 – 2016 
General Use Datasets - Other  
ASTHMA 2016 
CHF 2016 
COPD 2016 
HIV 2016 
HYPER 2016 
MOMBABY 2016 
OCCC 2016 
ODD 2016 
OMID 2016 
ONMARG 2006 
ORAD 2016 
Controlled Use Datasets  
OCR 2016 
Other Datasets  
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Project Amendments and Reconciliation 
ICES Project PIA Amendment 
History (add additional rows as 
needed): 
Privacy approval 
date 
Person who submitted 
amendment 
Note that any changes to the list of ICES Data or Project 
Objectives require an ICES Project PIA Amendment 
Date Name Amendment 
yyyy-mon-dd   
DCP Amendment History (add 
additional rows as needed): Date DCP 
amended 
Person who made the DCP 
amendment 
Note that any DCP amendments involving changes to the list 
of ICES Data or Project Objectives require an ICES Project PIA 
Amendment 
Date Name Amendment 
yyyy-mon-dd   
Date Programs/DCP reconciled The person(s) creating the dataset and/or analyzing the data are responsible for ensuring that the  final DCP 
reflects the final program(s) when the project is completed 
yyyy-mon-dd 
 
 
Project Cohort 
Study Design ☒ Cohort study  ☐ Matched cohort study  ☐ Case-control study 
☐ Cross-sectional study ☐ Other (specify):   
Index Event / Inclusion Criteria All patients admitted to the Prevention and Early Intervention Program for Psychoses 
(PEPP) between fiscal years 1997 and 2006, identified through a primary data linkage 
(previously linked on TRIM #2016 0900 300 010). Cohort members can be identified by the 
variable EPI_user (1). The index date from the linked dataset is admit_date (NOT the index 
date defined in the original database). 
Estimated Size of Cohort  
(if known) 
Approximately 450 people 
Exclusions (in order) Step Description 
1 Invalid IKN  
2 Admission date (admit_date) occurs after March 31 2007  
 
 
Project Time Frame Definitions 
 
 
 
 
 
 
Accrual Start/End Dates April 1 1997 to March 31 2007 (ie. fiscal years 1997 to 2006 inclusive) 
Max Follow-up Date March 31 2017 
When does observation window 
terminate? 
Index date + 10 years – censor people at date of last contact, loss of OHIP eligibility,  
death, or end of follow-up period 
Lookback Window(s) Identification of Control Group: 10 years prior to the index date 
Physical Comorbidities: 10 years prior to the index date 
 
Observation Window 
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Cohort Build- Unexposed Group 
Index Event / Inclusion Criteria 
for unexposed group 
General population comparison group 
Estimated Size of Cohort  
(if known) 
~1800 controls 
Exclusions (in order) Step     Description 
    1        Age < 16 or > 50 on index date 
    2        Non-Ontario resident (first 2 characters of PRCDDA is NE ‘35’ -  use %GETDEMO) on 
index date 
    3        Patient in exposed group 
    4   Presence of a diagnostic code for schizophrenia, schizoaffective disorder, or                    
psychosis NOS at any point in the medical records  
• OMHRS: AXIS1_DSM4CODE_DISCH1-3 code for schizophrenia, schizoaffective 
disorder, or psychosis NOS (lookback from database inception [October 2005] 
up to March 31, 2017, inclusive) 
• DAD: DXCODE or DX10CODE (dxtype=alldx) for schizophrenia, schizoaffective 
disorder, or psychosis NOS (lookback from database inception [April 1988]-
March 31, 2017, inclusive) 
• OHIP: DXCODE for schizophrenia, schizoaffective disorder, or psychosis NOS 
(lookback from database inception [July 1991]-March 31, 2017, inclusive) 
• NACRS: DXCODE or DX10CODE (dxtype=alldx) for schizophrenia, schizoaffective 
disorder, or psychosis NOS (lookback from database inception [July 2000]-
March 31, 2017, inclusive) 
            NOTE 1: Diagnostic codes listed in Appendix A. 
Matching Criteria  Match on age, sex, forward sortation area (FSA). Choose 4 unexposed patients for every 
exposed patient (1-4 matching exposed:unexposed). The control assumes the same index 
date as the matched case. 
 
 
Variable Definitions (add additional rows as needed) 
Variable/Concept Definition 
Main Comparison Groups 
fep People with first-episode psychosis, defined based on linked database from TRIM #2016 0900 
300 010. All cases from the linked databasee are classified as fep = 1, and people from the 
matched comparison group are classified as fep = 0 
censor_date Date that the person was censored – occurs at date of last contact, end of OHIP elibigility, death, 
or end of follow-up period  
 
Baseline Characteristics 
NOTE: These are already defined for the exposed group (fep = 1) but will need to be pulled for the comparison group 
sex Sex from RPDB 
age Age on the index date, calculated based on date of birth from RPDB 
age_cat Categories for variable age, classified as follows: 
     1 = age 16 to 20 
     2 = age 21 to 25 
     3 = age 26 to 30 
     4 = age 31 to 35 
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Variable Definitions (add additional rows as needed) 
     5 = age 36 to 40 
     6 = age 41 to 45 
     7 = age 46 to 50 
income INCQUINT from %GETDEMO ( 1 = lowest income quintile, 5 = highest incomes quintile) 
rural RURAL from %GETDEMO (1 = rural, 0 = non-rural) 
dependency DEPENDENCY_Q_CSD from ONMARG (1 = least marginalized, 5 = most marginalized) 
deprivation DEPRIVATION_Q_CSD from ONMARG (1 = least marginalized, 5 = most marginalized) 
ethnic ETHNICCON_Q_CSD from ONMARG (1 = least marginalized, 5 = most marginalized) 
instability INSTABILITY_Q_CSD from ONMARG (1 = least marginalized, 5 = most marginalized) 
odb Flag if patient covered by ODB on index date (1) 
 
Variables for Exposed Group Only 
NOTE: These are already defined and just need to be pulled from the original dataset 
pepp_dx Diagnosis at time of admission to the PEPP program, obtained from the linked database 
index_dx Classify index diagnosis as follows:  
1 = Schizophrenia & Schizoaffective Disorder (ICD-9 = 295.X; ICD-10 = F20, F25) 
2 = Delusional Disorder (ICD-9 = 297.X; ICD-10 = F22, F24) 
3 = Other Psychoses (ICD-9 = 298.X; ICD-10 = F23, F28, F29) 
source_dx Source of the index diagnosis (1 = DAD or OMHRS, 2 = OHIP and/or ED) 
source_ohip If source OHIP/ED, then type of physician who made the diagnosis (1 = GP, 2 = Psychiatrist, 3 = 
GP + Psychiatrist, 4 = Other) 
psychiatrist_index Flag if patient had a psychiatrist involved at the index diagnosis, defined as source_dx = 1 OR 
source_ohip = 2 or 3 (1 = psychiatrist involved, 0 = no psychiatrist involved) 
year Fiscal year of index diagnosis 
prior_alcohol Flag if patient had prior history of contact with services for alcohol-related disorders (Appendix 
D) 
prior_substance Flag if patient had prior history of contact with services for substance-related disorders 
(Appendix E) 
primcare_pre6m Number of primary care visits for a mental health reason, defined as all mental health service 
codes and general service codes with a mental health diagnostic code (Appendix F) 
psych_pre6m Number of visits with a psychiatrist 
edtotal_pre6m Number of ED visits with a main diagnosis - mental health diagnostic code (ICD-9 291.x,292.x,and 
294.x-319.x, ICD-10 F codes), by triage category (CTAS 1-3 vs. 4-5). Use %GETNACRS, 
INCLscheduled=T. Exclude transfers (FROM_TYPE=’E’). 
edharm_pre6m Number of ED visits from edtotal_pre6m that were for self-harm (ICD 10 codes X60-X84). Use 
%GETNACRS, INCLscheduled=T. Exclude transfers (FROM_TYPE=’E’). 
edmh_pre6m Number of ED visits from edtotal_pre6m that were not for self-harm (ie. edtotal_pre6m – 
edharm_pre6m) 
hosptotal_pre6m Number of psychiatric hospital admissions. Use %GETCIHI and limit to non-elective admissions 
(ADMCAT U or E) for all hospitalizations at acute care institution (INSTTYPE AT or AP). Select first 
visit in an episode of care (Sort data by EPI, EPIVISIT, EPIFLAG and pll the record with 
FIRST.EPI=1). Limit to main diagnosis ICD-9 codes 291.x,292.x,and 294.x-319.x ICD-10 codes F10-
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Variable Definitions (add additional rows as needed) 
F99 (exclude dementia and delirium). For psychiatric hospitalizations in OMHRS, use all codes 
except 293, 780, 290, 294, and V codes. Use only first diagnosis from Axis 1  or Axis 2, first 
position at discharge. Exclude discharges with no Axis 1 diagnosis 
hospdays_pre6m Total number of inpatient days for a mental health reason 
 
Psychiatric Outcomes (10 years post admission date) 
mhprimcareX_date Date of Xth primary care visit for a mental health reason, defined as follows (DXCODE found in 
Appendix B): 
• (FP/GP [SPEC=00] or Paediatrician [SPEC=26]) and MHA diagnosis code 
(DXCODE)  and outpatient (LOCATION: O, L, H)  and non-lab service 
[substr(FEECODE,1,1) ne 'G'] 
OR 
• Paediatrician [SPEC=26]  and undefined location (LOCATION =U) and MHA diagnosis 
code [DXCODE] and fee code (FEECODE=K122 or K123 or K704) 
primcareX_date Date of Xth primary care visit for non-mental health reason, defined as all visits to primary care 
that do not meet the definition of mhprimcareX_date (above) 
psychX_date Date of Xth outpatient visit with a psychiatrist [SPEC=19; LOCATION: O, L, H) for a non-lab service 
[substr(FEECODE,1,1) ne 'G']  
edX_date Date of Xth ED visit for a mental health reason, defined as follows: 
• DX10CODE1 = F04-F99 
OR 
• DX10CODE2 – DX10CODE10 = X60-X84, Y10-Y19, Y28 AND DX10CODE1 not equal to 
F04-F99 
Include suspect diagnoses (%getnacrs where suspect = T) 
Exclude scheduled ED visits (%getnacrs where INCLSCHEDULED = F) 
Exclude transfers from another ED (FROM_TYPE ≠ ‘E’) 
hospX_date Date of Xth psychiatric hospital admission. Use %GETCIHI and limit to non-elective admissions 
(ADMCAT U or E) for all hospitalizations at acute care institution (INSTTYPE AT or AP). Select first 
visit in an episode of care (Sort data by EPI, EPIVISIT, EPIFLAG and pll the record with 
FIRST.EPI=1). Limit to main diagnosis ICD-9 codes 291.x,292.x,and 294.x-319.x ICD-10 codes F10-
F99 (exclude dementia and delirium). For psychiatric hospitalizations in OMHRS, use all codes 
except 293, 780, 290, 294, and V codes. Use only first diagnosis from Axis 1  or Axis 2, first 
position at discharge. Exclude discharges with no Axis 1 diagnosis 
hospX_los Length of stay (days) for Xth psychiatric hospital admission 
involuntaryX_date Date of Xth involuntary admissions, defined as follows:  
• OMHRS: PT_STATUS = 1, 4 
• DAD: ADMMETH = D, E 
• OHIP: FEECODE = K623, K624 
ltc Flag if patient has an admission to a long-term care facilited, defined based on presence of IKN in 
CCRS database 
ltc_date Date of first admission to long-term care facility (ADMDATE in CCRS) 
ltc_10y Flag if patient is a resident of a long-term care facility at the end of the follow-up period 
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Variable Definitions (add additional rows as needed) 
alcoholX_date Date of Xth contact with services for alcohol-related disorders over the follow-up period (any 
diagnosis field in DAD, OMHRS, NACRS, OHIP – codes in Appendix C) 
substanceX_date Date of Xth contact with services for substance-related disorders over the follow-up period (any 
diagnosis field in DAD, OMHRS, NACRS, OHIP – codes in Appendix D) 
substance_opioid Flag if contact with services for substance-related disorder (above) was related to opioids, 
defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30400, 30401, 30402, 30403, 30470, 30471, 30472, 30473, 30550, 30551, 30552, 
30553  
• ICD-10: F11 
• DSM-IV: 304.00, 305.50 
substance_sedative Flag if contact with services for substance-related disorder (above) was related to sedatives or 
barbituates, defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30410, 30411, 30412, 30413, 30540, 30541, 30542, 30543 
• ICD-10: F13 
• DSM-IV: 304.10, 305.40 
substance_cocaine Flag if contact with services for substance-related disorder (above) was related to cocaine, 
defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30420, 30421, 30422, 30423, 30560, 30561, 30562, 30563 
• ICD-10: F14 
• DSM-IV: 304.20, 305.60 
substance_cannabis Flag if contact with services for substance-related disorder (above) was related to cannabis, 
defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30430, 30431, 30432, 30433, 30520, 30521, 30522, 30523  
• ICD-10: F12 
• DSM-IV: 304.30, 305.20 
substance_amphetamine Flag if contact with services for substance-related disorder (above) was related to amphetamines, 
defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30440, 30441, 30442, 30443, 30570, 30571, 30572, 30573  
• ICD-10: F15 
• DSM-IV: 304.40, 305.70 
substance_hallucinogen Flag if contact with services for substance-related disorder (above) was related to hallucinogens, 
defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30450, 30451, 30452, 30453, 30530, 30531, 30532, 30533   
• ICD-10: F16 
• DSM-IV: 304.50, 305.30 
substance_poly Flag if contact with services for substance-related disorder (above) was related to multiple 
substances, defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
• ICD-9: 30470, 30471, 30472, 30480, 30481, 30482, 30483    
• ICD-10: F19 
• DSM-IV: 304.80 
substance_unknown Flag if contact with services for substance-related disorder (above) was related to unknown 
substances, defined as follows (any diagnosis field in DAD, OMHRS, NACRS): 
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Variable Definitions (add additional rows as needed) 
• ICD-9: 2920, 29211, 29212, 2922, 29281, 29282, 29283, 29284, 29289, 2929, 30460, 
30461, 30462, 30463, 30490, 30491, 30492, 30493, 30580, 30581, 30582, 30583, 30590, 
30591, 30592, 30593    
• ICD-10: F18, F55 
• DSM-IV: 292.00, 292.11, 292.12, 292.81, 292.82, 292.83, 292.84, 292.89, 292.90, 304.60, 
304.90, 305.10, 305.90 
• OHIP: 292, 304 
odb_length Length of time (days) covered by ODB over the study follow-up period 
odb_10y Flag if patient is still covered by ODB at 10-year follow-up  
odb_plan If odb_10y = 1, note the plan code (PLANCODE from ODB database) 
death Whether the patient died from any cause over the follow-up period (DTH from RPDB) 
death_date Date of death (DTHDATE from RPDB) 
 
Physical Co-Morbidities (At any point in patient record) 
ami Flag if patient has a hospitalization for acute myocardial infarction, based on presence of IKN in 
OMID2016 database 
NOTE: Only includes patients over the age of 20 
ami_date Date of first admission for acute myocardial infarction (ADMDATE from OMID2016 database) 
asthma Flag if patient has a diagnosis of asthma, based on presence of IKN in ASTHMA2016 database 
asthma_date Date of first diagnosis of asthma (FIRSTOHIP from ASTHMA2016 database) 
asthma_10y Flag if patient is a prevalent case of asthma (PREVyyyy) at the end of the 10-year follow-up 
period 
cancer Flag if patient has diagnosis of cancer, based on presence of IKN in OCR database 
cancer_date Date of first diagnosis of cancer (DXDATE from OCR database) 
cancer_site Site of cancer, defined by PSITE from OCR database 
cancer_stage Stage of cancer at diagnosis, defined by BEST_STAGE_GRP from OCR database 
cancer_10yr Flag if date of last contact (DOLC) is within five years of the end of the 10-year follow-up period 
chf Flag if patient has diagnosis of congestive heart failure based on presence of IKN in CHF2016 
database 
NOTE: Only includes patients over the age of 40 
chf_date Date of first diagnosis of congestive heart failure (DIAGDATE from CHF database) 
chf_10y Flag if patient is prevalent case (PREVyyyy) at end of 10-year follow-up period 
ckd Flag if patient has diagnosis of chronic kidney disease, defined based on the presence of one  of 
the following codes in DAD, or two in OHIP within a 2-year period (ICD-9: DXCODE1-16; ICD-10: 
DXCODE1-25): 
• ICD-9: 40300, 40301, 40310, 40311, 40390, 40391, 40400, 40401, 40402, 40403, 40410, 
40411, 40412, 40413, 40490, 40491, 40492, 40493, 585, 586, 5888, 5889, 2504, V451 
• ICD-10: E102, E112, E132, E142, I12, I13, N08, N180, N181, N182, N183, N184, N185, 
N188, N189  N19, T824, Z492, Z992 
• OHIP: 403, 585 
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Variable Definitions (add additional rows as needed) 
ckd_date Date of first diagnosis of chronic kidney disease, as defined above. Use admission date 
(ADMDATE) when defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) 
when defined by outpatient visits 
ckd_10y Flag if patient has a hospitalization or visit for chronic kidney disease within 5 years of the 
maximum follow-up date 
copd Flag if patient has diagnosis of COPD, based on presence of IKN in COPD2016 database  
NOTE: Only includes patients over the age of 35 
copd_date Date of diagnosis of COPD (DIAGDATE from COPD database) 
copd_10y Flag if patient is prevalent case (PREVyyyy) at end of 10-year follow-up period 
cvd Flag if patient has diagnosis of cardiovascular disease, which includes MI, angina, peripheral 
vascular disease, and arrhythmia. Definitions found in the file below: 
CVD Case 
Def init ion.xlsx  
cvd_date Date of first diagnosis of cardiovascular disease, as defined above. Use admission date 
(ADMDATE) when defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) 
when defined by outpatient visits 
cvd_10y Flag if patient has hospitalization or visit for cardiovascular disease (as defined above) within 5 
years of the maximum follow-up date  
dementia Flag if patient has a diagnosis of dementia, based on presence of IKN in DEMENTIA2016 database 
NOTE: Only includes patients over the age of 40 
dementia_date Date of diagnosis of dementia (DIAGDATE from DEMENTIA2016) 
dementia_10y Flag if patient is a prevalent case of dementia (PREVyyyy) at the end of the 10-year follow-up 
period 
diabetes Flag if patient has a diagnosis of diabetes, based on presence of IKN in ODD2016 database 
diabetes_date Date of diagnosis of hypertension (DIAGDATE from ODD2016 database) 
diabetes_10y Flag if patient is a prevalent case of diabetes (PREVyyyy) at the end of the 10-year follow-up 
period 
hepatitis Flag if patient has diagnosis of hepatitis, defined based on the presence of one of the following 
codes in DAD, or two in OHIP (ICD-9: DXCODE1-16; ICD-10: DXCODE1-25): 
• ICD-9: 0700, 0701, 0702, 07020, 07021, 0703, 07030, 07031, 0704, 07041, 07042, 
07043, 07049, 0705, 07051, 07052, 07053, 07059, 0706, 0709  
• ICD-10: B15, B150, B159, B16, B160, B161, B162, B169, B17, B170, B171, B172, B178, 
B179, B18, B180, B181, B182, B188, B189, B19, B190, B199, B942, O98401, O98402, 
O98403, O98404, O98409, Z2250, Z2251, Z2258 
• OHIP: 070 
hepatitis_date Date of first diagnosis of hepatitis, as defined above. Use admission date (ADMDATE) when 
defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined by 
outpatient visits. 
hiv Flag if patient has diagnosis of HIV infection, based on presence of IKN in HIV2016 database 
NOTE: Only includes patients over the age of 18 
hiv_date Date of diagnosis of HIV infection (DIAGDATE from HIV2016 database) 
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Variable Definitions (add additional rows as needed) 
hypertension Flag if patient has a diagnosis of hypertension, based on presence of IKN in HYPER2016 database  
NOTE: Only includes patients over the age of 20 
hypertension_date Date of diagnosis of hypertension (DIAGDATE from HYPER2016 database) 
hypertension_10y Flag if patient is a prevalent case of hypertension (PREVyyyy) at the end of the 10-year follow-up 
period 
ibd Flag if patient has a diagnosis of inflammatory bowel disease, based on presence of IKN in 
OCCC2016 database 
ibd_date Date of diagnosis of inflammatory bowel disease (FIRSTCONTACTDATE from OCCC2016 database) 
ibd_10y Flag if patient is a prevalent case of inflammatory bowel disease (PREVyyyy) at the end of the 10-
year follow-up period 
lipids Flag if patient has a diagnosis of a disorder of lipid metabolism, based on DXCODE = 272 in OHIP 
database  
lipids_date Date of first diagnosis of disorder of lipid metabolism (SERVDATE from OHIP database) 
liver Flag if patient has diagnosis of chronic liver disease, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25) or two OHIP visit diagnoses 
(DXCODE) or fee codes (FEECODE) within 2 years: 
• ICD-9: 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824, V026, 571, 2750, 2751, 
7891, 7895   
• ICD-10: B16, B17, B18, B19, I85, R17, R18, R160, R160, B942, Z2225, E830, E831, K70, 
K713, K714, K715, K717, K721, K729, K73, K74, K753, K754, K758, K759, K76, K77 
• OHIPDX: 571, 573, 070 
• OHIPFEE: Z551, Z554 
liver_date Date of first diagnosis of chronic liver disease, as defined above. Use admission date (ADMDATE) 
when defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined 
by outpatient visits 
liver_10y Flag if patient has hospitalization or visit for chronic liver disease during 10-year follow-up period 
mood Flag if patient has diagnosis of a mood disorder, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25, DSM-IV: 
AXIS1_DSM4CODE_DISCH1-3) or two OHIP visit diagnoses (DXCODE) within 2 years: 
• ICD-9: 296, 2960, 29600, 29601, 29602, 29603, 29604, 29605, 29606, 2961, 29610, 
29611, 29612, 29613, 29614, 29615, 29616, 2962, 29620, 29621, 29622, 29623, 29624, 
29625, 29626, 2963, 29630, 29631, 29632, 29633, 29634, 29635, 29636, 2964, 29640, 
29641, 29642, 29643, 29644, 29645, 29646, 2965, 29650, 29651, 29652, 29653, 29654, 
29655, 29656, 2966, 29660, 29661, 29662, 29663, 29664, 29665, 29666, 2967, 29670, 
2968, 29680, 29681, 29682, 29689, 2969, 29690, 29699, 3004, 3090, 3091, 311 
• ICD-10: F300, F301, F302, F308, F309, F310, F311, F312, F313, F314, F315, F316, F317, 
F318, F319, F320, F321, F322, F323, F328, F329, F330, F331, F332, F333, F334, F338, 
F339, F341, F348, F349, F380, F381, F388, F39  
• DSM-IV: 296.0X, 296.2X, 296.3X, 296.4X, 296.5X, 296.6X, 296.7, 296.80, 296.89, 296.9, 
300.4, 301.13, 311.00  
• OHIP: 296, 311 
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Variable Definitions (add additional rows as needed) 
mood_date Date of first diagnosis of mood disorder, as defined above. Use admission date (ADMDATE) when 
defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined by 
outpatient visits 
mood_10y Flag if patient has hospitalization or visit for a mood disorder during 10-year follow-up period 
anxiety Flag if patient has diagnosis of an anxiety disorder, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25, DSM-IV: 
AXIS1_DSM4CODE_DISCH1-3) or two OHIP visit diagnoses (DXCODE) within 2 years: 
• ICD-9: 30000, 30001, 30002, 30009, 30010, 30011, 30012, 30013, 30014, 30015, 30016, 
30019, 30020, 30021, 30022, 30023, 30029, 3003, 3005, 3006, 3007, 30081, 30089, 
3009, 3090, 30900, 30921, 30922, 30923, 30924, 30928, 30929, 3093, 3094, 30981, 
30982, 30983, 30989, 3099, 30990 
• ICD-10: F400, F401, F402, F408, F409, F410, F411, F412, F413, F418, F419, F420, F421, 
F422, F428, F429, F431, F432, F438 
• DSM-IV: 300.XX, 300.00, 300.01, 300.02, 300.21, 300.22, 300.23, 300.29, 300.3, 308.3, 
309.21, 309.81  
• OHIP: 300, 309 
anxiety_date Date of first diagnosis of anxiety disorder, as defined above. Use admission date (ADMDATE) 
when defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined 
by outpatient visits 
anxiety_10y Flag if patient has hospitalization or visit for mood disorder during 10-year follow-up period 
osteoarthritis Flag if patient has diagnosis of osteoarthritis, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25) or two OHIP visit diagnoses 
(DXCODE) within 2 years: 
• ICD-9: 71500, 71504, 71509, 71510, 71511, 71512, 71513, 71514, 71515, 71516, 71517, 
71518, 71520, 71521, 71522, 71523, 71524, 71525, 71526, 71527, 71528, 71530, 71531, 
71532, 71533, 71534, 71535, 71536, 71537, 71538, 71580, 71589, 71590, 71591, 71592, 
71593, 71594, 71595, 71596, 71597, 71598 
• ICD-10: M150, M151, M152, M153, M154, M158, M159, M160, M161, M162, M163, 
M164, M165, M166, M167, M169, M170, M171, M172, M173, M174, M175, M179, 
M180, M181, M182, M183, M184, M185, M189, M190, M191, M192, M198, M199 
• OHIP: 715 
osteoarthritis_date Date of first diagnosis of osteoarthritis, as defined above. Use admission date (ADMDATE) when 
defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined by 
outpatient visits 
osteoarthritis_10y Flag if patient has hospitalization or visit for osteoarthritis during follow-up period 
osteoporosis Flag if patient has diagnosis of osteoporosis, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25) or two OHIP visit diagnoses 
(DXCODE) within 2 years: 
• ICD-9: 73300, 73301, 73302, 73303, 73309, 7331, 73320, 73321, 73322, 73329, 73329, 
73340, 73341, 73342, 73343, 73344, 73349, 7335, 7336, 7337, 73381, 73382, 73390, 
73391, 73392, 73399    
• ICD-10: M810, M811, M812, M813, M814, M815, M816, M818, M819, M820, M821, 
M828 
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Variable Definitions (add additional rows as needed) 
• OHIP: 733 
osteoporosis_date Date of first diagnosis of osteoporosis, as defined above. Use admission date (ADMDATE) when 
defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined by 
outpatient visits 
osteoporosis_10y Flag if patient has hospitalization or visit for osteoporosis during 10-year follow-up period 
deliveryX_date Date of Xth delivery (B_BDATE), based on presence of IKN in MOMBABY2016 database over 
follow-up period 
deliveryX_stillbirth Flag if delivery X was a stillbirth based on variable M_STILLBIRTH from MOMBABY2016 record 
rheumatoid Flag if patient has a diagnosis of rheumatoid arthritis, based on presence of IKN in ORAD2016 
database 
rheumatoid_date Date of diagnosis of rheumatoid arthritis (DIAGDATE from ORAD2016 database) 
rheumatoid_10y Flag if patient is prevalent case (PREVyyyy) at end of 10-year follow-up period 
stroke Flag if patient has diagnosis of osteoporosis, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25) or two OHIP visit diagnoses 
(DXCODE) within 2 years: 
• ICD-9: 3623, 36230, 36231, 36232, 36233, 36234, 36235, 36236, 36237, 430, 4300, 431, 
4310, 4320, 4321, 4329, 4330, 4331, 4332, 4333, 4338, 4339, 4340, 4341, 4349, 4350, 
4351, 4352, 4358, 4359, 436, 4360    
• ICD-10: H340, H341, G450, G451, G452, G453, G458, G459, I600, I601, I602, I603, I604, 
I605, I606, I607, I608, I609, I610, I611, I612, I613, I614, I615, I616, I618, I619, I620, I621, 
I629, I630, I631, I632, I633, I634, I635, I636, I638, I639, I64 
• OHIP: 3623, 430, 431, 432, 434, 436 
stroke_date Date of first diagnosis of stroke, as defined above. Use admission date (ADMDATE) when defined 
by hospitalization, and the date of first OHIP diagnosis (SERVDATE) when defined by outpatient 
visits 
stroke_10y Flag if patient has hospitalization or visit for stroke during follow-up period (1) 
urinary Flag if patient has diagnosis of osteoporosis, defined based on the presence of one 
hospitalization (ICD-9: DXCODE1-16; ICD-10: DX10CODE1-25) or two OHIP visit diagnoses 
(DXCODE) within 2 years: 
• ICD-9: 7883    
• ICD-10: N393, N394, R32 
• OHIP: 788 
urinary_date Date of first diagnosis of chronic urinary problem, as defined above. Use admission date 
(ADMDATE) when defined by hospitalization, and the date of first OHIP diagnosis (SERVDATE) 
when defined by outpatient visits 
urinary_10y Flag if patient has hospitalization or visit for a chronic urinary problem within 5 years of the 
maximum follow-up date 
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Analysis Plan and Dummy Tables (expand/modify as needed) 
Descriptive Tables (insert or append dummy tables), e.g.: 
 Table 1. Baseline characteristics according to primary/secondary exposure 
 Table 2. Outcomes according to primary/secondary exposure 
 Table 3. Covariates (baseline characteristics) according to outcomes  
Statistical Model(s) 
 Type of model  
 Primary independent variable  
 Dependent variable  
 Covariates  
Sensitivity Analyses  
 Type of model  
 Primary independent variable  
 Dependent variable  
 Covariates  
 
 
 
 
 
Quality Assurance Activities 
RAE Directory of SAS Programs  
RAE Directory of Final Dataset(s) The final analytic dataset for each cohort includes all the data required to create the 
baseline tables and run all the models. It should include all covariates for all models 
such as patient risk factors, hospital characteristics, physician characteristics, 
exposure measures (continuous, categorical) and outcomes. It should include 
covariates that were considered but didn’t make the final cut. This would permit an 
analyst to easily re-run the models in the future. 
 
RAE README file available: ☐Yes ☐No 
Date results of quality assurance tools for final dataset shared with project team (where 
applicable): 
 
 %assign yyyy-
mon
-dd 
 %evolution yyyy-
mon
-dd 
 %dinexplore yyyy-
mon
-dd 
 %track / %exclude yyyy-
mon
-dd 
 %codebook yyyy-
mon
-dd 
Additional comments:  
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APPENDIX A – List of Diagnostic Codes to Exclude from Comparison Group 
 
OMHRS: 
29510 = SCHIZOPHRENIA, DISORGANIZED TYPE 
29520 = SCHIZOPHRENIA, CATATONIC TYPE 
29530 = SCHIZOPHRENIA, PARANOID TYPE 
29540 = SCHIZOPHRENIFORM DISORDER 
29560 = SCHIZOPHRENIA, RESIDUAL TYPE 
29570 = SCHIZOAFFECTIVE DISORDER 
29590 = SCHIZOPHRENIA, UNDIFFERENTIATED TYPE 
29710 = DELUSIONAL DISORDER 
29730 = SHARED PSYCHOTIC DISORDER 
29880 = BRIEF PSYCHOTIC DISORDER 
29890 = PSYCHOTIC DISORDER NOS 
 
DAD (ICD-10): 
F20 = SCHIZOPHRENIA 
F200 = PARANOID SCHIZOPHRENIA 
F201 = HEBEPHRENIC SCHIZOPHRENIA 
F202 = CATATONIC SCHIZOPHRENIA 
F203 = UNDIFFERENTIATED SCHIZOPHRENIA 
F204 = POST-SCHIZOPHRENIC DEPRESSION 
F205 = RESIDUAL SCHIZOPHRENIA 
F206 = SIMPLE SCHIZOPHRENIA 
F208 = OTHER SCHIZOPHRENIA 
F209 = SCHIZOPHRENIA, UNSPECIFIED 
F22 = PERSISTENT DELUSIONAL DISORDERS 
F220 = DELUSIONAL DISORDER 
F228 = OTHER PERSISTENT DELUSIONAL DISORDERS 
F229 = PERSISTENT DELUSIONAL DISORDER, UNSPECIFIED 
F23 = ACUTE AND TRANSIENT PSYCHOTIC DISORDERS 
F230 = ACUTE POLYMORPHIC PSYCHOTIC DISORDER WITHOUT SYMPTOMS OF SCHIZOPHRENIA 
F231 = ACUTE POLYMORPHIC PSYCHOTIC DISORDER WITH SYMPTOMS OF SCHIZOPHRENIA 
F232 = ACUTE SCHIZOPHRENIA-LIKE PSYCHOTIC DISORDER 
F233 = OTHER ACUTE PREDOMINANTLY DELUSIONAL PSYCHOTIC DISORDERS 
F238 = OTHER ACUTE AND TRANSIENT PSYCHOTIC DISORDERS 
F239 = ACUTE AND TRANSIENT PSYCHOTIC DISORDER, UNSPECIFIED 
F24 = INDUCED DELUSIONAL DISORDER 
 
F25 = SCHIZOAFFECTIVE DISORDERS 
F250 = SCHIZOAFFECTIVE DISORDER, MANIC TYPE 
F251 = SCHIZOAFFECTIVE DISORDER, DEPRESSIVE TYPE 
F252 = SCHIZOAFFECTIVE DISORDER, MIXED TYPE 
F258 = OTHER SCHIZOAFFECTIVE DISORDERS 
F259 = SCHIZOAFFECTIVE DISORDER, UNSPECIFIED 
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F28 = OTHER NONORGANIC PSYCHOTIC DISORDERS 
F29 = UNSPECIFIED NONORGANIC PSYCHOSIS 
 
DAD (ICD-9): 
295 = SCHIZOPHRENIAS 
29500 = SIMPL SCHIZOPHREN-UNSPEC 
29501 = SIMPL SCHIZOPHREN-SUBCHR 
29502 = SIMPLE SCHIZOPHREN-CHR 
29503 = SIMP SCHIZ-SUBCHR/EXACER 
29504 = SIMPL SCHIZO-CHR/EXACERB 
29505 = SIMPL SCHIZOPHREN-REMISS 
2951 = HEBEPHRENIA-UNSPEC 
29510 = HEBEPHRENIA-UNSPEC 
29511 = HEBEPHRENIA-SUBCHRONIC 
29512 = HEBEPHRENIA-CHRONIC 
29513 = HEBEPHREN-SUBCHR/EXACERB 
29514 = HEBEPHRENIA-CHR/EXACERB 
29515 = HEBEPHRENIA-REMISSION 
2952 = CATATONIA-UNSPEC 
29520 = CATATONIA-UNSPEC 
29521 = CATATONIA-SUBCHRONIC 
29522 = CATATONIA-CHRONIC 
29523 = CATATONIA-SUBCHR/EXACERB 
29524 = CATATONIA-CHR/EXACERB 
29525 = CATATONIA-REMISSION 
2953 = PARANOID SCHIZO-UNSPEC 
29530 = PARANOID SCHIZO-UNSPEC 
29531 = PARANOID SCHIZO-SUBCHR 
29532 = PARANOID SCHIZO-CHRONIC 
29533 = PARAN SCHIZO-SUBCHR/EXAC 
29534 = PARAN SCHIZO-CHR/EXACERB 
29535 = PARANOID SCHIZO-REMISS 
2954 = AC SCHIZOPHRENIA-UNSPEC 
29540 = AC SCHIZOPHRENIA-UNSPEC 
29541 = AC SCHIZOPHRENIA-SUBCHR 
29542 = AC SCHIZOPHRENIA-CHR 
29543 = AC SCHIZO-SUBCHR/EXACERB 
29544 = AC SCHIZOPHR-CHR/EXACERB 
29545 = AC SCHIZOPHRENIA-REMISS 
2955 = LATENT SCHIZOPHREN-UNSP 
29550 = LATENT SCHIZOPHREN-UNSP 
29551 = LAT SCHIZOPHREN-SUBCHR 
29552 = LATENT SCHIZOPHREN-CHR 
29553 = LAT SCHIZO-SUBCHR/EXACER 
29554 = LATENT SCHIZO-CHR/EXACER 
29555 = LAT SCHIZOPHREN-REMISS 
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2956 = RESID SCHIZOPHREN-UNSP 
29560 = RESID SCHIZOPHREN-UNSP 
29561 = RESID SCHIZOPHREN-SUBCHR 
29562 = RESIDUAL SCHIZOPHREN-CHR 
29563 = RESID SCHIZO-SUBCHR/EXAC 
29564 = RESID SCHIZO-CHR/EXACERB 
29565 = RESID SCHIZOPHREN-REMISS 
2957 = SCHIZOAFFECTIVE-UNSPEC 
29570 = SCHIZOAFFECTIVE-UNSPEC 
29571 = SCHIZOAFFECTIVE-SUBCHR 
29572 = SCHIZOAFFECTIVE-CHRONIC 
29573 = SCHIZOAFF-SUBCHR/EXACER 
29574 = SCHIZOAFFECT-CHR/EXACER 
29575 = SCHIZOAFFECTIVE-REMISS 
2958 = SCHIZOPHRENIA NEC-UNSPEC 
29580 = SCHIZOPHRENIA NEC-UNSPEC 
29581 = SCHIZOPHRENIA NEC-SUBCHR 
29582 = SCHIZOPHRENIA NEC-CHR 
29583 = SCHIZO NEC-SUBCHR/EXACER 
29584 = SCHIZO NEC-CHR/EXACERB 
29585 = SCHIZOPHRENIA NEC-REMISS 
2959 = SCHIZOPHRENIA NOS-UNSPEC 
29590 = SCHIZOPHRENIA NOS-UNSPEC 
29591 = SCHIZOPHRENIA NOS-SUBCHR 
29592 = SCHIZOPHRENIA NOS-CHR 
29593 = SCHIZO NOS-SUBCHR/EXACER 
29594 = SCHIZO NOS-CHR/EXACERB 
29595 = SCHIZOPHRENIA NOS-REMISS 
297 = DELUSIONAL DISORDERS 
2970 = PARANOID STATE, SIMPLE 
2971 = PARANOIA 
2972 = PARAPHRENIA 
2973 = SHARED PARANOID DISORDER 
2978 = PARANOID STATES NEC 
2979 = PARANOID STATE NOS 
298 = OTHER PSYCHOSES 
2980 = REACT DEPRESS PSYCHOSIS 
2981 = EXCITATIV TYPE PSYCHOSIS 
2982 = REACTIVE CONFUSION 
2983 = ACUTE PARANOID REACTION 
2984 = PSYCHOGEN PARANOID PSYCH 
2988 = REACT PSYCHOSIS NEC/NOS 
2989 = PSYCHOSIS NOS 
 
OHIP 
295 = SCHIZOPHRENIA 
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297 = PARANOID STATES 
298 = OTHER PSYCHOSES 
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APPENDIX B – OHIP fee codes for identifying primary care visits for mental health reasons 
 
Psychotic Disorders 
295 Schizophrenia 
296 Manic-depressive psychoses, involutional melancholia 
297 Other paranoid states  
298 Other psychoses 
 
Non-Psychotic Disorders  
300 Anxiety neurosis, hysteria, neurasthenia, obsessive-compulsive neurosis, reactive depression 
301 Personality disorders  
302 Sexual deviations  
306 Psychosomatic illness  
309 Adjustment reaction  
311 Depressive disorder 
 
Substance Use Disorders  
303 Alcoholism  
304 Drug dependence 
 
Social Problems 
897 Economic problems  
898 Marital difficulties  
899 Parent-child problems  
900 Problems with aged parents or in-laws  
901 Family disruption/divorce 
902 Education problems  
904 Social maladjustment  
905 Occupational problems  
906 Legal problems  
909 Other problems of social adjustment 
 
Other  
291 Alcoholic psychosis, delirium tremens, Korsakov's psychosis  
292 Drug psychosis  
299 Childhood psychoses (e.g., autism)  
307 Habit spasms, tics, stuttering, tension headaches, anorexia nervosa, sleep disorders, enuresis  
313 Behaviour disorders of childhood and adolescence  
314 Hyperkinetic syndrome of childhood  
315 Specified delays in development (e.g., dyslexia, dyslalia, motor retardation) 
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APPENDIX C – Alcohol Related Diagnostic Codes 
 
OMHRS (DSM-IV) 
291.00 = ALCOHOL – INTOXICATION OR WITHDRAWAL DELIRIUM 
291.10 = ALCOHOL – INDUCED PERSISTING AMNESTIC DISORDER 
292.20 = ALCOHOL – INDUCED PERSISTING DEMENTIA 
291.30 = ALCOHOL – INDUCED PSYCHOTIC DISORDER, WITH HALLUCINATIONS  
291.50 = ALCOHOL – INDUCED PSYCHOTIC DISORDER, WITH DELUSIONS  
291.81 = ALCOHOL – WITHDRAWAL  
291.89 = ALCOHOL – INDUCED ANXIETY/MOOD DISORDER OR SEXUAL DYSFUNCTION  
291.90 = ALCOHOL – RELATED DISORDER NOT OTHERWISE SPECI ED (NOS)  
303.00 = ALCOHOL INTOXICATION 
303.90 = ALCOHOL DEPENDENCE 
305.00 = ALCOHOL ABUSE 
 
DAD/NACRS (ICD-10) 
F10 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF ALCOHOL 
 
DAD (ICD-9) 
2910 = DELIRIUM TREMENS 
2911 = ALCOHOL AMNESTIC SYND 
2912 = ALCOHOLIC DEMENTIA NEC 
2913 = ALCOHOL HALLUCINOSIS 
2914 = PATHOLOGIC ALCOHOL INTOX 
2915 = ALCOHOLIC JEALOUSY 
2918 = ALCOHOLIC PSYCHOSIS NEC 
2919 = ALCOHOLIC PSYCHOSIS NOS 
30300 = AC ALCOHOL INTOX-UNSPEC 
30301 = AC ALCOHOL INTOX-CONTIN 
30302 = AC ALCOHOL INTOX-EPISOD 
30303 = AC ALCOHOL INTOX-REMISS 
30390 = ALCOH DEP NEC/NOS-UNSPEC 
30391 = ALCOH DEP NEC/NOS-CONTIN 
30392 = ALCOH DEP NEC/NOS-EPISOD 
30393 = ALCOH DEP NEC/NOS-REMISS 
30500 = ALCOHOL ABUSE-UNSPEC 
30501 = ALCOHOL ABUSE-CONTINUOUS 
30502 = ALCOHOL ABUSE-EPISODIC 
30503 = ALCOHOL ABUSE-IN REMISS 
 
OHIP 
291 = ALCOHOLIC PSYCHOSIS 
303 = ALCOHOLISM 
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APPENDIX D – Substance Related Diagnostic Codes 
 
OMHRS (DSM-IV) 
292.00 = SUBSTANCE – WITHDRAWAL 
292.11 = SUBSTANCE – INDUCED PSYCHOTIC DISORDER, WITH DELUSIONS  
292.12 = SUBSTANCE – INDUCED PSYCHOTIC DISORDER, WITH HALLUCINATIONS  
292.81 = SUBSTANCE – INTOXICATION OR WITHDRAWAL DELIRIUM  
292.82 = SUBSTANCE – INDUCED PERSISTING DEMENTIA 
292.83 = SUBSTANCE – INDUCED PERSISTING AMNESTIC DISORDER 
292.84 = SUBSTANCE – INDUCED MOOD DISORDER 
292.89 = SUBSTANCE – INTOXICATION OR INDUCED ANXIETY DISORDER/SEXUAL DYSFUNCTION  
292.90 = SUBSTANCE – RELATED NOS 
304.00 = OPIOID DEPENDENCE 
304.10 = SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE 
304.20 = COCAINE DEPENDENCE 
304.30 = CANNABIS DEPENDENCE 
304.40 = AMPHETAMINE DEPENDENCE 
304.50 = HALLUCINOGEN DEPENDENCE 
304.60 = INHALANT OR PHENCYCLIDINE DEPENDENCE 
304.80 = POLYSUBSTANCE DEPENDENCE 
304.90 = OTHER (OR UNKNOWN) SUBSTANCE DEPENDENCE 
305.10 = NICOTINE DEPENDENCE 
305.20 = CANNABIS ABUSE 
305.30 = HALLUCINOGEN ABUSE 
305.40 = SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE 
305.50 = OPIOID ABUSE 
305.60 = COCAINE ABUSE 
305.70 = AMPHETAMINE ABUSE 
305.90 = OTHER (OR UNKNOWN) SUBSTANCE ABUSE  
 
DAD/NACRS (ICD-10) 
F11 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF OPIOIDS 
F12 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF CANNABINOIDS 
F13 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF SEDATIVES OR HYPNOTICS 
F14 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF COCAINE 
F15 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF OTHER STIMULANTS, INCLUDING CA EINE 
F16 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF HALLUCINOGENS 
F18 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO USE OF VOLATILE SOLVENTS 
F19 = MENTAL AND BEHAVIOURAL DISORDERS DUE TO MULTIPLE DRUG USE AND USE OF OTHER 
PSYCHOACTIVE SUBSTANCES  
F55 = ABUSE OF NON-DEPENDENCE-PRODUCING SUBSTANCES  
 
DAD (ICD-9) 
2920 = DRUG WITHDRAWAL SYNDROME 
29211 = DRUG PARANOID STATE 
29212 = DRUG HALLUCINOSIS 
2922 = PATHOLOGIC DRUG INTOX 
29281 = DRUG-INDUCED DELIRIUM 
29282 = DRUG-INDUCED DEMENTIA 
29283 = DRUG AMNESTIC SYNDROME 
29284 = DRUG DEPRESSIVE SYNDROME 
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29289 = DRUG MENTAL DISORDER NEC 
2929 = DRUG MENTAL DISORDER NOS 
30400 = OPIOID DEPENDENCE-UNSPEC 
30401 = OPIOID DEPENDENCE-CONTIN 
30402 = OPIOID DEPENDENCE-EPISOD 
30403 = OPIOID DEPENDENCE-REMISS 
30410 = BARBITURAT DEPEND-UNSPEC 
30411 = BARBITURAT DEPEND-CONTIN 
30412 = BARBITURAT DEPEND-EPISOD 
30413 = BARBITURAT DEPEND-REMISS 
30420 = COCAINE DEPEND-UNSPEC 
30421 = COCAINE DEPEND-CONTIN 
30422 = COCAINE DEPEND-EPISODIC 
30423 = COCAINE DEPEND-REMISS 
30430 = CANNABIS DEPEND-UNSPEC 
30431 = CANNABIS DEPEND-CONTIN 
30432 = CANNABIS DEPEND-EPISODIC 
30433 = CANNABIS DEPEND-REMISS 
30440 = AMPHETAMIN DEPEND-UNSPEC 
30441 = AMPHETAMIN DEPEND-CONTIN 
30442 = AMPHETAMIN DEPEND-EPISOD 
30443 = AMPHETAMIN DEPEND-REMISS 
30450 = HALLUCINOGEN DEP-UNSPEC 
30451 = HALLUCINOGEN DEP-CONTIN 
30452 = HALLUCINOGEN DEP-EPISOD 
30453 = HALLUCINOGEN DEP-REMISS 
30460 = DRUG DEPEND NEC-UNSPEC 
30461 = DRUG DEPEND NEC-CONTIN 
30462 = DRUG DEPEND NEC-EPISODIC 
30463 = DRUG DEPEND NEC-IN REM 
30470 = OPIOID/OTHER DEP-UNSPEC 
30471 = OPIOID/OTHER DEP-CONTIN 
30472 = OPIOID/OTHER DEP-EPISOD 
30473 = OPIOID/OTHER DEP-REMISS 
30480 = COMB DRUG DEP NEC-UNSPEC 
30481 = COMB DRUG DEP NEC-CONTIN 
30482 = COMB DRUG DEP NEC-EPISOD 
30483 = COMB DRUG DEP NEC-REMISS 
30490 = DRUG DEPEND NOS-UNSPEC 
30491 = DRUG DEPEND NOS-CONTIN 
30492 = DRUG DEPEND NOS-EPISODIC 
30493 = DRUG DEPEND NOS-REMISS 
30520 = CANNABIS ABUSE-UNSPEC 
30521 = CANNABIS ABUSE-CONTIN 
30522 = CANNABIS ABUSE-EPISODIC 
30523 = CANNABIS ABUSE-IN REMISS 
30530 = HALLUCINOG ABUSE-UNSPEC 
30531 = HALLUCINOG ABUSE-CONTIN 
30532 = HALLUCINOG ABUSE-EPISOD 
30533 = HALLUCINOG ABUSE-REMISS 
30540 = BARBITURATE ABUSE-UNSPEC 
30541 = BARBITURATE ABUSE-CONTIN 
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30542 = BARBITURATE ABUSE-EPISOD 
30543 = BARBITURATE ABUSE-REMISS 
30550 = OPIOID ABUSE-UNSPEC 
30551 = OPIOID ABUSE-CONTINUOUS 
30552 = OPIOID ABUSE-EPISODIC 
30553 = OPIOID ABUSE-IN REMISS 
30560 = COCAINE ABUSE-UNSPEC 
30561 = COCAINE ABUSE-CONTINUOUS 
30562 = COCAINE ABUSE-EPISODIC 
30563 = COCAINE ABUSE-IN REMISS 
30570 = AMPHETAMINE ABUSE-UNSPEC 
30571 = AMPHETAMINE ABUSE-CONTIN 
30572 = AMPHETAMINE ABUSE-EPISOD 
30573 = AMPHETAMINE ABUSE-REMISS 
30580 = ANTIDEPRESS ABUSE-UNSPEC 
30581 = ANTIDEPRESS ABUSE-CONTIN 
30582 = ANTIDEPRESS ABUSE-EPISOD 
30583 = ANTIDEPRESS ABUSE-REMISS 
30590 = DRUG ABUSE NEC-UNSPEC 
30591 = DRUG ABUSE NEC-CONTIN 
30592 = DRUG ABUSE NEC-EPISODIC 
30593 = DRUG ABUSE NEC-IN REMISS 
 
OHIP 
292 = DRUG INDUCED PSYCHOSIS 
304 = DRUG DEPENDENCE, DRUG ADDICTION 
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